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CHAPTER 1
Introduction
1.1

Introduction to Nucleic Acids
Nucleic acids play a vital role in biological systems. Nucleic acids, more

specifically DNA and RNA, are present in all organisms. Though DNA and RNA
have very few differences chemically, their three-dimensional structures and
biological functions are very different. The presence of a 2'-OH group and uracil,
instead of thymine, are the main chemical differences in RNA compared to DNA.
In secondary structures, DNA is generally helical and double stranded, whereas
RNA contains numerous tertiary structures and is quite diverse (5-7). With an
increasing number and types of RNAs still being discovered, our understanding
of RNA structure and function also has to increase greatly. Traditionally, there
are three major classes of RNAs: messenger RNA (mRNA), transfer RNA
(tRNA), and ribosomal RNA (rRNA), which are responsible for the conversion of
genetic information in DNA to proteins (8). In the past, other cellular RNAs were
considered as junk or degraded pieces of mRNA. Later, catalytic activities of
these RNA molecules were identified (9-13). In 1989, Thomas Cech and Sidney
Altman were awarded the Nobel Prize in chemistry for the discovery of catalytic
properties of RNA. They discovered the catalytic activity of the group I intron (9)
and ribonuclease P, respectively (11). These catalytic RNA, called ribozymes,
are found to be involved in a number of cellular processes. In the last decade,
the number of newly discovered small RNAs (sRNAs) in bacteria and non-coding
RNAs (ncRNAs) in eukaryotes has increased dramatically (14). They have been
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shown to carry out important regulatory functions such as transcriptional
regulation, RNA processing and modification, as well as mRNA stability and
translation (15-16). Although the overall function of known non-coding RNAs is
similar, the mechanism of action and processing of these RNAs is very different
(17-18). Riboswitches, upon binding to small molecules, refold and control
expression (19-20), while double-stranded short interfering RNAs (siRNAs)
suppress gene expression by cleaving target mRNA at specific sites (21). The
discovery of RNA interference (RNAi) and its role in defending cells against
parasitic genes has significantly increased its application in therapeutics (22-23).
In addition, RNAi has been used as a genetic tool in molecular biology to
suppress gene expression selectively. In 2006, Andrew Z. Fire and Craig C.
Mello received the Nobel Prize in physiology or medicine for the discovery of
RNA interference. With cutting-edge techniques and genome sequencing, more
non-coding RNAs, along with their functions and applications, are expected to be
uncovered in the future.

1.2

Introduction to the Ribosome
The ribosome is a large and complex organelle of living organisms,

identified as a ribonucleoprotein particle by Palade (24). The E. coli ribosome is
composed of 65% ribosomal RNA and 35% proteins, although the ratio varies a
little from organism to organism. In bacteria, the size of the ribosome is about 20
nm and it has a mass of more than 2 x 106 Daltons (25-26). The ribosome is an
essential component of all living organisms because of its important role in
protein synthesis. The cell uses a large amount of energy for its biogenesis.

3
1.2.1 Composition
The ribosome of all organisms consists of two unequal subunits, each
contains one third proteins and two thirds RNA. The unequal subunits of the
ribosome are measured in terms of their sedimentation coefficient unit (Svedberg
constant) rather than their size. In bacteria, the ribosome (70S) consists of a
larger 50S subunit and smaller 30S subunit. The larger 50S subunit is composed
of 23S ribosomal RNA with 2900 nucleotides and 5S ribosomal RNA with 120
nucleotides. Along with RNA, the larger subunit also contains 34 different
proteins. The smaller 30S subunit consists of 16S ribosomal RNA (1546
nucleotides) and 21 different proteins (Figure 1.1). In eukaryotes, the 80S
ribosome consists of a larger 60S subunit and a smaller 40S subunit. The large
subunit is composed of 28S ribosomal RNA (4700 nucleotides), 5.8S rRNA (160
nucleotides) and 49 proteins. The small subunit contains 18S ribosomal RNA
(1800 nucleotides) and 33 proteins. Despite the differences in size and
composition, the ribosome has common important functional regions such as the
decoding region, peptidyl transferase center, and peptide exit tunnel.
High-resolution X-ray crystal structures of the bacterial ribosome in
bacteria reveal that the smaller 30S subunit consists of four distinct structural
domains, previously referred to as the head, neck, body and platform based on
EM images (Figure 1.2 A) (27). The 30S subunit of the ribosome is mainly
involved in the formation of a pre-initiation complex and the selection of correct
aminoacyl tRNAs during protein synthesis.
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Figure 1.1. The composition of bacterial ribosomes is shown. The bacterial 70S ribosome
is composed of 50S and 30S subunits, which are also composed of ribosomal RNA and
proteins. This figure was created with Pymol using PDB: 3I1M and 3I1N (28).
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Figure 1.2. Crystal structures of the E. coli 30S and 50S subunits as seen from the
interface side are shown: (A) 30S crystal structure (PDB: 3I1M) and (B) 50S crystal
structure (PDB: 3I1N) (28).

6
The larger 50S subunit consists of a body and three protuberances (Figure 1.2
B). The central protuberance consists of 5S rRNA and associated proteins, while
the other two arms that extend to the right and left are formed by L1 and L7/L12
proteins. The catalytic center of the ribosome, or peptidyl transferase center
(PTC), is located in the 50S subunit and catalyzes peptide-bond formation.
Because of this property, the ribosome is also called a ribozyme (29). Another
important component of the 50S subunit is the peptide exit tunnel, which provides
a stable path for the growing polypeptide. The assembly and maturation
processes of the ribosomal subunits consist of a complex series of events,
including the processing of the ribosomal RNA, modification of nucleotides,
binding of ribosomal proteins and metal ions, as well as conformational changes
in sequential order (30-31).

1.2.2 Structure
The ribosome is organized into distinct three-dimensional structures (32).
The folded RNA makes the ribosome very diverse in secondary and tertiary
structures. The standard Watson-Crick base pairs found in RNA are G-C and AU; however, G-U and G-A non-canonical base pairs are also observed. Along
with these, there are several modified nucleotides and mismatches, which further
increase the diversity of the rRNA structure. Some of the common secondary
structures found in the ribosomal RNA, such as a hairpin loop, double-stranded
region, bulge, internal loop, and junction are shown in Figure 1.3. The secondary
structure of RNA is mainly composed of single- and double-stranded regions, but
when they fold on themselves, they form various complex tertiary structural
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Figure 1.3. Common secondary structures of RNA are shown: (A) single- and doublestranded regions, (B) hairpin, (C) bulge, (D) internal loop, and (E) four-way junction.
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motifs, such as the pseudoknot and A-minor motif. These tertiary structural motifs
stabilize loop-loop interactions, contact between helices, and conformations of
junctions (32).
Phylogenetic sequence analysis was initially used to predict the rRNA
secondary structure (33). Sequence comparison is a robust method to predict the
secondary and tertiary structure of RNA. It is based on the principle that
homologous RNA molecules, consisting of unique primary sequences, adopt the
same secondary and tertiary structures (34). It identifies base pairing by finding
sites of covariation between sequences in an alignment. Secondary structure
predicted by this approach was initially validated by chemical and enzymatic
probing. It was further confirmed when the crystal structure of tRNA was solved,
and all of the predicted secondary interactions were shown to be accurate. After
this, other RNA structures including 5S, 16S and 23S were also predicted based
on covariation approach (35-36). With continuous improvements in the
covariation algorithms and increase in the diversity of ribosomal RNA sequences,
the secondary structure of 16S rRNA and 23S rRNA was further refined. This
secondary map was validated initially with chemical probing, and afterwards with
the subunit and later complete ribosome crystal structures. Approximately ~98%
of the base pairs predicted by sequence comparison in 16S rRNA and 23S rRNA
were found to be correct when the crystal structure was solved (34). The
secondary structure of 16S rRNA is divided into four domains: the 5' domain
(nucleotides 1-556), central domain (nucleotides 557-918), 3' major (nucleotides
919-1396), and 3' minor domain (nucleotides1397-1542) (Figure 1.4) (37-38).
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Similarly, the secondary structure of 23S has six domains (domains I-VI)
(Figure1.5) (39).
Secondary and tertiary structures found in the ribosome have very
important roles in RNA stability and function. In ribosomal RNA, about 60% of the
nucleotides are involved in Watson-Crick base pairing and 62% of adenosines
are unpaired, while only about 30% of G, C and U are unpaired (34). However,
the majority of nucleotides are involved in some kind of interaction within the
folded RNA structure, and nucleotides that are not involved in any kind of
interaction are very rare (40). The secondary structure of rRNA contains short
helices that are connected by bulge or internal loops of unequal lengths. They
have important roles in initiating RNA folding, stabilizing helical stems, making
contacts with proteins, and participating in long-range tertiary interactions (4041). In all domains of life, the functional center of rRNA is highly conserved.
Several studies have shown that the key functional part of the ribosome is in fact
ribosomal RNA. Noller and coworkers treated 50S subunits of T. thermophilus
with sodium dodecyl sulfate and proteinase K followed by phenol extraction, and
found that 80% activity of the peptidyl transferase reaction was retained (42-43).
In addition, these structural motifs are important target sites for a number of
antibiotics.
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Figure 1.4. The secondary structure of 16S rRNA of E. coli is shown (34). Domains are
indicated and shown in different colors. (Figure taken from: http://rna.ucsc.edu/rnacenter).

Figure 1.5. The secondary structure of E. coli 23S rRNA and 5S rRNA is shown Domains are indicated
and shown in different colors. (Figure taken from: http://rna.ucsc.edu/rnacenter).
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1.2.3 Function
The main function of the ribosome is protein synthesis. For this process to
occur, the DNA sequence is first transcribed into mRNA by an RNA polymerase
(44). In bacteria, the transcribed mRNA is directly used for translation and does
not undergo post-transcriptional modifications. In eukaryotes, the transcribed
mRNA from DNA is called the primary transcript and undergoes different
maturation steps such as capping and splicing to produce mature mRNA (45).
The process of capping adds a 7-methyl guanosine to the 5' end, and splicing
removes non-coding sequences.
Both ribosomal subunits have three tRNA binding sites: the A site
(aminoacyl), which accepts the aminoacylated tRNA; the P site (peptidyl), which
catalyzes peptide-bond formation; and the E site (exit), from which deacylated
tRNAs leave during elongation. Protein synthesis begins with the binding of
mature mRNA to the 30S subunit, guided by the Shine-Dalgarno sequence (46).
Initiation factor 3 (IF3) prevents binding of the 50S, and initiation factor 1 (IF1)
blocks initiator fMet-tRNA binding to the A site of the 30S subunit (47-48). After
the f-Met-tRNA is correctly positioned, IF3 and IF1 are released and 50S binds to
30S to form the 70S initiation complex. During this process GTP bound to IF2 is
hydrolyzed. At this stage, all three initiation factors dissociate from the ribosome.
This process leads to the formation of a functional 70S ribosome called the
initiation complex (Figure 1.6) (49).
The next step of protein synthesis is elongation, in which a new aminoacyl
tRNA complex with GTP and EF-Tu (elongation factor thermo unstable) binds to

Figure 1.6. An overview of initiation of protein synthesis in bacteria is shown.
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the A site (50). The decoding region present in the 16S rRNA of the small subunit
selects the cognate tRNA according to the mRNA codon (51-52). Upon
aminoacyl tRNA binding to the A site, GTP is hydrolyzed and EF-TU-GDP is
released from the ribosome. After the correct aminoacyl tRNA is placed in the A
site, peptide-bond formation occurs at the peptidyltransferase center (PTC) of the
50S (50, 53). The amino acid f-Met from the initiator tRNA is then transferred to
the aminoacid of the A-site tRNA. In the process of translocation, the deacylated
tRNA and A-site tRNA, along with mRNA, move to the E site and P site,
respectively. GTP hydrolysis and EF-G (elongation factor G) are the driving
forces for this translocation step (54-55). This translocation process makes the
ribosome ready for the next round of elongation, which continues until the
ribosome reaches the stop codon on the mRNA (Figure 1.7).
The final step of protein synthesis is termination and recycling of the
ribosome. Termination occurs when the mRNA stop codon reaches the A site.
The stop codon is recognized by release factors, RF1 and RF2 (56). Binding of
release factor in the ribosome activates hydrolysis of the peptide chain from
tRNA, and RF3 then promotes dissociation of RF1 and RF2. The ribosome is left
with mRNA and deacylated tRNA in the P site after the peptide chain is released.
This complex is dissociated by RRF (ribosome recycling factor) and EF-G with
subsequent hydrolysis of GTP (57-59).

Figure 1.7. An overview of elongation and termination steps of protein synthesis is shown.
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It is necessary to accurately match the correct aminoacyled-tRNA with the
mRNA codon for protein translation. Before the sequence of 16S rRNA was
known, it was observed that the modification of 16S rRNA by kethoxal abolished
binding of tRNA to the ribosome (60). Afterward, footprinting techniques revealed
that binding of the A-site tRNA strongly protected G529, G530, A1492, and
A1493 against chemical modification (3). In further experiments, it was found that
A1492 and A1493 of helix 44, as well as G530 of helix 18, are involved in the
decoding process (48). This process selects the cognate tRNA and rejects the
non-cognate or near-cognate tRNA. The accuracy of translation is 10-3 to 10-4
per amino acid residue (61). Similarly, two residues, A2451 and G2447, of the
50S subunit in the PTC are crucial for peptide-bond formation. It has been shown
that peptidyl transferase remains mildly active once many of the ribosomal
proteins are removed, indicating this activity is largely catalyzed by rRNA (42). In
addition, several structural and mutational studies have been carried out to
establish the role of nucleotides in peptide-bond formation (62-64). To investigate
the role of individual nucleotides in various regions of the ribosome, a number of
mutational and structural studies have been carried out. From the random mutant
library of 30S and 50S subunits, changes at 53 positions in 16S rRNA and 77
positions in 23S rRNA displayed deleterious phenotypes (2, 65). In the decoding
region, all 15 possible mutations were constructed at conserved nucleotides
C1402 and A1500 of helix 44 of 16S rRNA. The results showed that most of the
mutations lead to deleterious phenotypes showing the importance of these
nucleotides for proper ribosome functioning (66).
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1.3

Ribosome as a Drug Target and Antibiotic Resistance
The ribosome is a well-validated drug target site because of its

accessibility, structural diversity, and lack of known repair enzymes. Various
classes of antibiotics bind within the functional centers of the ribosome and inhibit
protein synthesis by different mechanisms. About 40% of the known drugs bind
to the ribosome (67-68). The binding sites are found to be within a limited
functional

region

of

the

ribosome,

such

as

the

decoding

region,

peptidyltransferase center, peptide exit tunnel, and intersubunit regions. The
smaller subunit, 30S, is targeted by many antibiotics, including tetracycline,
pactamycin

and

aminoglycosides

(Figure

1.8

A,

Table

1.1)

(69-71).

Aminoglycosides, such as neomycin, paromomycin, and geneticin, bind to the
decoding region and cause bases 1492 and 1493 to flip out (70, 72). In addition,
binding of these antibiotics to helix 44 of 16S rRNA causes a conformational
change,

which

interferes

with

translational

fidelity

by

increasing

the

misincorporation of aminoacylated tRNAs (73). Recent crystal structures of 30S
complexed with aminoglycosides have greatly increased our understanding of
antibiotic sites in the ribosome (69, 74). Before the success of crystallography,
model systems of RNA were used to map the binding sites and interaction of
antibiotics by chemical probing and NMR spectroscopy (70, 75-77). This early
work in solution allowed researchers to compare and validate the results
obtained from crystallography.
Several important regions of the large subunit, 50S, are also targeted by
antibiotics (Figure 1.8 B, Table 1.1). Several clinically important antibiotics such
as macrolides, streptogramins, chloramphenicol, and oxazolidinones, bind to the
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Figure 1.8. Various antibiotics bound to the ribosome are shown. A) Common antibiotics
binding to the 30S subunit (PDB: 1FJG, 1HNX, 1HNJ, and 1HNW) are overlaid. B) Common
antibiotics binding to the 50S subunit (PDB: 3CC4, 3CPW, 1K9M, 2ZJP 1NJI, and 1YJN) are
shown.
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Table 1.1. Common antibiotics targeting to the ribosome. Helix number and subunits are
indicated.

Antibiotics

Binding sites

Mechanism of action

Aminoglycosides

A site

Decrease translational

(neomycin, paromomycin,

(30S subunits)

accuracy and inhibit

geneticin) (69, 78-79)

ribosomal translocation

Tetracycline (78, 80)

helix 34/31
(30S)

Inhibits A-site tRNA
binding

Peptides (viomycin,

30S subunits

Inhibit translocation

Spectinomycin (69)

helix 34 (30S)

EF-G binding inhibitor

Pactamycin (78)

helix 24/P site (30S)

Inhibits initiation factor

Macrolides (erythromycin,

Peptide exit tunnel

Block outlet of

azithromycin) (81-82)

near PTC

polypeptide

Lincosamides (lincomycin,

Peptide exit tunnel

Interfere with peptide-

capreomycin, edeine) (80)

clindamycin) (82)

bond formation

Chloramphenicol (82-83)

A site, PTC

Inhibits peptide-bond
formation

Oxazolidinones (linezolid)

P site (50S)

Compete with incoming

(84-85)

aminoacyl-tRNA
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large subunit near the PTC and inhibit protein synthesis (86). The macrolides are
one of the important classes of ribosome-targeting antibiotics. Crystal structures
of macrolides complexed with the 50S ribosomal subunit revealed that they block
the ribosomal exit tunnel for the progress of nascent polypeptide (81). Similarly,
streptogramins and chloramphenicol bind to the PTC and lock the conformation
of the ribosome (83). Still, there are several antibiotics for which binding sites and
mechanism of action have yet to be determined in detail.
The enormous use of antibiotics and increasing antibiotic resistance of
pathogens are the current challenges for scientists.

Bacteria may become

resistance to antibiotics by various mechanisms, including target site
modification, drug modification, and efflux (Figure 1.9) (87). To keep antibiotic
concentrations low, drugs such as tetracyclines or erythromycins are pumped out
through efflux mechanisms by bacteria (88). Penicillins were found to be
destroyed by β-lactamases, while aminoglycosides such as kanamycin are
chemically modified, which blocks binding to the recognition site (89). Mutations
or nucleotide modifications such as methylation of the target residue have also
been observed with several antibiotics targeting the ribosome. Modifications or
mutations are found in both ribosomal proteins and ribosomal RNA. In
spectinomycin resistance, mutation of a serine to proline at position 21 of the S5
protein has been observed (90). Similarly, a lysine to arginine change at position
42 of the S12 protein leads to streptomycin resistance (90). In RNA, modification
of target residues has been found in several antibiotic resistance strains.
Methylation of A1408 or G1405 leads to resistance to many aminoglycosides
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Figure 1.9. Various mechanisms of antibiotic resistance in bacteria are shown.
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(91-92). Similarly, N7 methylation of G1405 produces resistance to the geneticin
class of aminoglycosides (93). Mutation of key residues in the decoding region,
such as A1408G and C1409G, also causes resistance to most of the
aminoglycosides (94-96). In the large subunit, methylation of A2058 at N6 leads
to resistance of macrolide, clindamycin, lincosamide and spreptogramin, whereas
methylation of C1920 makes bacteria resistant to capreomycin (97-100). In
anisomycin resistance, mutations of U2500A and C2453U have been observed
(101). Target-site mutation for ribosome-binding drugs is difficult because
eubacteria carry multiple copies of ribosomal operons. E. coli has seven
ribosomal operons, and at least half of them must be in the mutant form to confer
antibiotic resistance (102-103). In addition, mutations often alter the ribosomal
structure, which prevents binding without impairing the biological function.
Mutations of certain nucleotides in the ribosome have been found to be lethal
and several of them are essential for fidelity of protein synthesis (103).
The antibiotic binding sites and resistance mechanisms determined from
biochemical and genetic approaches are clarified by the high-resolution crystal
structures (85, 104). High-resolution crystal structures can now be used to
predict novel drug-binding sites as well as modified versions of existing drugs in
order to overcome resistance. The binding sites of about half of the known
antibiotics are found to be clustered in the central functional regions of the
ribosome (71). A greater challenge is to identify and target unexploited sites in
the ribosome. We do not know whether the known sites are the only ones for
effective inhibition, or whether there are more possible target sites on the
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ribosome. The ribosome is a complex and dynamic molecule that directs
translation in several steps. For the purpose of identifying novel target sites or
designing drugs on the basis of structure, a better understanding of the ribosome
structure in solution, as well as functional importance of individual nucleotides, is
needed.

1.4

RNA Structural Studies
There are a variety of methods for studying RNA structure. Cryo-electron

microscopy (cryo-EM) X-ray crystallography and nuclear magnetic resonance
(NMR) spectroscopy are the most popular methods for obtaining structural
information of biomolecules. X-ray crystallography and cryo-EM are particularly
well suited for large macromolecular complexes such as the ribosome. Solution
studies such as NMR spectroscopy are typically limited to smaller systems.
Other biophysical methods such as circular dichroism (CD) spectroscopy, UV
melting, and fluorescence energy transfer (FRET) experiments are also very
useful for understanding RNA structure and function (105-106). Another method
to understand the RNA structure is chemical and enzymatic probing. The
available probes are widely used to understand the environment of individual
nucleotides at physiological conditions (e.g., solvent exposure, base pairing
interactions, etc.) (107-108).

1.4.1 Biophysical methods
Cryo-EM in combination with single-particle reconstruction has been
utilized by Joachim Frank and coworkers to obtain pictures of the ribosome
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during different stages of translation (109). In cryo-EM, molecules are rapidly
frozen to maintain them in a nearly native state. Unlike crystallography, cryo-EM
does not require highly ordered crystals (110). A 6.7 Å map of the E. coli
ribosome was published in association with aminoacyl-tRNA (111). By this
method, it is possible to analyze the motions and dynamic changes of the
ribosome during translation. The resolution, however, is not as high as that
obtained by X-ray crystallography.
X-ray crystallography is the most powerful technique for studying larger
RNA structures such as the ribosome. The first RNA structure determined by Xray crystallography was tRNAPhe (112). After that, the crystal structures of several
small RNA were determined; however, the requirement of highly ordered crystals
and solving the phase problem took a much longer time to solve in order to
obtain crystal structures of the ribosome. In 1998, Tom Steitz and coworkers
published the first crystal structure of the 50S ribosomes from Haloarcula
marismortui at 9 Å (113). In 2000, Yonath’s, Steitz’s, and Ramakrishnan’s groups
succeeded in determining the 30S or 50S subunit crystal structures at ~ 3 Å
resolutions (69, 114-116). A considerable amount of effort has been made to
obtain high-resolution structures of the ribosome, and for this groundbreaking
work, the 2009 Nobel prize in chemistry was awarded to the three pioneers of
ribosome crystallography, Thomas Steitz, Ada Yonath, and Venketash
Ramakrishanan. Recent success in obtaining 70S ribosome structures in the
presence of various antibiotics and initiation factors at highresolution has greatly
increased our understanding of protein translation and the mechanism of
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antibiotic action (104, 117). It has not only helped to understand ribosome
function, but also increased information about antibiotic binding sites in various
regions (118). For instance, neomycin binding was previously believed to occur
only in the A site of the small subunit; however, a recent crystal structure showed
that it also binds to helix 69 of 23S ribosomal RNA in the large subunit (119).
Despite these successes from X-ray crystallography, detailed structural
information in solution has not been obtained.
NMR spectroscopy is a powerful tool for studying RNA structure in
solution. This method gives high-resolution structural information of RNA in
solution. The RNA folding and interactions with various ligands such as peptides,
antibiotics, and proteins can also be determined by this method (120). However,
the structure of a larger RNA structure such as rRNAs cannot be determined by
this method. The current size limit is ~100 nucleotides (121). Another limitation of
this method is the requirement for a large amount of highly pure sample and
technical expertise.
Several other biophysical methods are used extensively to obtain RNA
structural information. Single-molecule spectroscopy and FRET measurements
have been widely used to understand RNA folding, metal ion effects, and ligand
binding. Notably, it was used to understand the movement of ribosomes at
various stages of translation (106, 122). CD spectroscopy and UV melting are
also helpful in determining the conformations and stabilities of small RNA
constructs (105, 123).
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1.4.2 Probing RNA Structure
Structure probing carried out in solution is a popular method for RNA
structure determination. It is based on the reactivity of RNA molecules with
various chemicals or enzymes that target specific regions or nucleotides of the
RNA (124). These probes can react with RNA in free form or in complex with
ligands. Various chemical and enzymatic probes have been used to obtain RNA
structural information (Figure 1.10). Though there are many advantages of using
chemical and enzymatic probes, they also have their limitations. One advantage
of this method is being able to test the reactivity of individual nucleotides in near
physiological conditions. In addition, the effects of changing pH or salt
concentrations can also be monitored (125). The RNA does not need to be highly
pure, and any size of RNA molecule can be used. Due to their larger size,
enzymes are not accessible to all small-molecule binding sites in the RNA.
Similarly, chemical probes are limited to in vitro studies due to their inability to
penetrate the cell due to size and/or charge. Only limited chemical probes such
as dimethyl sulfate (DMS), Pb2+, and hydroxyl radicals have been utilized to gain
structural information in vivo (108, 124). More recently, in-line probing (126) and
selective 2’-hydroxyl acylation analyzed by primer extension (SHAPE) chemistry
have been developed to determine RNA structure and to locate the binding sites
of small molecules (127). For in-line probing, labeled RNA is incubated for
extended periods of time (e.g., 40 hours) at higher pH (9.0), and spontaneous
cleavage is detected. Small-molecule-binding sites can be observed as protected
sites, whereas the other regions undergo strand scission. In SHAPE chemistry,
reactivity of the 2'-OH groups with a bulky reagent is determined (128). Due to
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Figure 1.10. Sites of RNA modification by base specific chemical probes and sequence
independent probing methods are shown (129).
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steric hindrance of the bulky group on the reagent, reverse transcriptase stop
sites can be detected. The geometrical constraints of the 2'-OH group only allow
the reaction to occur in the flexible regions, such as loop or bulges. Hence, this
method is independent of the nucleotide type and measures the local dynamics
of the nucleotide. This method is also useful for determining small-moleculebinding sites and for acquiring information about secondary structure of RNA
(129).

1.4.2.1 Enzymatic probing
RNases are structure or nucleotide specific and widely used for probing
RNA structure (130). The commonly used nucleases with their specificity are
listed in Table1.2. RNase V1 is specific to the double-stranded region (131). This
ribonuclease cleaves in a sequence-independent manner, but requires at least
two residues on either side of the cleavage site to be double stranded or stacked.
Nucleotide-specific enzymes cleave after certain nucleotides. RNases A, T1, and
T2 are the most common enzymes used to determine single-stranded regions
(132). RNase T1 cleaves on the 3’ side of guanosine, whereas RNase A cuts
single-stranded UpN and CpN containing sequences. RNase T2 cleaves all
phosphodiester bonds in a single-stranded region, irrespective of the sequences
(124, 132). RNases are useful for obtaining structural information and ligand
binding sites in vitro. Unfortunately, RNases are bulky molecules and susceptible
to steric hindrance, so in the folded RNA structure, the accessibility information
obtained from enzymatic probing is less informative.
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Table 1.2. Structure-specific enzymes for RNA structure probing.

Nuclease

Specificity

Detection method

RNase V1

Paired or stacked
nucleotides

A and B

(131)

Nuclease S1

Unpaired nucleotides

A and B

(108)

RNase T1

Unpaired G

A and B

(133)

RNase U2

Unpaired A>G>>C>U

A and B

(134)

RNase T2

Unpaired A>C, U, G

A and B

(135)

Mung bean
nuclease

Single-strand specific

A and B

(136)

RNase H

RNA only from DNA-RNA
hybrids

A and B

(137)

A: detection of cleavage on end-labeled RNA and B: detection by primer extension
method.
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1.4.2.2

Chemical probing

Chemical reagents are smaller in comparision to enzymes and able to
react with nucleotides of the RNA molecule (125). Chemical probes can react
with nucleotide bases or the backbone of RNA. Their reactivity with nucleotide
bases or the backbone is directly influenced by interactions present in the
molecule. Base pairing or interactions with ligands strongly reduce reactivity
towards the chemical probe. Chemical probes were developed based on specific
criteria such as single-hit reactions per molecule of RNA, small size, and easy
detection. Depending on the size of the RNA, identification of strand scission or
modification sites is achieved by two different methods. For small RNA
constructs, the RNA is directly radiolabeled on either the 3' or 5' end, and strand
scission can be monitored by gel electrophoresis. This direct detection method
works best for short RNAs containing less than 200 nucleotides (108). For larger
RNAs, the strand scission or modification is detected by using primer extension.
Reverse transcriptase shows pauses or stops before the 3' side of modified or
cleaved nucleotides. The most commonly used chemical probes with their
respective modification or cleavage sites and the methods for their detection are
listed in Table 1.3.
Chemical probes are basically of two types on the basis of their target
sites; base-specific and backbone (ribose-phosphate) specific. The base-specific
probes are the most widely used to gain information about the secondary
structure of RNA. Dimethyl sulfate (DMS) methylates the N1 position of adenine,
and N3 of cytosine, which are not involved in Watson-Crick base pairing.
Similarly, kethoxal reacts with N1 and N2 of guanine, while CMCT (1-cyclohexyl
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Table 1.3. Structure-specific chemical probes for RNA.

Probing agents

DMS

Specificity
A (N1), C (N3),
G (N7)

Nucleotide

Detection method

A, B, C
C

DEPC

A(N7)

agents

Kethoxal

G (N1-N2)

(107, 124, 138)

CMCT

G (N1), U(N3)

Hydrazine

U>>C

Fe(EDTA)2-

Solvent-exposed
backbone (C1', C4')

A, B

Cu(phen)2+

Accessible SS
regions

A, B

Rh(DIP)33+

SS solvent exposed
G & Ψ, 3' side of GU
wobble pairs

A, B

CoCl2

SS solventaccessible G

A, B

modifying

Radical
generators/
metal
complexes
(139-141)

Synchrotron X-rays (142)

Solvent-exposed
backbone (C1', C4')

A, B, C
B, D
B
A, B. C

A, B, C

Backbone
modifying

Ethylnitrosourea

Phosphate

A, B

agent (124)
A: detection of cleavage on end-labeled RNA; B: detection by primer extension; C:
chemical treatment is necessary for strand scission prior to the detection; D: RNaseT1
hydrolysis can be used after modification; SS: single stranded (108, 124-125).
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-(2-morpholinoethyl)carbodiimide metho-p-toluene sulfonate) modifies N3 of
uridine (138, 143). Based on the reactivity of these chemical probes, the folded
structure of RNA can be determined. Since the modification occurs in the
Watson-Crick base pair regions, these sites of modification can be detected by
primer extension directly. However, DMS and diethyl pyrocarbonate (DEPC) can
also methylate the N7 position of guanine and adenine, respectively. To detect
these modifications, aniline treatment and strand scission are required (124).
These chemical probes are not only used for smaller RNA structures, but also
larger RNA structures such as 16S and 23S rRNA. Danesh Moazad and Harry
Noller have mapped nucleotide reactivity in free rRNA, in intact subunits, and
70S ribosomes (144-145). They have not only determined the higher-order
structure of rRNA, but also explored protected and exposed nucleotides after
ribosome assembly (145-147).
Another class of probes attacks the ribose-phosphate backbone, resulting
in strand scission. This type of chemical probe generates free radicals from a
reaction between the reagents, such as the Fe•EDTA complex and H2O2 (148).
The hydroxyl radical generated by the Fe•EDTA attacks the C1' and C4'
hydrogens of the ribose sugar, which leads to strand scission. More recently,
synchrotron X-ray beams were used to generate hydroxyl radicals in the
millisecond range. This time-resolved probing method is very useful in
determining the larger RNA folding pathway (149-150). Another reagent,
ethylnitrosourea, ethylates phosphates, which become unstable and easily
cleaved with mild alkaline treatment (151).
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1.4.2.3

Probing RNA structure in vivo

Structural features of RNA are significant for biological function. The use
of X-ray crystallography, NMR spectroscopy, and other biochemical and
biophysical approaches have enhanced the ability for determining RNA structure.
Since the folding of RNA might be different in a more complex environment such
as living cells, it is highly important to study RNA structures in vivo. Methods and
probes that are useful for studying RNA structure in vivo are limited. The most
commonly used are DMS, kethoxal, and lead (II) (152-153). DMS can cross the
cell wall and membrane efficiently by diffusion, but other reagents need
permeabilization of the cells.
Chemical and enzymatic probes are very useful to test the reactivity of
individual nucleotides and predict their accessibility, as well as function in RNA
structures. Several chemical and enzymatic probes have been used to probe the
RNA structure, but most of them are limited for in vitro study. Another limitation is
that enzymes can induce conformational rearrangements, which generates
possible new target sites and makes the results harder to interpret. In addition,
these chemical and enzymatic probes cannot be utilized to monitor the kinetics of
the reaction. Hence, a chemical probe that can be used for probing and
monitoring kinetics would be very useful. The aquated platinum complex to be
discussed is positively charged and can be utilized as a model to understand the
kinetics of charged small molecules. Further, it has already been shown to have
potential for probing the ribosome structure in vitro and in vivo. Another
advantage of cisplatin is that its size and charge can be altered easily, and hence
would be useful to gain more information of RNA structure.
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1.5

Cisplatin
Cisplatin, cis-diamminedichloridoplatinum (II), is an anticancer drug used

to treat various cancers such as testicular, head and neck, and cervical (154156). The cure rate is over 90% in testicular cancer when tumors are diagnosed
early (157). Despite its success, cisplatin is only active against limited cancers
and causes several side effects such as nephrotoxicity, neurotoxicity, and
hearing loss (158-159). The biological activity of cisplatin was first discovered in
the 1960 by Rosenberg and co-workers at Michigan State University (160). While
testing the effects of electric current in E. coli, they observed inhibition of cell
growth. They observed that cells were unable to divide and the morphology
changed. Cells were elongated 300 times longer than the normal cells (160). It
was later found that this effect was not caused by the electric current, but rather
the production of the cisplatin from platinum electrodes. This result led
Rosenberg to test cisplatin in several mice with tumors, and subsequently
anticancer activity was observed (161). After the successful treatment of several
tumors in clinical trials, cisplatin was finally approved by the FDA in 1978.

1.5.1

Biological targets of cisplatin
Cisplatin can enter the cell by passive diffusion or using by copper

transporters (162-163). The low chloride concentration in the cell facilitates the
exchange of a chlorido ligand with water to form the aquated species. The
resulting species [PtCl(NH3)2(H2O)]+ is more reactive and subsequently attacks
the N7 of purine bases. The primary target of cisplatin is found to be DNA, but it
can also attack RNA, proteins, and sulfur-containing biomolecules (156, 163).
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Cisplatin preferentially binds to G-rich sequences in DNA. The number of
platinum molecules bound to these macromolecules has been determined in
HeLa cells with a colony forming assay (164). This result showed that one DNA
contained 22 platinum atoms, while only one platinum atom was found per
mRNA. Similarly, one platinum atom was observed per 30 ribosomes and one
per 1500 tRNA. Proteins contained a fewer number of platinum atoms; out of
1500 protein molecules, only one equivalent cisplatin was observed. Another
study was carried out with 195mPt-radiolabeled cisplatin to determine the
number of platinum atoms that would bind to macromolecules in Hela cells (165).
This study showed similar results, which indicated DNA as the main cellular
target. These early studies showed that the most important cellular target of
cisplatin was DNA, while its effects on RNA and other macromolecules was
mostly overlooked. The binding of cisplatin to DNA has been discussed
extensively in the literature (156, 163, 165-166), but only a handful of
publications focus on RNA as a target.
Recent studies showed that RNA is a competitive target for cisplatin under
similar conditions as DNA reactions (167-169). When DNA and RNA molecules
with similar structures and sizes were compared, RNA was found to be the
kinetically preferred target over DNA (167). In addition, RNA showed a more
pronounced salt dependence, indicating that electrostatic interactions are
important (167). A similar result was published by DeRose and coworkers, in
which the kinetic preference for cisplatin in the U2/U6 RNA compared well to its
DNA counterpart (170). They have compared cisplatin binding to RNA with an
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internal loop, double-stranded RNA, and a corresponding looped DNA. Among
these constructs, the RNA with an internal loop had the highest reactivity, while
DNA had the lowest. Another study was done with tRNA by Elmorth and
coworkers (168). Mapping of the binding sites in tRNA and its corresponding
microhelix revealed that cisplatin forms cross-links in a common site on the
RNAs, despite the difference in their sizes (168).

1.5.2 Types of platinum-DNA adducts and their effects
The identification of major cisplatin cross-links formed with DNA was
carried out by digestion of cisplatin-treated salmon sperm DNA (171). After
enzymatic digestion, the products were separated by a chromatographic
technique and analyzed by NMR spectroscopy (172). The most common crosslinks were the 1,2-intrastrand adducts with purine bases, mostly the 1,2intrastrand d(GpG) and d(ApG) adducts which constitute ~65% and ~25% of all
adducts respectively. Less common was the 1,3-intrastrand d(GpXpG) adduct
(Figure 1.11). Cisplatin also formed a small amount of interstrand and
monofunctional adducts with guanine (171-172).
The formation of cisplatin DNA cross-links leads to distortion of the DNA
structure. Previous studies showed that cisplatin lesions cause bending,
unwinding, and destabilization of the DNA double helix (173-174). The formation
of cisplatin cross-links also inhibits DNA and RNA polymerases for replication
and transcription processes (163). Bifunctional adducts inhibit polymerases more
effectively than monofunctional adducts (175-177). In addition, the bending of
DNA serves as a recognition site for a number of cellular proteins, such as high
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mobility group proteins (HMG), histones, and transcriptional proteins (178-179).
The binding of these proteins is believed to shield the platinum adducts from
repair so that when the DNA repair machinery works to fix the cross-links, failed
attempts activate apoptosis and cell death (166).

Figure 1.11. The types of cisplatin DNA cross-links and their corresponding ratios are
shown.
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1.5.3 Cisplatin analogues
Compared to cisplatin, its trans isomer, trans-DDP, is clinically ineffective.
This might be due to its inability to form adducts similar to that of cisplatin.
Although both of these isomers form bifunctional adducts through the N7 position
of purine bases, trans-DDP is unable to form 1,2-intrastrand cross-links due to its
stereochemistry. More than 3000 analogues of cisplatin have been synthesized
to overcome cisplatin resistance (180); however, only less than 30 compounds
have entered clinical trials and only one has been approved by the FDA (166).
Hitherto, only four platinum compounds are listed as marketed drugs, namely,
cisplatin, carboplatin, oxaliplatin, and nedaplatin (Figure 1.12) (166, 181). Among
these, carboplatin is less toxic than cisplatin, but has the same spectrum of
antitumor activity (182). Oxaliplatin is the only platinum compound that shows
acitivity against cisplatin-resistant colorectal cancers (181). Most of the useful
antitumor analogues are mostly associated with the property of labile group.
Complexes with highly labile groups are very toxic and cannot be used as drugs.
Those types of complexes react with almost all types of nucleophiles available in
the cell. In contrast, strongly bound ligands produce kinetically inactive
complexes (183). The second generation platinum drug, carboplatin, has lower
reactivity due to the weaker labile carboxylate group. This effect causes a slower
rate of conversion of carboplatin to aquated reactive species. Due to slower
reactivity, higher doses can be tolerated and give fewer side effects. Carboplatin
has been used for ovarian cancer, but shows cross resistance with cisplatin (166,
184). Another analogue, oxaliplatin, is most effective against colon cancer (163).
In this compound, both the ammine ligands and chlorido groups are altered from
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those of cisplatin (166). Most recently, water-soluble platinum complexes and
complexes that can be used orally, such as JM216, have been synthesized (166,
185).

Figure 1.12. Cisplatin and its analogues are shown.

Several amino-acid and peptide-conjugated cisplatin analogues have
been synthesized and tested against various tumor cell lines (Figure 1.13) (186187). Modifications include platinum complexes with charged, neutral, or
hydrophobic amino acids coordinated to the platinum (188-189). Those
modifications increase the charge or hydrophobicity of the complex, and could
potentially alter the binding interactions with the target. Similarly, peptidetethered platinum conjugates were also synthesized and their interactions with
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Figure 1.13. Structures of platinum(II) amino acid complexes are shown.

DNA were studied; however, additional functionalities did not increase their
reactivity (186, 190). The uncharged compounds have lower reactivity compared
to cisplatin and positively charged compounds have higher reactivity than the
negatively charged compounds, possibly due to electrostatic interactions (186).
Although the overall reactivity of the amino-acid platinum complexes was lower
than cisplatin in DNA, their interactions with RNA have not been discussed in the
literature, to the best of my knowledge.

1.6

Objective of Research
With the continually expanding antibiotic resistance of pathogens it has

been a challenge for researchers to design and develop new antibiotics. Out of
the various drug target sites, the ribosome is an important target to which
different classes of antibiotics bind at its key functional regions, such as the
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decoding center, peptidyltransferase center, and peptide exit tunnel. Recent
crystal structures have revealed a number of antibiotic-binding sites in the
ribosome, and it is interesting to note that many of these sites are overlapping.
Now, it is important to develop novel target sites and to design new drugs that
can help to solve the ever-growing problem of resistance. To achieve this goal,
the ideal target sites should not only be functionally important, but also
accessible to various small molecules. A number of chemical and enzymatic
probes have been used to gain structural information and to understand solvent
accessibility of the ribosome, but most of them are limited to in vitro studies or
they are difficult to detect in solution. Cisplatin has advantages due to its stable
coordination chemistry, which makes its detection easier; thus, more information
about structural accessibility can be gained. Further, the platinum complexes can
be modified with various ligands to alter the charge and size. A number of
antibiotics bind to the ribosome by electrostatic interactions and it is difficult to
monitor the kinetics. Cisplatin and its charged analogues can be utilized as a
model to understand how charged small molecules such as neomycin find their
target sites out of the numerous possible sites on the ribosome.
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CHAPTER 2
Binding Studies and Adduct Characterization of Cisplatin in 16S
Ribosomal RNA
2.1

Abstract
DNA is a well-validated target of cisplatin and various mechanisms leading

to the anticancer activity have been extensively studied. In comparison to DNA,
much less is known regarding the extent to which cisplatin interacts with cellular
RNAs and whether that influences the activity and toxicity of the drug. Recently,
cisplatin binding to small RNA constructs and tRNA has been studied. In this
chapter, the binding sites of cisplatin on 16S rRNA, which were mapped by the
primer extension method, are discussed. Most of the consecutive guanosines in
free 16S rRNA were found to be reactive with cisplatin. In addition, the number,
as well as types, of adducts formed with cisplatin on 16S rRNA were also
characterized.

2.2

Introduction
Cis-diamminodichloridoplatinum(II), or cisplatin, is an antitumor drug that

has been utilized effectively in the treatment of several types of cancers, such as
testicular, breast, ovarian, lung, and head and neck (156, 163, 166). After the
discovery of its antitumor activity, much research has focused on understanding
the mode of action of this compound (160-161). The formation of several types of
stable adducts with nucleic acids, such as 1,2-intrastrand and 1,3-intrastrand
along with a lower number of interstrand, through coordination to the N7 position
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of purines, is believed to contribute to its antitumor activity (172, 191). The
formation of these adducts with DNA causes structural changes, which block
replication and transcription processes (163). An X-ray crystal structure revealed
that the 1,2-intrastrand adduct induces a bend in a DNA duplex by 35-40º and
unwinds the DNA by ~25º; however, solution structures by NMR showed 60-70º
bend angles (Figure 2.1) (192-194). Cellular proteins recognize these DNA
lesions and undergo a series of events, eventually leading to cell death (163,
166, 195). The reaction of cisplatin with DNA has been studied and discussed
extensively in the literature (163, 166, 172, 191, 196-197); however, the effects of
cisplatin on RNA function are poorly understood. Despite RNA’s chemical
similarity to DNA and its greatly increased role in various cellular processes (198199), very little is known about cisplatin’s effects on cellular processes involving
RNA.
Previous reports suggested that the amount of cisplatin reacting with RNA
is much less than with DNA (165, 200), which might be the reason why RNA has
been overlooked as a target of cisplatin. However, there are several pieces of
evidence that show RNA is a competitive target for cisplatin. Previously, cisplatin
was found to cause disruption of translation and splicing in cell extracts (201203). This fact is further supported by recent in vitro studies showing disruptions
in the activity of various enzymes (170, 204), so it can be expected that the
binding of cisplatin to RNA may also contribute to the drug’s anticancer effect. In
another study, when similar structures and sizes of DNA and RNA hairpins were
compared for cisplatin reaction, RNA was found to be the kinetically preferred
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target (167, 205). A similar result was reported by DeRose and coworkers in
U2/U6 RNA; they have shown that platination of the U2/U6 RNA a has higher
kinetic preference for RNA than the corresponding DNA construct (169).

Figure 2.1. X-Ray crystal structures of double-stranded DNA containing the cisplatin
adduct are shown: A) cisplatin 1,2-d(GpG) intrastrand cross-link (3LPV) (193) and B)
cisplatin 1,3-d(GpTpG) intrastrand cross-link (1DA4) (206).
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Cisplatin binds DNA in a structure specific manner and forms cross-links
at specific sites despite the sizes of the nucleic acids (168, 207). Elmroth and coworkers studied the rate of platination of 17-nucelotide DNA sequences with
guanosines at different locations (﴾TnGT16-n﴿ DNA constructs) (207). The rate of
adduct formation was found to be the highest when guanosine was in the middle
of the sequence. In addition, they compared cisplatin reactions with tRNAAla and
a corresponding micro-helix, which revealed similar platination sites at the G○U
wobble pair in an acceptor stem of tRNA, despite the different RNA sizes (168).
Furthermore, cisplatin binding to tRNAPhe observed in a crystal structure showed
cross-links at certain GG and AG sites that caused a distortion in the tRNA
structure (208-209). Hence, targeting RNAs such as tRNA, mRNA, and rRNA
may provide another potential pathway for cisplatin and related drugs’
mechanism of action (210). Cisplatin effects in model RNA systems have been
studied to some extent; however, the mechanistic details and binding sites in
larger RNA have yet to be discovered.
Although the primary structure of DNA and RNA are very similar, larger
RNAs such as ribosomal RNAs have a tendency to fold into complex threedimensional structures (40). The folding of RNA creates local microenvironments
with various properties in terms of solvent accessibility and metal coordination.
Various metal complexes have been used to identify structural motifs or
mismatches in DNA and RNA structure (139-140, 211-212). Metal complexes are
capable of specific interactions with target sites in nucleic acids. Rhodium
complexes such as Rh(byp)2(chrysi)3+ bind with high specificity and affinity to
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single base mismatches (213). Similarly, Rh(DIP)33+ induces a strand scission in
RNA near the G○U mismatches, as well as exposed Gs (211). Cisplatin has
been found to react with G-rich sequences in DNA and small RNA constructs.
Hence, metal complexes were found to have some specific interaction with
nucleic acids. The study of cisplatin binding to the ribosome may increase our
understanding of its interactions with much larger RNA structures.
The number and types of cross-links formed with DNA by cisplatin and
various analogues have been well characterized (171-172). Two research
groups, Eastman and Fichtinger-Schepman et al., have determined various
adducts formed with DNA (171-172, 191). Both of these research groups
observed intrastrand bifunctional cross-links as the major adducts along with a
small amount of monofunctional adducts with guanosine (171). In the context of
RNA, the number of cisplatin binding sites and possible types of adducts have
not been well documented.
The overall goal of this chapter is to find the cisplatin binding sites in 16S
rRNA and determine the types of adducts formed by using various methods
(Figure 2.2). The results from these experiments will be significant to understand
the mechanism of cisplatin action on large folded RNA structures. Due to
structural differences, it was expected that the binding sites and types of adducts
formed with RNA might be different than DNA. In this study, mapping of the
cisplatin binding sites in 16S rRNA, as well as characterization of the cisplatin
adducts was performed.
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Figure 2.2. An overview of the cisplatin binding study in 16S rRNA is shown. Cisplatin, the
corresponding monoaquated species, tertiary structure of 16S rRNA, and various methods
used in this study are indicated.

2.3

Materials and Methods

2.3.1

Chemicals, solutions, and DNA
[5'-32P-γ]ATP was purchased from Perkin-Elmer Life Sciences, Inc.

(Waltham, MA), and T4 polynucleotide kinase was obtained from New England
Biolabs (Ipswich, MA). RNaseT1 and P1 nuclease were purchased from Sigma
Chemicals. A reverse transcriptase kit (Improm_IITM Reverse Transcriptase) was
purchased from Promega (Madison, WI). The remaining chemicals for buffers,
and reagents such as DTT (dithiothreitol), EDTA (ethylenediaminetetraacetic
acid), DMF (N, N-dimethyl formamide) were obtained from Sigma Chemicals or
Fisher. RNase-free, distilled, deionized water (ddH2O) was used for all
experiments.
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Cisplatin, cis-diamminedichloridoplatinum(II), was purchased from Alfa
+

Aesar (MA, USA). The complexes cis-[PtCl(NH3)2X]+/0 or cis-[Pt(NH3)2X2]2 /0, in
which X was H2O, DMF, or NO3-, were prepared by addition of 0.98 or 1.96
equivalents of AgNO3 to a DMF solution of cis-[PtCl2(NH3)2], respectively. The
reaction mixture was vortexed in the dark for 12 hours, the AgCl precipitate was
removed by centrifugation, and the supernatant containing platinum complex was
recovered. Platinum-DMF complex stock solutions were stored at -20 °C up to 1
week and diluted as required just prior to use.
Single-stranded DNA primers were purchased from Sigma Genosys and
purified

by

using

polyacrylamide

gel

electrophoresis

(20%,

19:1

acrylamide:bisacrylamide, 7 M urea ) in 1X TBE (90 mM Tris·HCl, 90 mM boric
acid, 2.5 mM EDTA, pH 8.3) followed by electroelution in 0.5X TBE in an Amicon
CentrilutorTM and desalted. Aqueous solutions of DNA were kept frozen at -20 °C
and concentrations were determined spectrophotometrically at 260 nm.
Sequences of the DNA primers were named according to the position of the
transcribed nucleotides, and are as follows:
1) 5'-CAC TCG TCA GCA AAG AAG-3 (p_86), 2) 5'-GCG ACG TTA TGC GGT
AT-3' (p_171), 3) 5'-GTT ACC CCA CCT ACT AGC T-3 (p_245), 4) 5'-AGT CTG
GAC CGT GTC TC-3' (p_323), 5) 5'-CCC GCT GAA AGT ACT TT-3 6) (p_431),
5'-GTG CTT CTT CTG CGG GTA-3' (p_485), 7) 5′-CGC TTT AGG CCC AGT
AAT-3 (p_561), 8) 5′-GCC AGT ATC AGA TGC AGT-3 (p_631), 9) 5′-CTA CGC
ATT TCA CCG CT-3′ (p_686), 10) 5'-CGC ACC TGA GCG TCA GTC T-3'
(p_746), 11) 5′-ACC AAG TCG ACA TCG TTT-3′ (p_813), 12) 5′-CCG TCA ATT
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CAT TTG AGT TT-3′ (p_906), 13) 5′-GTC AAG ACC AGG TAA GGT-3′ (p_982),
14) 5′ GAG CTG ACG ACA GCC AT-3′ (p_1054)) 15) 5′-GCA ACA AAG GAT
AAG GGT-3 (p_1110), 16) 5′-TCG TAA GGG CCA TGA TG -3′(p_1199), 17) 5′GCG AGG TCG CTT GTC TTT-3′ (p_1251), 18) 5′-CTC CAA TCC GGA CTA
CG-3 (p_1296), 19) 5′-GAA CGT ATT CAC CGT GGC-3 (p_1365), 20) 5'-GTT
AAGCTA CCT ACT TCT-3′ (P_1430), 21) 5'-TAC CTT GTT ACG ACT TC-3'
(p_1490).
The primer hybridization sites on the secondary structure of 16S rRNA are
shown in Figure 2.3, with primer numbers 1 to 21.

2.3.2

Isolation of 16S rRNA
The 70S ribosomes and 30S subunits were isolated from E. coli DH5

strain by the sucrose gradient method (145, 214). E. coli was grown to 0.6 OD
and cooled on ice for 20 min followed by centrifugation at 7,000 rpm for 15 min to
pellet the cells. The pellet was resuspended in buffer A (50 mM Tris·HCl, 100
mM ammonium chloride, 10 mM MgCl2 and 1 mM EDTA). The cells were lysed
by using a French Press at 1800 psi. In the lysate, 5 U of DNase I was added
and incubated on ice for 15min. The lysate was centrifuged at 15,000 rpm for 20
min to remove the cellular debris and about 2/3 of the supernatant was
transferred to a new tube. After a second centrifugation, the supernatant was
transferred to a new tube and the ammonium chloride concentration was raised
to 200 mM. To pellet the ribosome, centrifugation was carried out in an
ultracentrifuge at 42,000 rpm for 4 hrs. The supernatant was discarded and the
pellet was washed with buffer B (50 mM Tris·HCl, 100 mM ammonium chloride,

50

Figure 2.3. Secondary structure map of 16S rRNA with primer hybridization sites with
primer numbers (1 to 21) is shown.
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10 mM MgCl2). The 70S ribosome pellet was resuspended in buffer B by shaking
overnight at 4 ºC. The dissolved ribosome was taken carefully and its
concentration was measured spectrophotometrically. To get pure 70S ribosomes,
50S subunits and 30S subunits, the crude ribosomes were layered in a 10% to
30% sucrose gradient in buffer B with 5 mM MgCl2 and centrifuged in a swinging
bucket rotor at 18,000 rpm for 16 hrs. Fractions corresponding to the 70S
ribosomes, 50S subunits, and 30S subunits were pooled and the Mg2+
concentration was again raised to 10 mM. Sucrose was removed by
centrifugation in an ultracentrifuge at 42,000 rpm for 18 hrs and the pellet was
dissolved in buffer E (10 mM Tris·HCl, 60 mM ammonium chloride, 10 mM
MgCl2). Naked 16S rRNA was isolated from 30S subunits by three extractions
with phenol and two with chloroform in the presence of 6 mM EDTA. The 16S
rRNA was precipitated by addition of 0.1 volumes of 3 M sodium acetate, pH 5.3,
and 2.5 volumes of ethanol. The isolated 16S rRNA was renatured in 20 mM
Tris·HCl (pH 7.5), 25 mM NaCl, and 10 mM MgCl2 by heating to 90 °C for 2 min
and slowly cooling to room temperature.

2.3.3

Platination reactions
The platination reactions with naked 16S rRNA were performed with

monoaquated cisplatin. Prior to platination, the 16S rRNA was renatured as
stated above. Platination was carried out in 20 mM sodium phosphate buffer, pH
6.5, 10 mM MgCl2 and 10 mM NaCl (buffer P) (215). Alternatively, 20 mM
HEPES, pH 6.5, 10 mM MgSO4 and 10 mM Na2SO4 (buffer H) was used, which
had a lower chloride concentration. The 16S rRNA was incubated at 37 °C with
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aquated complex in 1:150, 1:75, and 1:30 ratios of metal complex to nucleotides
(16S rRNA to metal complex is 1:10, 1:20, and 1:50). The reactions were
quenched with 2 M NaCl followed by immediately freezing. A salt dependence
study was carried out with the 1:75 ratio of complex to nucleotides in the same
buffer (buffer H) with increasing concentration of Na+ using NaClO4.

2.3.4 Primer labeling and primer extension
Primers were labeled at the 5' end in T4 PNK buffer (50 mM Tris·HCl, pH
7.6, 10 mM MgCl2, 5 mM DTT, 0.1 mM spermidine, 0.1 mM EDTA) with 10 µCi [γ
32
- P]

–ATP and 10 units T4 polynucleotide kinase in a volume of 50 µl at 37 °C.

RNA was ethanol precipitated after the reaction. The labeled primer was used for
primer extension on the free 16S rRNA (216). Primer extension was carried out
with 2 pmol of 16S rRNA after reaction with cisplatin. Next, 2 μl of the appropriate
5'-end-labeled primer (200,000 cpm) and 2 μl of 1 pmol/μl 16S rRNA were mixed
with 6 μl ddH2O and heated to 90 °C and then slowly cooled to room temperature
for hybridization. The extension mix was prepared by mixing 4 μl of reverse
transcriptase buffer (Promega), 2.4 μl of 25 mM MgCl2 and 1 μl of 10 mM dNTPs
(10 mM each dATP, dCTP, dGTP, and dTTP), 5.6 μl H2O and 1 μl reverse
transcriptase (Promega). For sequencing, 1 μl of the 10 mM dNTP mix and 1 μl
of the appropriate 1 mM ddNTP were used. Unmodified RNA (no cisplatin
treatment) was used as a template for sequencing and for control lanes to
monitor artifacts of reverse transcriptase. Extension of the primer was carried out
at 42 °C for one hour and terminated by heating at 80 °C for 15 minutes. To each
sample, 2 μl of loading buffer (80% formamide, 1X TBE, 0.02% bromophenol
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blue, and 0.02% xylene cyanol) was added and the products were denatured by
heating to 95 °C for 2 min followed by rapid cooling on ice. To the sequencing gel
(0.4 mm thick, 8% polyacrylamide, acrylamide:bisacrylamide 19:1, 1X TBE, 7 M
urea), 60,000 cpm per sample was loaded. The gel was run at 1500 volts for
approximately 2 hours until the bromophenol blue migrated off the gel. The
products were identified by imaging on a Molecular Dynamics Phosphorimager
and Image QuantTM Software.
The gels were quantified using Image Quant software. The intensity was
normalized by calculating the percentage intensity at the corresponding stop with
respect to intensity of the whole lane. More than 1% intensity at the
corresponding stops were considered as strong hits, 0.5 to 1.0% were moderate
hits, and less than 0.5% were considered as weak stops. The reaction ratio
cisplatin:nucleotide (1:75) and control were used for quantification.

2.3.5 High performance liquid charomatography
HPLC was carried out with a Waters system equipped with a C18
Discovery column (250 x 4.6 mm, 0.5 µm). Separation was carried out by using
buffer A (40 mM ammonium acetate) and B (40% acetonitrile) with a linear
gradient in which the ratio of A to B changed from 95:5 to 70:30 over 30 minutes
at a constant flow of 1 ml/min. The retention times of the standard nucleosides
were confirmed by injection of known standard nucleosides. Control and
platinated 16S rRNAs were digested with nuclease P1 to convert to nucleotides,
and calf intestinal phosphatase (CIP) was used to remove phosphates and give
free nucleosides. Nuclease P1 digestion was carried out in 50 µl of digestion
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buffer (1 mM ZnCl2, 20 mM sodium acetate, pH 5.3), for both the control and the
platinated 16S rRNAs with 10 µl (10 U) of nuclease P1 at 37 ºC overnight. The
enzyme was then deactivated by heating at 75 ºC for 15 min. Five µl of 1.5 M
Tris·HCl, pH 8.8, and 1 µl (10 U) of CIP was added to each sample, which were
incubated for 4 hrs at 37 ºC. After 4 hrs of incubation, samples were again
heated at 75 ºC for 15 min, vortexed, and centrifuged at 12,000 rpm for 5 min.
Finally, samples were filtered through YM-3 microcon filters before injection into
the HPLC or LC-MS.
Samples were analyzed by HPLC and peaks areas were normalized to
account for the differences in extinction coefficients at 260 nm (C = 9,100 M-1 cm1

, U= 10,100 M-1 cm-1, G= 13,600 M-1 cm-1, A= 14,900 M-1 cm-1) (217) and then

peak ratios were calculated relative to the cytidine peak.

2.3.6 Liquid chromatography mass sectrometry
LC-MS (Liquid Chromatography Mass Spectrometry) is a powerful
technique to separate and analyze complex mixtures with high sensitivity. LC-MS
was carried out on an AQUITY Ultra Performance LC chromatography (UPLC)
system (Waters Corporation, MA USA) equipped with an HSST3 C18 column
(2.1 X 100 mm 1.8 µm). The column was maintained at 50 ºC and elution was
carried out with a linear gradient of acetonitrile and 100 mM ammonium acetate,
pH 6.0. The gradient was run for 3 min with a flow rate 700 µl/min, starting at
100% ammonium acetate and decreasing to 60% over the course of the gradient.
The column eluent was analyzed by directing it to the mass spectrometer. Mass
spectra were collected in the positive ion mode. The percentage of adducts were
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calculated by normalizing the area with extinction coefficients followed by relative
ratios of adduct present in sum of adducts.

2.4

Results

2.4.1 Mapping platination sites in 16S rRNA
Cisplatin, after aquation, was used to probe 16S rRNA. The monoaquated
complex was employed because it is cationic and has ideal reaction kinetics
compared to the slowly reacting cisplatin. The binding sites of monoaquated
cisplatin were mapped on free 16S rRNA by primer extension. In order to map
the binding sites, 16S rRNA was first isolated from E. coli, renatured, and then
incubated with monoaquated cisplatin (1:10, 1:20 and 1:50 molar ratios of 16S
rRNA:cisplatin; or 1:150, 1:75, and 1:30 molar ratios of cisplatin:nucleotides) in
20 mM HEPES buffer, pH 6.5, at 37 °C in the dark for 5 hrs. The binding sites of
cisplatin were observed by reverse transcriptase pauses or stop one nucleotide
prior to the coordination site. A set of 20 DNA primers were used, covering from
nucleotides 1 to 1513 of the 16S rRNA. The 5'-32P-end-labeled primers were
hybridized with the RNA and extended with reverse transcriptase in the presence
of dNTPs. The transcripts were separated by 8% denaturing polyacrylamide gels.
Coordination sites of cisplatin were then determined by comparing with dideoxy
sequencing lanes on the same gel. Bands on the gel arising due to nicks in the
RNA or strong secondary structures were distinguished from the cisplatin binding
sites by comparing with a control treated in a similar manner, but lacking
cisplatin.
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The magnitudes of the reactivity were classified by the intensities of the
bands on the autoradiograms. The intensities of bands could be measured up to
approximately 100 nucleotides from the transcription start site. The reactive
nucleotides were mostly found to be consecutive Gs, mismatched or present in
loop regions. Since cisplatin was known to prefer Gs in DNA targets, it was not
surprising that major hits on the 16S rRNA were consecutive Gs. There are 488
guanosines in 16S rRNA and 103 sites with consecutive Gs, some of which
include two or more guanosines (consecutive Gs are considered as one reactive
site). Out of these 103 sites, strong reactivity was observed in 56 sites, 29 were
moderate hits, and 3 showed very weak hits. In addition, several nonconsecutive
Gs also showed strong or moderate reactivity. There were 11 consecutive Gs
that were not reactive with cisplatin (excluding 4 sites with consecutive Gs in
helix 45, which were not probed). Figures 2.4 to 2.6 show representative
autoradiograms of the cisplatin probing experiments with free 16S rRNA.
Additional gels are shown in the Appendix. The overall summary of results of
cisplatin binding to naked 16S rRNA in Figure 2.7 show a secondary structure
model of 16S rRNA with reactive sites in red (strong hits) and green (moderate
hits).
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Figure 2.4. Probing results of 16S rRNA at the 5' domain with primers 245 and 561 are
shown. (A) The autoradiogram shows the reverse transcriptase pauses or stops by using
primer 245. (B) The autoradiogram shows the reverse transcriptase pauses or stops by
using primer 561. In both gels, C, U, A, G represent the sequencing lanes, 0 represents the
control, and remaining 3 lanes are 16S rRNA treated with increasing concentrations of
monoaquated cisplatin (cisplatin:nucleotide is 1:150, 1:75, and 1:30). The strong and
moderate hits are indicated with arrows and corresponding nucleotides numbers (▲
﴾strong hits﴿ and Δ ﴾moderate hits﴿).
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Figure 2.5. Probing results of 16S rRNA at the central domain with primers 825 and 910 are
shown. (A) The autoradiogram shows the reverse transcriptase pauses or stops by using
primer 825. (B) The autoradiogram shows the reverse transcriptase pauses or stops by
using primer 910. In both gels, C, U, A, G represent the sequencing lanes, 0 represents the
control, and remaining 3 lanes are 16S rRNA treated with increasing concentrations of
monoaquated cisplatin (cisplatin:nucleotide is 1:150, 1:75, and 1:30). The strong and
moderate hits are indicated with arrows and corresponding nucleotides numbers (▲
﴾strong hits﴿ and Δ ﴾moderate hits﴿).
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Figure 2.6. Probing results of 16S rRNA at the 3' domain with primers 1110 and 1435 are
shown. (A) The autoradiogram shows the reverse transcriptase pauses or stops by using
primer 1110. (B) The autoradiogram shows the reverse transcriptase pauses or stops by
using primer 1435. In both gels, C, U, A, G represent the sequencing lanes, 0 represents
the control, and remaining 3 lanes are 16S rRNA treated with increasing concentrations of
monoaquated cisplatin (cisplatin:nucleotide is 1:150, 1:75, and 1:30). The strong and
moderate hits are indicated with arrows and corresponding nucleotides numbers (▲
﴾strong hits﴿ and Δ ﴾moderate hits﴿).
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Figure 2.7. Secondary structure map of 16S rRNA (34) with probing results is shown.
Strong hits (reactive nucleotides) are colored red (shown with ▲), moderate hits are
colored green (shown with Δ), and very weak stops are colored blue (shown with ●). The
helix numbers are also indicated (1-45).
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The cisplatin binding sites are distributed throughout the bacterial 16S
rRNA. Inspection of Figure 2.7 shows that in 16S rRNA, more than 50% Gs are
reactive towards cisplatin (286/476), excluding helix 45. In the 5' domain
(nucleotides 1-566), a number of prominent strong stops were observed, such as
at G147, A160, U166, G203, G242, G260, and C352 (Figures 2.4 A, 2.8 and
Appendix). All of these stops are on the 3' side of consecutive guanosines that
contained at least one G○U pair or a mismatch, or resided next to a loop region.
One of the very strong stops observed at G203 contain a G-C-rich sequence and
G○U mismatch, similar to the binding sites observed previously in the tRNA
acceptor stem (168). In addition to these sites, a number of minor and weak
stops were also observed in this region, such as A129, C214, and A319, which
were also before consecutive guanosines (Figures 2.4 and Appendix). Most of
these weaker sites contain repeating G-C pairs without a mismatch. None of the
single guanosines in this region showed strong stops, and not all of the
consecutive Gs were targeted. Only moderate or weak stops were observed on
the 3' side of non-consecutive guanosines or with guanosines adjacent to
adenosines.
In the upper part of the 5' domain, the stops at C379, C418, U426, A456,
U463, and U543 (Figures 2.4 B, 2.8 and Appendix) were the strongest hits
observed with cisplatin. Most of the strongest hits in this region were before
consecutive guanosines, except for U463 which is on the 3' side of a single
guanosine. In this region, several of the strong reactive sites contain either a
mismatch, unpaired
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Figure 2.8. The 5' domain secondary structure map of 16S rRNA with probing results is
shown. Strong hits (reactive nucleotides) are colored red (shown with ▲), moderate hits
are colored green (shown with Δ), and very weak stops are colored blue(shown with ●).
The helix numbers are also indicated.
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bases in loop regions, or G○U wobble base pairs, indicating that cisplatin
binding preferences are not simply limited to GG sites as was observed with
DNA.
In the central domain (nucleotides 567-915), which includes helices 19 to
27, also showed a number of strong as well as moderate hits by cisplatin. The
majority of the strong hits were observed in helices 22 and 24, such as at A743,
A777, A792, U801, and U804 (Figure 2.5 A). These strong stops also appeared
on the 3' side of the consecutive guanosines, except for U804, which occurred
before the closing base-pair of the internal loop of helix 24. Most (22/28)
consecutive guanosines in other helices with 16S rRNA also showed reactivity
towards cisplatin. Strong stops occurred at C618 and A629 in helix 21 at two sets
of GGG sites. Similarly, strong stops at U683 and A715 were observed on helix
23. The functionally important helix 27 also contains a strong stop at A889
(Figure 2.5 B) before a cluster of four consecutive Gs containing a G○U pair. In
addition to these, several moderate and weak stops were observed, as shown in
Figures 2.5 and 2.9.
The 3' side of 16S rRNA contains two domains: 3' major (nucleotide 9161396) and 3' minor (nucleotide 1397-1542). Nucleotides in helix 45 of the 3'
minor domain could not be mapped due to lack of appropriate nucleotides
needed for primer hybridization. In the 3' major domain, C1059, G1187, C1208,
and A1339 (Figures 2.6, 2.10 and Appendix) were a few of the very strong
stops observed. The 3' minor domain contains two important helices: helix 44
and 45. Helix 44 contains the decoding region, which has a key role in protein
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synthesis. Several consecutive Gs in this helix are targeted by cisplatin and
strong stops were observed at G1416, U1424, U1440, C1460, and G1488
(Figures 2.6 B and Appendix), which are all located adjacent to consecutive
guanosines.

Figure 2.9. The central domain secondary structure map of 16S rRNA with probing results
is shown. Strong hits (reactive nucleotides) are colored red (shown with ▲), moderate hits
are colored green (shown with Δ), and very weak stops are colored blue(shown with ●).
The helix numbers are also indicated.
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Figure 2.10. The 3' domain secondary structure map of 16S rRNA with probing results is
shown. Strong hits (reactive nucleotides) are colored red (shown with ▲), moderate hits
are colored green (shown with Δ), and very weak stops are colored blue (shown with o). A)
3' Major and B) 3' minor domains with helix numbers are represented.
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2.4.2 Salt dependence binding study
The interaction of charged metal complexes with oligomers is known to be
strongly influenced by salt concentration (218). The salt dependence of the
cisplatin reaction with 16S rRNA under various Na+ concentrations (10 to 300
mM) was carried out. First, reactivity increased in the presence of 20 mM Na+,
and then further increases of the salt concentration resulted in decreased
platination (Figure 2.11), which suggests that electrostatic interactions play an
important role in cisplatin binding to RNA.

2.4.3 Quantification of the platinum adducts on 16S rRNA
The number of platinum atoms bound per molecule of 16S rRNA was
determined by using atomic absorption spectrometry (AAS). Free 16S rRNA and
monoaquated cisplatin were reacted at various ratios to determine the total
number of possible adducts. After the reaction, excess platinum was removed by
ethanol precipitation followed by dialysis for 12 hrs at 4 ºC. The 16S rRNA was
then hydrolyzed with NaOH to obtain individual nucleotides. The absorbance of
16S rRNA was measured spectrophotometrically in triplicate by using a
NanoDrop UV visible spectrometer and the concentration was calculated by
using the extinction coefficient of hydrolyzed 16S rRNA (ε = 17,588,970 M-1 cm1

). The concentration of platinum was measured by AAS with a graphite furnace

and hollow cathode platinum lamp. At lower reaction ratios, all of the platinum
atoms were bound to the 16S rRNA. More specifically, at reaction ratios of 1:50
and 1:100 (16S rRNA:Pt) the number of platinum atoms per rRNA molecule was
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52±3 and 101±8, respectively (Figure 2.12), suggesting that all Pt complexes
reacted with 16S rRNA.

Figure 2.11. An autoradiogram illustrating salt dependence of the cisplatin reaction with
16S rRNA and quantification of the gel is given. A) The autoradiogram shows a strong
cisplatin stop site at U801 at various Na+ concentrations. B) Quantification of the reverse
transctiptase stop site at U801 after cisplatin reaction is given. Quantification was
performed using ImageQuant software. The gel data were normalized over the entire lane
to account for loading differences and then compared at the level of intensity at U801. The
relative intensity at U801 was calculated by percentage intensity at U801 with respect to
the total intensity of that lane. The data represents an average of two independent
experiments.

Figure 2.12. The number of platinum atoms bound on each molecule of 16S rRNA at
different reaction ratios determined by AAS is shown. The data represents an average of
three independent experiments.
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2.4.4 Identification of the platinum adducts on 16S rRNA
In DNA, cisplatin forms various types of adducts, such as 1,2-intrastrand
and interstrand crosslinks; however, the types of adducts formed with RNA have
not been well characterized previously. For this purpose, control 16S rRNA and
RNA treated with cisplatin were digested with P1 nuclease and calf intestinal
phosphatase (CIP) to generate free nucleosides or possibly dinucleotides. The
products were separated and identified by HPLC and high-resolution LC-MS.
In HPLC, four unknown peaks along with four standard nucleoside peaks
were observed (Figure 2.13 A). The retention times of standard nucleosides
were confirmed by injection of standard nucleosides separately. Quantification
was carried out by Empower HPLC software and the peak areas were divided by
the corresponding extinction coefficients to account for the differences in
absorbance at 260 nm. Then, peak ratios were calculated relative to the cytidine
peak. Quantification of the nucleosides revealed that free guanosine and
adenosine levels decreased with increasing cisplatin concentrations (Figure 2.13
B and C). To identify other unknown peaks, LC-MS was carried out with an
Acquity UPLC system equipped with an HSST3 (2.1 × 100 mm, 1.8 µm) C18
column. The chromatogram and mass of the corresponding peaks are shown in
Figure 2.14. The observed and calculated masses with retention times are
shown in Table 2.1. The major peak at retention time 0.96 min is assigned as the
bifunctional adduct, GpGPt(NH3)2, with a molecular mass of 856.14 Da. Similarly,
the peak at 1.61 min with mass 840.14 Da corresponds to ApGPt(NH3)2, and the
peak at 1.69 min with mass 795.19 Da is assigned as GGPt(NH3)2. The peak at
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Figure 2.13. HPLC chromatogram and the quantification of digested 16S after reaction with
aquated cisplatin are shown. A) An overlay of HPLC chromatograms of control (digested
16S rRNA) and platinated 16S rRNA after digestion is given. New peaks following
platination of 16S rRNA are indicated by symbols (♦Δ●o). B) The relative molar
concentration of unreacted nucleosides vs. reaction ratios of 16S:cisplatin is plotted. C)
The relative number of unreacted guanosines after the reaction in various ratios is shown
graphically. The data represents an average of two independent experiments.
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Figure 2.14. LC-MS data of digested 16S rRNA after reaction with cisplatin are shown. The
chromatogram with retention times (upper) and mass spectra of the corresponding peaks
(lower) are shown.
Table 2.1. Masses, rentention time and % of various adducts of cisplatin with 16S rRNA.

Types of
adducts

+1 charged state (Da)

+2 charged state (Da)

Calculated Observed Calculated Observed

Retention Relative
time
%

GpG[Pt(NH3)2] 857.13

856.14

428.56

428.57

0.96 min

63 ± 5

ApG or
GpA[Pt(NH3)2]

841.15

840.14

420.57

420.57

1.61 min

20 ± 3

GG[Pt(NH3)2]

796.20

795.19

398.1

397.60

1.70 min

6±2

AG or
GA[Pt(NH3)2]

780.21

778.19

390.1

389.60

2.10 min

11 ± 2
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2.12 min with mass 778.19 Da is assigned as AGPt(NH3)2. The above assigned
adducts are shown in Figure 2.15. These results show that cisplatin
preferentially reacts with guanosine, forming bifunctional adducts as the major
products. The coordination site is presumed to be N7 of the purine, but this has
not been confirmed.

Figure 2.15. Proposed structures of adducts obtained after digestion of 16S rRNA are
shown.

2.5

Discussion
Probing data reveal strong and weak stops of reverse transcriptase due to

cisplatin cross-links with RNA. Similar to DNA, a majority of the adducts formed
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with RNA are observed at consecutive guanosines. On DNA, cisplatin prefers Grich regions and forms the major bifunctional adducts with purines (191).
Therefore, it is not surprising that the preference for RNA reactivity is at GG sites.
Most of the consecutive Gs that showed strong reactivity with cisplatin contained
G-C-rich sequences with a G○U wobble pair. The structural distortion at this base
pairing type in RNA might enhance the accessibility for reaction with platinum
complex. There are several G-C-rich regions that do not contain G○U pairs or
mismatches, and these showed relatively weaker reactivity towards cisplatin. The
G○U pair has very important functional roles. For example, in E. coli tRNAAla, it
serves as a recognition element for cognate synthetase (219-220). In addition,
the G○U pair is also important for ribosomal protein recognition (221). Thus, the
cisplatin complex may reveal preferred sites for protein binding on RNA that have
ideal accessibility, electrostatics, and/or structural compatibility. Furthermore, it is
possible that such RNA reactivity might be an alternate pathway leading to
cisplatin toxicity.
Upon examination of the crystal structure of the bacterial ribosome, the
strong and weak cisplatin coordination sites do not display major structural
differences. The distances between the N7 position of two consecutive Gs N7
are 3-4 Å when they are stacked (Figure 2.16); however, several single
guanosines that showed strong reactivity were observed to have their
neighboring nucleotide flipped out. This conformational change may provide
more space for cisplatin to form monofunctional adducts.
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Figure 2.16. Structural features of cisplatin binding sites in 16S rRNA with nucleotide
numbering are shown: A) strong binding sites observed in helix 24 with consecutive
guanosines; B) strong binding sites observed in helix 17 with single guanosines; C)
strong and no hits with consecutive guanosines in helix 44. Secondary structures of the
corresponding helices are shown in the lower panel. Nucleotides with strong hits (red) and
no hits (black) are represented. This figure is created with Pymol (2AVY) (222).

The reactivity of monoaquated platinum species showed differences in
reactivity with each of the guanosines in 16S rRNA. This result might be primarily
due to the folding and tertiary interactions which change accessibility of the
nucleotides within the RNA structure. In addition, RNA may contain preferred
ligand-binding pockets that serve as unique recognition sites for small molecules
(223). The negatively charged phosphodiester groups on the RNA could attract
the positively charged platinum complexes, which increases the local
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concentration of complex in the RNA environment. Hence, due to preassociation
of the complexes, adduct formation at certain sites might be kinetically favored.
Similarly, the binding of ligands in the reactive sites might alter the RNA
structures, which makes other sites more or less accessible for the reaction.
Cisplatin reactions with RNA can be greatly influenced by cation
concentrations and reaction times (167-168). Reactivity of cisplatin can be based
on oligonucleotide length, electronegativity, target site geometry, as well as
secondary and tertiary structures (197, 224-225). An increase in cation
concentration decreases cisplatin binding due to altered electrostatic interactions
(167). Hence, it can be expected that larger RNA structures might have charged
pockets that are preferable for metal coordination (226). The positively charged
aquated cisplatin complex is known to associate with nucleic acid surfaces by an
electrostatic-driven process prior to formation of the final adduct (218). It has
been observed that the reactivity of platinum at G-N7 is influenced by the
presence of Na+ concentration. The maximum reactivity was obtained at the
middle of an oligonucleotide (17 mer DNA) at 34.5 mM Na+ concentration (218).
With the increase in reactivity at the middle of the sequence, the reactivity
towards 5' and 3' ends was decreased. Similar results were observed in this work
with 16S rRNA, in which reactivity increased at U801 with increasing Na+, then
decreased with higher salt concentrations. In this study, only helix 24 was
monitored and changes in reactivity at other sites are not known.
On DNA, adduct formation is more specific (at lower platinum
concentrations); however, at higher concentrations adduct formation with
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adenosines also increases (227). The monoaquated cisplatin derivative readily
coordinated with the N7 position of purines to form a monofunctional adduct (t1/2
= 0.1 hr) (Figure 2.17) (156, 228-229). The second chlorido ligand was aquated
with a half-life of ~2 hr and finally a bifunctional adduct was formed (166, 229).
Hence, the monoaquated species used for the reaction can ultimately result in
formation of a stable bifunctional adducts.

Figure 2.17. Schematic representation of proposed mechanism (229) for the binding of
cisplatin to double-stranded DNA is shown.

The types of adducts formed with RNA are similar to those found with
DNA. The major peak observed in HPLC following cisplatin reaction and rRNA
digestion was assigned as a 1,2-intrastrand bifunctional adduct with two
neighboring guanosines. The molecular mass corresponding to GpG-Pt(NH3)2
indicates a product that is not susceptible towards hydrolysis by P1 nuclease at
the phosphodiester linkage between adjacent Gs, suggesting protection by the
cisplatin coordination. In contrast, the product with a molecular mass
corresponding to GG-Pt(NH3)2 could be either a 1,2-intrastrand, 1,3-intrastrand,
or interstrand bifunctional adduct, since these nucleosides were linked by
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cisplatin, but not by a phosphodiester bond. Along with these bifunctional
adducts, adducts with adenosine and guanosine were also observed (i.e.,
AG(PtNH3)2 or GA(Pt(NH3)2). The higher reactivity with non-consecutive
guanosines and formation of ApG adducts in RNA are unique compared to DNA.
This result is likely because of structural difference between RNA and DNA. In
RNA, the structure is more diverse and with a large number of unique secondary
and tertiary structural motifs, which leads to different reactivity than DNA.
If indeed cisplatin has a kinetic preference for RNA over DNA, then once it
enters the cell, it could react with various cellular RNAs, including the ribosome.
Previous studies have shown that modification of 16S rRNA by kethoxal greatly
affected ribosome assembly (60); similar results might be expected with cisplatin.
The binding of cisplatin to the spliceosome greatly inhibits its assembly and
function (202). Several of the functionally important helices such as 18, 24, 28
and 44 showed reactivity with cisplatin. In helix 18, G530 is a universally
conserved residue and plays an important role in decoding (3). Similarly, helix 24
is present in the subunit interface and has contact with tRNA and initiation factors
(230-231). Helix 28 and 44 also contain several conserved nucleotides that are
involved in decoding (232). A number of nucleotides that are universally
conserved, such as G530 and G926, showed reactivity with cisplatin. The binding
of cisplatin at these functionally important regions could impair its function of
protein synthesis.
The repair machinery for the ribosome is largely unknown; hence, the cell
may be unable to remove cisplatin adducts from the ribosome. From the
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abundance and lifetimes of RNAs, it is suggested that platinum binding may
affect RNA function. The transport of cisplatin in the cell and possible
intermediate binding with RNA and proteins is still largely unknown. With the
increasing number of roles of cellular RNAs that are being identified, detailed
binding studies of cisplatin and its effects in vivo will determine possible
complementary modes of cisplatin action.
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CHAPTER 3
Exploring Novel Drug Target Sites in the Ribosome by Using
Cisplatin as a Chemical Probe
3.1

Abstract
Knowledge of RNA structure and its relationship to function is fundamental

to understanding the biological mechanisms of RNA. Large RNA molecules, such
as those in the ribosome, have complex three-dimensional structures. Due to its
diverse structure, the ribosome is an ideal target for antibiotics. A number of
biophysical and biochemical methods have been utilized to understand its
structure-function relationship. In this study, to gain knowledge about smallmolecule accessibility on the ribosome, cisplatin has been utilized as a chemical
probe. Cisplatin forms stable adducts through coordination to the N7 position of
purines and can be detected by primer extension. A number of guanosines in the
structurally and functionally important helices are found to be accessible to
cisplatin.
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3.2

Introduction
The ribosome, the molecular machine for protein synthesis, is a large,

folded RNA assembled with proteins (27, 48, 222). The folded rRNA can form a
number

of

different

secondary

and

tertiary

structural

motifs

and

microenvironments that are solvent accessible (233). Due to its structural
diversity, solvent accessibility, and general lack of repair enzymes, the bacterial
ribosome has been a well-known target of antibiotics (71, 104). Various classes
of antibiotics such as aminoglycosides and macrolides bind within the ribosome
and inhibit protein synthesis (234-235). Unfortunately, many strains of bacteria
have become resistant to antibiotics, and it is therefore important to design new
drugs, as well as explore potential new target sites. Much of the current research
is focused on the development of new antibiotics; however, fewer attempts have
been made to explore new target sites (2, 103, 236).
The first step towards the development of novel therapeutics or target
sites is to carry out structure studies. In addition to high-resolution techniques,
such as X-ray crystallography and NMR spectroscopy, there are several methods
to elucidate the solution structure of nucleic acids, such as chemical or enzymatic
probing (124, 130). Among these methods, RNA modification or cleavage,
induced by a variety of structure-specific enzymes or chemicals, followed by
various detection systems, such as reverse transcription or mass spectrometry
have been widely used to gain structural information (108, 129-130). Highresolution structural analyses of the 70S ribosomes and the 30S subunits have
greatly expanded our understanding of the overall folding of the ribosomal RNA
when assembled with proteins (237-238); however, cooperative interactions
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between nucleotides and the formation of charged pockets might occur during
the process of ribosome assembly, which have yet to be determined in detail. In
addition, RNA structures might differ under various buffer concentrations,
temperature, or levels of protein binding.
Several probes have been used to obtain structural information of nucleic
acids, but most of them are limited to in vitro studies because of their inability to
penetrate the cell wall due to their size, structure, and/or charge (124). Only a
few compounds have been used to probe RNA structure in vivo, such as DMS
(152), kethoxal (239), and lead(II) (240); however, some of these compounds are
toxic to the cell and the detection of their cleavage or reactive sites is also
challenging. The various structural features of RNA will be important for
biological function in vivo. The RNA structures obtained by various in vitro
methods might be different than the corresponding RNAs present in the complex
environment found in living cells; thus, methods to compare the in vitro and in
vivo structures would be useful.
Recent crystal structures have revealed a number of antibiotic binding
sites in the ribosome, and it is interesting to know that many of these sites are
overlapping (117). Now, it is important to develop novel target sites to design
new drugs that can help to overcome the ever-growing problem of resistance. In
this context, a chemical probe able to work both in vitro and in vivo can be
utilized to explore structure accessibility in RNA. The accessible sites of the RNA
can be compared with their functional importance, which might be useful to
develop as a new drug target sites. Previously, we have shown that cisplatin can
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be used to probe larger RNA structure, the ribosome, in vitro and in vivo (204).
Cisplatin has several advantages, such as the formation of stable adducts and an
easy detection system. Further extended studies to map the accessible regions
in the 30S subunits and the 70S ribosomes with cisplatin in vitro and in vivo were
carried out.

3.3

Materials and Methods

3.3.1 Chemicals, solutions, and DNA
[5'-32P-γ]ATP was purchased from Perkin-Elmer Life Sciences, Inc. and
T4 polynucleotide kinase was obtained from New England Biolabs. A reverse
transcriptase kit (Improm_IITM Reverse Transcriptase) was purchased from
Promega. The remaining chemicals for buffers and reagents were obtained from
Sigma Chemicals or Fisher. RNase-free, distilled, deionized water (ddH2O) was
used for all experiments.
Cisplatin, cis-diamminedichloridoplatinum(II), was purchased from Alfa
+

Aesar. The complexes cis-[PtCl(NH3)2X]+/0 or cis-[Pt(NH3)2X2]2 /0, in which X was
H2O, DMF, or NO3-, were prepared as described in Chapter 2. Platinum-DMF
complex stock solutions were stored at -20 °C for up to 1 week and diluted as
required just prior to use.
Single-stranded DNA primers that were used to probe the free 16S rRNA
were also used to probe the 30S subunits and the 70S ribosomes. Purification of
primers was carried out as described in Chapter 2. Sequences of the DNA
primers were named according to the beginning position of the transcribed
nucleotides, and are same as those in Chapter 2.
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3.3.2 Isolation of the 30S subunits and the 70S ribosomes
The 70S ribosomes and 30S subunits were isolated from E. coli MRE600
strain by the sucrose gradient method (145, 241) as described in Chapter 2.

3.3.3 Platination reactions
The platination reactions with the 30S subunits and the 70S ribosomes
were performed with monoaquated cisplatin. Prior to platination, the 30S subunits
and the 70S ribosomes, were activated by incubating in ribosome buffer (20 mM
HEPES, pH 7.2, 50 mM KCl, and 10 mM MgCl2) at 40 ºC for 30 min (241).
Platination was carried out in 20 mM HEPES, pH 6.5, 20 mM potassium acetate,
and 10 mM MgSO4 (buffer H). The 30S subunits and the 70S ribosomes were
incubated at 37 °C with aquated complex in 1:150 and 1:75 ratios of metal
complex to nucleotides. After the reactions, samples were quenched with NaCl
by raising the concentration to 200 mM, followed by immediate freezing.

3.3.4 Primer extension
Samples for primer extension were prepared by three times extraction with
an equal volume of phenol (phenol:chloroform:isoamyl alcohol; 25:24:1) followed
by two times with chloroform in the presence of 6 mM EDTA. Finally, samples
were ethanol precipitated with 0.1 volumes of 3.0 M sodium acetate, pH 5.3, and
2.5 volumes of ethanol. Samples were dried in a speed vacuum and dissolved in
ddH2O. The concentrations were measured spectrophotometrically at 260 nm
using a Nano Drop spectrometer in triplicate. For primer extension, 1 µg
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equivalent of 16S rRNA was used. Primer labeling and primer extension was
carried out as described in Chapter 2.

3.3.5

In vivo probing
E. coli cells MRE600 were streaked from a glycerol storage culture on

Luria–Bertani (LB) agar and incubated at 37 °C overnight. A single colony was
picked to inoculate a starter culture, which was grown at 37 °C overnight. The
starter culture was used to seed 3 ml medium (1/100–1/250 dilution), which was
grown with shaking to 0.2–0.3 OD600. Cisplatin dissolved in DMSO was added to
0 to 200 µg/ ml and the cells were further incubated in a shaker at 37 °C for 2 hrs
to an OD600 of 0.6 to 0.8. Cells were then chilled on an ice bath for 30 min and
harvested in pre-chilled 15 ml tubes at 5,000 r.p.m. for 10 min at 4 °C. Cells
pellet were washed 3 times with buffer A (50 mM Tris•HCl, pH 7.5 and 10 mM
MgCl2 and 100 mM NH4Cl) and resuspended in 100 µl buffer A. Cell lysis was
carried out with lysozyme (0.1 mg/ml) by freezing and thawing (242), and then 1
unit of RNase-free DNase I (Promega) was added, and the mixture was
incubated in ice for 15 min. The cell lysate was centrifuged at 5,000 r.p.m. for 10
min at 4 °C. The supernatant was transferred to a new tube and extracted with
an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1).The aqueous
phase was separated by centrifugation at 12,000 r.p.m. for 15 min at 4 °C and
was extracted one more time with phenol:chloroform:isoamyl alcohol followed by
3 times extraction with chloroform to remove all proteins. RNA was precipitated
from the final aqueous phase with 3 M sodium acetate (pH 5.3) and 2.5 volumes
of ethanol. The RNA was collected by centrifugation for 15 min at 12,000 g (4
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°C), washed with 70% ethanol and resuspended in 20 μl RNase-free water. The
RNA (2 µl) was analyzed on a 1.0% agarose gel prepared in 50 mM Tris–acetate
and 1 mM EDTA. Primer extension was carried out as described for the in vitro
method after isolation of RNA.

3.4

Results

3.4.1 Probing the 30S subunits and the 70S ribosomes in vitro
The 30S subunits and the 70S ribosomes were isolated from E. coli MRE
600 by the sucrose gradient method (145). The platination reaction was carried
out similar to that with free 16S rRNA, as described in Chapter 2. Concentrations
of the 30S subunits (1 A260 unit is equivalent to 69 pmol) and the 70S ribosomes
(1 A260 unit is equivalent to 23 pmol) (241, 243) were determined
spectrophotometrically. The reaction was carried out in 1:75 and 1:150 ratios of
monoaquated species to nucleotides. Before the reaction, both the 30S subunits
and the 70S ribosomes were activated by incubating in ribosome buffer at 42 ºC
for 30 min. The reaction with monoaquated metal complex was carried out at 37
ºC for 5 hours and quenched with NaCl, followed by freezing. Samples for the
primer extension were prepared by removing proteins with phenol-chloroform
extraction followed by ethanol precipitation.
Primer extension was carried out as described in Chapter 2 with free 16S
rRNA. The same primers that were used for free 16S rRNA was used to map
the cisplatin coordination sites on 16S rRNA of the 30S subunits and the 70S
ribosomes. Cisplatin coordination sites were then determined by pauses or
stops of reverse transcriptase compare to a corresponding control in the same
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gel. Bands on the gel arising due to nicks in the RNA or strong secondary
structures were distinguished from the cisplatin binding sites by comparing with
a control treated in a similar manner, but lacking aquated complex. The
magnitudes of the reactivity were classified based by the intensities of the bands
on the autoradiograms. Representative autoradiograms of the cisplatin probing
experiments with the 30S subunit and the 70S ribosomes are shown in Figures
3.1 to 3.3. Additional gels are shown in the Appendix. The gels were quantified
by using ‘Image Quant’ software as described in Chapter 2. Similar to the free
16S, the intensities of bands could be measured up to approximately 100
nucleotides from the transcription start site. The reactive nucleotides were
mostly found to be consecutive Gs, predominantly near mismatches or loop
regions. Since cisplatin was known to prefer Gs in the DNA targets, it was not
surprising that the major hits on the 16S rRNA from the 30S subunits, as well as
70S ribosomes, were also consecutive Gs. Out of 103 sites with consecutive Gs
(two or more Gs present are counted as one site), strong reactivity was
observed in 38 sites, and 36 were moderate hits. In addition, several
nonconsecutive Gs also showed strong or moderate reactivity. The overall
results of cisplatin binding to 16S rRNA in the 30S subunits and the 70S
ribosomes are shown in Figure 3.4 on a secondary structure model of 16S
rRNA with reactive sites in red (strong hits) and green (moderate hits).
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Figure 3.1. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the
5' domain with primers 245 and 561 are shown. (A) The autoradiogram shows the reverse
transcriptase pauses or stops by using primer 245. (B) The autoradiogram shows the
reverse transcriptase pauses or stops by using primer 561. In both gels, C, U, A, G
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿, Δ ﴾moderate hits﴿, and ●
(minor hits)).
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Figure 3.2. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the
central domain with primers 831 and 906 are shown. (A) The autoradiogram shows the
reverse transcriptase pauses or stops by using primer 831. (B) The autoradiogram shows
the reverse transcriptase pauses or stops by using primer 906. In both gels, C, U, A, G
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿, Δ ﴾moderate hits﴿, and ●
(minor hits)).
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Figure 3.3. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the
3' domain with primers 1110 and 1435 are shown. (A) The autoradiogram shows the
reverse transcriptase pauses or stops by using primer 1110. (B) The autoradiogram shows
the reverse transcriptase pauses or stops by using primer 1435. In both gels, C, U, A, G
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿, Δ ﴾moderate hits﴿, and ●
(minor hits)).
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Figure 3.4. Secondary structure map of 16S rRNA (244) with probing results from the 30S
subunits and the 70S ribosomes is shown. Strong hits (reactive nucleotides) are colored
red (shown with▲), moderate hits are colored green (shown with Δ), and weak hits are
colored blue (shown with ●). The helix numbers are also indicated (1 to 45).
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Figure 3.5. Secondary structure map of 16S rRNA (244) with probing results from the 30S
subunits and the 70S ribosomes is shown. Strong hits (reactive nucleotides) are colored
red (shown with▲), moderate hits are colored green (shown with Δ), and very weak hits
are colored blue (shown with ●). Nucleotides with lower reactivity in 30S/70S compared to
free 16S rRNA are indicated with green circles and with higher reactivity with red circles.
The helix numbers are also indicated (1 to 45).
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The 5' domain of 16S rRNA (nucleotides 1-566), which includes helices 1
to 18, is the main body of the 30S subunit. This domain is mainly stabilized by
RNA-RNA interactions (115, 222). Culver and coworkers found that modification
of five nucleotides (G301, G302, G529, G530, and G558) in this domain of the
ribosome were critical for the ribosome assembly (1). Previously, Moazed and
Noller have shown that, upon A-site tRNA binding, G529 and G530 were strongly
protected (3). Furthermore, Mankin and coworkers showed that mutations of
several nucleotides in helix 18 were deleterious, including G529 and G530 (2). In
cisplatin probing, moderate stops were observed before these consecutive Gs in
the 30S subunits and the 70S ribosomes (Figure 3.1 B). Furthermore, G529 and
G530 reacted strongly in free 16S, but were more protected in 30S/70S. Many of
the sites in 5' domain of 16S rRNA were less reactive within the context of
ribosomes. The significance of the result is that critical residues that are
protected are also functionally important; therefore targeting of these sites might
be feasible.
Mutation of G299A (helix 12) was found to increase both missense and
nonsense errors during translation (4). Structure studies showed that in helix 12,
G299 forms a Hoogsteen pair with G566 in helix 19, and the pair was found to
involve Mg+2 coordination (245). This functionally important nucleotide G299 also
showed a moderate reactivity with cisplatin, in which a reactivity difference was
observed between free 16S and 30S/70S. In addition to these sites, a number of
prominent stops were observed at G147, A160, U166, G201, G260, and G319
(Figures 3.1 A and 3.6). All of these stops are on the 3' side of consecutive Gs.
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a: role in ribosome assembly (1)
b: antibiotic binding
c: mutations are deleterious
to RNA function (2)
d: contact with tRNA (3)
e: role in fidelity (4)
f: Mg+2 coordination (4)

Figure 3.6. Secondary structure map at the 5' domain of 16S rRNA with probing results
from the 30S subunits and the 70S ribosomes is shown. Strong hits (reactive nucleotides)
are colored red (shown with ▲), moderate hits are colored green (shown with Δ), and very
weak hits are colored blue (shown with ●). A) The lower part of the 5' domain and B) the
upper part of the 5' domain with probing results are given. Green circles represent
nucleotides that showed strong hits on the free 16S rRNA, but are absent or very weak in
the 30S subunits and the 70S ribosomes. The (*) indicates the difference in reactivity
between 30S subunits and 70S ribosomes.
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In the upper part of the 5' domain, strong stops were observed at C418, G454,
U462, C507, and U543 (Figure 3.1 B). Among these strong stops, all were
before consecutive guanosines, except for U463, which is on the 3' side of a
single guanosine. In addition to these, several other consecutive and single
guanosines showed moderate to weak stops in this region (Figure 3.6).
A majority of the nucleotides that showed reactivity with cisplatin in free
16S rRNA also showed reactivity in the 30S subunits and the 70S ribosomes.
However, numerous differences in reactivity were also observed, such as the
strong stop observed at U426 in free 16S rRNA, which is not present in the 30S
subunits and the 70S ribosomes. Helix 16 forms a contact with protein S4, which
might protect these nucleotides from cisplatin reaction in the 30S subunits and
the 70S ribosomes (246). In addition, the reactive nucleotides (G416-417)
contain a G○U pair compared to unreactive G-C pairs (G423-425); this cisplatin
binding preference was observed on the free 16S rRNA as well. Similarly, a
moderate hit at G446 was observed in 16S rRNA, but is not present in 30S or
70S ribosome. In contrast, the stop at C507 is comparatively stronger in the 30S
subunits and the 70S ribosomes (Figures 3.1 and 3.6). Helix 18 was shown
previously to be dynamic in nature and several of its nucleotides are in contact
with ribosomal protein S12 (246). Hence, in the 30S subunit and the 70S
ribosome, the conformation and accessibility of nucleotides might be different
than the naked 16S rRNA, which results in different reactivity with cisplatin.
The central domain of 16S rRNA (nucleotides 567-915), which includes
helices 19 to 27, folds to form the platform of the small subunit (115). Culver and
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coworkers found six nucleotides in this region that are functionally important, and
assembly was impaired when they were modified (1). Out of these six
nucleotides, three are guanosines; G575, G791, and G818. Mankin and
coworkers found clustering of moderately deleterious mutations in helix 24, and
Cunningham and coworkers observed that none of the functional mutants in the
790 loop of helix 24 involved G791 or U793 (2, 247). In addition, G791 is located
on the functionally important 790 loop, which makes contact with initiation factor
(IF3) and the P-site tRNA (248-249). In cisplatin probing, G575 in the 30S
subunits and the 70S ribosomes showed strong reactivity. In contrast, G791 in
the 30S subunit was a weak hit, but in the 70S ribosomes was a strong hit
(Figures 3.2 A and 3.7), indicating that cisplatin reactivity is different in the 30S
subunits and the 70S ribosomes.
Several other strong cisplatin hits were observed on the 3' side of G799800, G773-776, and G741-742 (Figure 3.2 A and B). All of these consecutive Gs
showed strong reactivity with the naked 16S rRNA, the 30S subunits and the 70S
ribosomes. However, compared to the free 16S rRNA, reactivity at G799-G800 is
stronger in the 30S subunits and the 70S ribosomes. G803 showed reactivity
only in the naked 16S rRNA. Previously, G791 was found to be protected from
kethoxal modification; however, this residue becomes more accessible when 30S
subunits were converted from the active to inactive conformation (144).
Similarly, in helices 22 and 23, several nucleotides showed differences in
reactivity, such as G721-722, G730-731, and G733-734, which were not reactive
in the 30S subunits and the 70S ribosomes but were in free 16S rRNA.
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Previously, protection of G733, G734, and the 720 to 730 regions from kethoxal
reactions has been observed due to S15 binding (145, 250), which is consistent
these cisplatin probing results in which reactivity was reduced from free 16S
rRNA to ribosome.

a: role in ribosome assembly
b: antibiotic binding
c: mutations are deleterious
to RNA function
d: contact with tRNA
e: role in fidelity

Figure 3.7. Secondary structure map at the central domain of 16S rRNA with probing
results from the 30S subunits and the 70S ribosomes is shown. Strong hits (reactive
nucleotides) are colored red (shown with ▲), moderate hits are colored green (shown with
Δ), and weak hits are colored blue (shown with ●). Red circles represent strong reactivity
in the 70S ribosome compared to 30S and free 16S and green circles represent
nucleotides that showed strong hits on the free 16S rRNA but are absent or weak in the
30S/70S ribosomes. The (*) indicates the difference in reactivity between 30S subunits and
70S ribosomes.
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The 3' region of 16S rRNA, contains the 3' major (nucleotides 916-1396)
and 3' minor (nucleotides 1397-1542) domains. The 3' major domain includes
helices 28 to 43, and mainly constitutes the head of the small subunit, whereas
the 3' minor domain extends from the body to head of the 30S subunit, which
includes helices 44 and 45 (115). Modifications of 30 nucleotides in the 3' major
domain were found to affect ribosome assembly (1). Mutational studies showed a
cluster of deleterious mutations in helices 34 to 37, which are located far from the
known functional centers (2). G1058A and G1068A lead to a strong deleterious
phenotype. In cisplatin probing, the consecutive Gs, G1057-G1058, showed
strong reactivity only in free 16S rRNA, whereas in 30S subunits and 70S
ribosomes, a strong stop appeared just before a single guanosine G1064 (Figure
3.3 A and 3.8). In crystal structures of the ribosome, these consecutive Gs
(G1057-1058) are in contact with ribosomal protein S3, which might protect them
from cisplatin reactivity in 30S/70S ribosomes (246). Some other strong cisplatin
stops were observed at G1185, C1267, and A1339. All of these stops are on the
3' side of either single or consecutive guanosines.
Modifications of 13 nucleotides on the 3’ minor domain were found to
disrupt the assembly of the small subunit,t and a number of deleterious mutations
were also located in this domain (1-2). However, due to limitations of cisplatin
reactivity with guanosines, the accessibility of most of these functionally
important nucleotides could not be monitored. The strong and moderate stops
observed with cisplatin were at U1424, U1440, C1460, and U1490, which are all
on the 3' side of the consecutive Gs (Figure 3.3 B). Due to the lack of
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appropriate primer hybridization sites, a number of guanosines in the helix 45
also could not be probed.

a: role in ribosome
assembly
b: antibiotic binding
c: mutations are
deleterious to RNA
function
d: contact with tRNA

Figure 3.8. Secondary structure map at the 3' domain of 16S rRNA with probing results
from the 30S subunits and the 70S ribosomes is shown. Strong hits (reactive nucleotides)
are colored red (shown with▲), moderate hits are colored green (shown with Δ), and very
weak hits are colored blue (shown with ●). A) The 3' major domain, and B) the 3' minor
domain are shown. Red circles represent strong reactivity in the 70S ribosome compared
to 30S and free 16S and green circles represent nucleotides that showed strong hits on
the free 16S rRNA but are absent or weak in the 30S/70S ribosomes. The (*) indicates the
difference in reactivity between 30S subunits and 70S ribosomes.
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3.4.2 In vivo probing
Cisplatin is believed to enter cells by passive diffusion and undergoes
hydration to form the aquated species due to low chloride concentration inside
the cell (163). Therefore, it is hypothesized that cisplatin can be used to probe
the bacterial ribosome in vivo. Cisplatin coordination sites can be mapped in a
manner similar to in vitro studies by using reverse transcription. This type of
probing could reveal new target sites for antibacterials on the ribosome. To probe
the ribosome in vivo using cisplatin, E.coli DH5α was grown to ~ 0.2 to 0.3 OD600,
100 to 200 µg/ml of cisplatin was added, and the cells were further incubated for
two hours. After cooling on ice for 15 min, the cells were pelleted by
centrifugation. The cells were washed three times with buffer (50 mM Tris·HCl,
100 mM NH4Cl and 10 mM MgCl2) and total RNA was isolated. To carry out the
primer extension analysis, total RNA was isolated by phenol-chloroform
extraction followed by ethanol precipitation. A primer complementary to positions
831 through 814 of 16S rRNA, as used for in vitro probing, was annealed, and
then reverse transcription was carried out.
Primer extension of 16S rRNA showed a prominent stop at U801, one
nucleotide prior to the consecutive guanines G799 and G800 (Figure 3.9). This
result is consistent with the strong stop observed with in vitro probing. Along with
this, a minor stop also appeared before G791, which was seen only in the 70S
ribosomes. This result demonstrates that cisplatin can be used to probe
accessible guanosine residues in vitro and in vivo. Furthermore, the differences
in nucleotide accessibility in free 16S rRNA vs. that in the ribosomes can be
determined. It should be noted, however, that the in vivo results shown here
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represent an average of all the ribosomes at various stages of protein synthesis
in the cell.

Figure 3.9. Probing results in 16S rRNA from in vivo studies are shown. A) An overview of
the in vivo probing method, B) a partial secondary structure map of 16S rRNA h24
(residues 769–820) with the primer-binding site, and C) an autoradiogram showing reverse
transcription mapping of in vivo reactive sites (indicated by arrows; **major, *minor) of
cisplatin on 16S rRNA/70S ribosomes (the concentrations of cisplatin are given for each
lane, 0–200 µg/ml of cells) are shown. Dideoxy sequencing lanes are labeled as C, U, A,
and G. Sites that are identical in the in vitro and in vivo probing experiments are indicated
with symbols (▲,•).
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3.4.3 Active and inactive conformations
Opposite reactivity of purines at the N1 and N7 positions has been
observed previously in activated and inactivated ribosomes by chemical probing
(249). Cisplatin showed similar reactivity as DMS in the 30S subunits and the
70S ribosomes when used to probe the active form of the 30S subunit. For
example, in helix 44, G1415-G1417 showed enhanced reactivity with DMS in the
inactive form, and G1422-G1423 showed enhanced reactivity in the active
conformation. Probing results with cisplatin showed similar reactivity with the
activated 30S subunit, more specifically enhanced reactivity at G1422-G1423
and no reactivity at G1415-G1417 in the 30S subunits and the 70S ribosomes.
However, all of these Gs showed reactivity with naked 16S rRNA (Figure 3.10).
These results demonstrate that cisplatin can be used to identify functionally
important nucleotide and distinguish accessible nucleotide under active biological
states. These results can be compared to accessible residues in inactive RNAs
in the absence of protein factors.
Another similarity of our probing results with DMS studies is observed at
G926 and G1401. These nucleotides showed opposite reactivity at the N1 and
N7 positions of guanosine when probed with DMS. In the active form, the
reactivity of G926 at N1 was higher and there was no reactivity at N7. This result
was opposite in an inactive ribosomal conformation (144). Cisplatin probing
results showed reactivity of these nucleotides in free 16S rRNA and
comparatively weaker reactivity in the 30S subunits or the 70S ribosomes;
suggesting similar reactivity at the N7 of Gs. Since, both the 30S subunits and
the 70S ribosomes were activated before the incubation with cisplatin, these
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results indicate that the ribosome was in an active conformation during probing
experiments.

Figure 3.10. Secondary structure map at the 3' minor domain of 16S rRNA with probing
results from free 16S rRNA and the 30S subunits and the 70S ribosomes are shown.
Strong hits (reactive nucleotides) are colored red (shown with▲), moderate hits are
colored green (shown with Δ), and weak hits are colored blue (shown with ●). A) Probing
results from free 16S rRNA and B) results from 30S/70S are compared.

3.5

Discussion
Although a number of chemical and enzymatic probes have been utilized

to explore the accessibility of nucleotides in the ribosome, very little information is
available regarding the reactivity of the N7 position of guanosines. Although DMS
can react with the N7 position of guanosine, efficient strand scission is required
for detection, which may be difficult to achieve. Cisplatin is believed to react with
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the N7 position of guanosines and form a stable coordination complex; hence, it
will be useful to provide information about the nucleotide accessibility and
reactivity of the N7 position.
The ribosome is a potential target for a number of antibiotics, and half of
the known antibiotics already target the ribosome (104). However, pathogens
become resistant to the common drugs by more than one mechanism. To
overcome the problem of resistance, significant efforts have been made, mostly
by modifying the existing antibiotics (251-252). Despite being a validated target,
only a few attempts have been made to explore novel target sites in the ribosome
(2, 103, 236). Cunningham and coworkers have carried out instant evolution
experiments to investigate the nucleotides that do not undergo mutation, and if
mutated are lethal. These nucleotides are found to be involved in interactions
with tRNA, mRNA, or initiation factors, and are therefore functionally important. In
the 790 and 690 loops of the small subunit, nucleotides such as G791, U793,
and G691 were not mutated (247, 253). Previous probing experiments and now
high-resolution crystal structures revealed that the 790 loop is in contact with
tRNA and initiation factor 3 (238, 249). By targeting these functionally important
nucleotides that cannot be mutated, we can be one step ahead of bacterial
resistance involving target modification.
To explore the potential drug target sites, in a similar manner, Mankin and
coworkers carried out random mutagenesis in the small and the large subunits of
the ribosome (2, 65). They observed 53 mutations in the small subunits and 54 in
the larger subunits that were deleterious. These mutations either affect the
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function of the ribosome or disrupt its structure leading to a deleterious
phenotype. Deleterious mutations were clustered in certain functional regions
that show >98% conservation in 16S rRNA (65). Hence, it can be expected that
these nucleotides may be functionally important in other bacteria as well. Despite
this information, more knowledge about the accessibility of these nucleotides will
be needed to target these sites. Probing the 30S subunits and the 70S
ribosomes with cisplatin revealed a number of strong and moderate hits. The
binding sites of cisplatin in the ribosome are found to be distributed throughout
the ribosome and a number of functionally important sites showed reactivity. The
functionally important sites that are reactive towards cisplatin should be
accessible to small molecules and, hence, could be exploited as novel target
sites.
Helix 17 and 18 are promising drug target sites in the ribosome because
of their structural and functional importance. Helix 17 is structurally different in
bacteria and eukaryotes (103). The internal loop is conserved in bacteria and
absent in eukaryotes. Helix 18 is located on the surface of the small subunit at
the interface that contacts the large subunit, and the 530 loop (nucleotides 515536) is highly conserved (244). The 530 loop is an essential component of
ribosomal decoding and controls the accuracy of aminoacyl-tRNA selection (79).
The lack of functional mutants in the 530 loop further indicates its functional
importance (103). Another study showed that mutations of nine nucleotides in
this loop are deleterious including G506, G521, and G527 (2). Cisplatin showed
reactivity with several nucleotides in this region, including consecutive Gs in the
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internal loop of helix 17 (G453-455), the pseudoknot region of helix 18 (G506507), and conserved nucleotides G529-530. These nucleotides are accessible to
cisplatin and, hence, could be accessible to small molecules. Due to structural
differences and the functional importance, these sites could be utilized as a novel
target for antibiotics. Recently, a model system of helix 18 has been used as a
target to find ligands by phase display (254).
Helix 24 of 16S rRNA is very important because of its location near the
decoding region, interactions with initiation factor (230, 248, 255), and key
contacts with 50S subunit (231, 247, 249). In addition, the 790 loop in the smallsubunit platform and the nucleotides ridge (G1338-U1341 (helix 42)) in the head
form a 13 Ǻ gap, which separates the anticodon stem-loop of the P-site tRNA
from the E site (Figure 3.11 A) (222). The universally conserved residues G1338
and A1339 also play a role in discrimination of initiator tRNAf-met by initiation
factor (IF3) (256). Furthermore, helix 24 is located at the interface between the
large and small subunits and is known to be exposed to solvent (231, 257). The
antibiotic pactamycin is already known to bind to this helix (258). Hence,
nucleotides in this helix need to be accessible to assist these numerous
functional interactions, and blocking them could be an effective antibiotic
strategy.
All of the consecutive Gs present in helix 24 are accessible for cisplatin
reactivity in free 16S, 30S subunits, and 70S ribosomes. However, specific
residues such as G803 and G791 show different reactivity. G803 showed
reactivity only with the naked 16S and G791 showed higher reactivity in the 70S
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ribosomes. Instant evolution experiments with the 790 loop by Cunningham and
coworkers showed that positions G791 and U789 do not allow for any viable
mutations (103), indicating their functional importance. Nucleotides G773-776 are
involved in forming bridge 7b and the mutation G775A is found to be lethal (2).

Figure 3.11. Various functionally important helices of 16S rRNA in 70S ribosome crystal
structures are shown. A) Helix 24 (790 loop) and helix 42 are in contact with tRNA and
mRNA, B) the 790 loop and helix 28 are in close contact with tRNA and mRNA, C) the 790
loop is in contact with functionally important 690 loop (helix 23), and D) helix 34 is in
association with the antibiotic spectinomycin. Nucleotides that showed strong hits in
cisplatin probing are shown in red color and moderate are shown in green color. This
figure was created with Pymol using PDB: 2I2P and 2QOU (27, 74).
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In addition, in the crystal structures, the 790 loop makes contacts with the 690
loop through N1 and N6 of A696 and the 2'-OH of C797 (Figure 3.11 C) (78,
253). The 690 loop is also found to be functionally important and involved in
tRNA binding at the P site (3, 232, 249), initiation factor binding (230), and
subunit association (147, 259). Further, mutational studies carried out on this
loop also indicate its functional importance (253). Thus, due to its functional
importance and extensive contacts with other helices, tRNA, and initiation factor,
helix 24 is one of the most promising new drug target sites. All consecutive
guanosines in this helix showed reactivity with cisplatin; it is therefore expected
that they will be accessible to other small molecules. Binding of small molecules
even in the stem regions can disrupt the conformation or contacts of this helix
with other helices, tRNA, and the initiation factor.
Similarly, helix 34 can also be exploited as a target site in the ribosome.
This helix lies in the head region of the small subunit, and in the folded structure
it is very close to the decoding region (74). Hence, it has been expected that it
has an important role in the selection of the correct aminoacyl tRNA. The
reactivity of nucleotides in this helix are different in free 16S rRNA, the 30S
subunit, and the 70S ribosome. The consecutive Gs at positions 1058-1059
showed strong reactivity within the free 16S rRNA and no reactivity in the 30S
subunits, suggesting that these nucleotides become protected after the ribosome
is assembled with proteins. The crystal structure of E. coli 70S revealed that
ribosomal protein S3 binds to this helix and it contacts several nucleotides in this
region (Figure 3.12) (246). Interestingly, a neighboring nucleotide, G1064, shows
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higher reactivity towards cisplatin in 30S subunits and 70S ribosomes, but very
weak reactivity in free 16S rRNA. Helix 34 is also a known binding site for the
antibiotic spectinomycin, which contacts G1064 along with other nucleotides
(Figure 3.11 D) (74). The lack of cisplatin reaction at the consecutive Gs may be
due to protection or conformational changes that occur upon binding of protein
S3, which conversely makes the neighboring G1064 accessible for smallmolecule interactions.

Figure 3.12. Ribosomal protein S3 and part of 16S rRNA secondary structure
corresponding to helix 34 are shown. A) The ribosomal protein S3 and helix 34 with
cisplatin probing results are compared; nucleotides with strong hits on free 16S and
protected in 30S/70S are shown in black, strong hits observed in 30S/70S are shown in
red. B) The secondary structure of 16S rRNA shows the contacts of ribosomal protein S3.
The nucleotides in contact with S3 are circled with: blue (backbone only), red (base only),
and green (both backbone and base). Figure A was created with Pymol (PDB: 2AVY) and B
was reprinted with permission (Brodersen et al.) (246).

Thus, these results demonstrate the ability to discover potential antibiotic
sites of both structure accessibility and functional importance. The platinum
complex is sensitive to variations in the ribosome structure, and thus could be
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employed to examine ribosomes at various stages of protein synthesis, or
complexed with various factors, mRNA, or tRNAs. Most importantly, it is revealed
that a positively charged platinum complex is useful for targeting rRNA, and has
the ability to provide key information about helix or loop accessibility in the
ribosomes. Sites that differ in platinum reactivity between 30S subunits and the
70S ribosomes could reveal compelling regions for mechanism-based drug
design. Furthermore, the fact that the platinum complex generates stable adducts
is significant because the kinetics of the reaction can be monitored, which will
allow the determination of how positively charged compounds such as
aminoglycosides identify target sites with favorable electrostatic contributions
from a number of possible reactive sites on the ribosome (204).
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CHAPTER 4
Study

of

Cisplatin

Binding

to

a

Small

RNA

Construct

Representing the 790 Loop of 16S Ribosomal RNA
4.1

Abstract
DNA has been considered to be the major target of cisplatin, while RNA

has

been

essentially

overlooked.

Previous

studies

in

our

laboratory

demonstrated that RNA is the kinetically preferred target over DNA when similar
sizes and structures of nucleic acids are compared. In the present study, we are
extending our understanding of cisplatin binding to the 790 loop of E. coli 16S
ribosomal RNA (rRNA). On the model RNA constructs, the number of platinum
adducts were determined by using enzymatic digestion in conjunction with HPLC
and atomic absorption spectroscopy. In addition, the binding sites, number, and
types of adducts formed with RNA constructs were identified by using MALDITOF mass spectrometry and LC-MS spectroscopy. The aquated platinum
complex formed a variety of adducts with the 790 RNA hairpins. This information
may be helpful towards understanding the usefulness of cisplatin as a probe of
RNA structure and function, or to consider rRNA as a potential target of the
antitumor drug.

4.2

Introduction
The ribosome is composed of rRNA and proteins, which are organized

into the large and small subunits (48, 222). For the 70S ribosome of E. coli, the
large subunit (50S subunit) is composed of 5S and 23S rRNAs and 34 ribosomal
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proteins and the small subunit (30S subunit) is composed of 16S rRNA and 21
proteins (222, 260). The ribosome is important because it catalyzes protein
synthesis in all forms of life. The majority of ribosomal functions rely on the rRNA
structure (222).
This dependence of ribosome function on RNA is only possible because of
the large variety of secondary and tertiary structures formed by RNA (34). Singlestranded RNAs fold upon themselves to form well-defined structures that are of
great functional importance (35). An example of this, which is found in, but not
exclusive to, the ribosome is the structural motif called the stem-loop or hairpin
(41, 244). Although most hairpins rely heavily on hydrogen bonding in the socalled stem region, mismatch base pairing can also occur.
Aside from studying RNA structural regions to understand their functions,
such work may also lead to the discovery of new antibiotic binding sites (119,
261). It has been reported that human pathogens from infections in patients from
various sources have been growing more resistant to commonly used antibiotics
(262). Since nearly half of the currently used antibiotics target the ribosome, it is
important to find new regions for novel antibiotics to bind (86). Combined with
genetic approaches, biophysical methods and chemical probing may be used as
a discovery tools for new antibiotic binding sites (2, 103, 236).
The work reported here focuses on a model structure of the 790 loop of E.
coli 16S rRNA. This loop contains residues 783 to 799 and has been shown to be
important for ribosomal function, due to its presence in the inter-subunit region
(231) and its binding to protein IF3 (230). The 790 loop is exposed to solvent in
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the small subunit, and it is present in the small subunit rRNAs of all organisms. It
has also been shown to have decreased ribosomal function following mutations
(247). So, not only is it accessible, but information pertaining to molecular binding
to the 790 loop is useful for other organisms.
While cisplatin is commonly used as a chemotherapeutic drug for several
forms of cancer (163, 166), it has also been reported to be a probe for accessible
residues of ribosomal RNA (204). In DNA, the aquated cisplatin coordinates to
the N7 positions of adjacent purine bases to form primarily 1,2-intrastrand
crosslinks, but the formation of interstrand and monofunctional adducts is known
as well (172, 197, 263). The types of adducts formed with RNA have not yet
been verified, but are presumed to be the same as DNA. The advantages that
cisplatin probing has over other chemical probes is its ability for active or passive
cellular uptake, activation within the cell, and stability of the adduct formation with
nucleic acids (163, 264). Following passive diffusion, this square-planar complex
is activated by the replacement of one chlorido ligand by hydrolysis in an
aqueous environment because of the decreased chloride ion concentration in the
cell (156). This reaction produces the mono-aquated form of cisplatin
[Pt(NH3)2ClH2O]+ and following coordination, the remaining chlorido ligand is
displaced by hydrolysis to produce the bis-aquated form of cisplatin, thus
allowing the platinum to more easily coordinate to a second purine base (229). In
vitro, hydrolysis products of cisplatin can be generated by using silver nitrate in
order to precipitate the chloride ions out of solution as silver chloride.
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Probing the RNA structure with cisplatin provides information concerning
the environment of individual nucleotides that can be compared to RNA structural
models and hypotheses about RNA function. This is important because a limited
number of studies have revealed further details concerning interactions of
cisplatin with RNA (169). In order to determine the location of cisplatin binding on
the 790 RNA hairpin constructs and quantify the number of adducts, matrixassisted

laser

desorption/ionization

time-of-flight

(MALDI-TOF)

mass

spectrometry, atomic absorption spectroscopy (AAS), high-performance liquid
chromatography (HPLC), and liquid chromatography-mass spectrometry (LCMS) were employed (Figure 4.1).

4.3

Materials and Methods

4.3.1 General
Cisplatin (cis-diamminedichloridoplatinum (II)) was obtained from Alfa
Aesar (Ward Hill, MA). Silver nitrate and ammonium acetate were obtained from
Fisher Scientific. DMF (dimethylformamide) from Acros Organics was used for
the preparation of the monoaquated and bioaquated cisplatin species. TBAF
(tetrabutylammonium fluoride) was obtained from Aldrich, CIP (calf intestinal
alkaline phosphatase) was obtained from Promega Corp (Madison, WI). P1
nuclease was purchased from Sigma Chemicals. The remaining chemicals for
buffers and reagents were obtained from Sigma Chemicals or Fisher. RNasefree, distilled, deionized (ddH2O) was used for all experiments.
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Figure 4.1. The basic outline of cisplatin activation, secondary structure of 16S rRNA,
close-up to show 790 RNA constructs, and summary of various techniques used for study
of cisplatin binding in RNA model system are shown. Three different RNA constructs used
in this study (790 A○C wt, 790 A○C and 790 G○U hairpins) are indicated in the box.

4.3.2 Preparation of aquated complexes
For monoaquated cisplatin, molar equivalents (116 µmol) of cisplatin (35
mg) and silver nitrate (18 mg) were added to 1 ml dH2O or DMF and dissolved by
agitation in the dark overnight. Silver nitrate was introduced in order to precipitate
out chloride ions. The solution was centrifuged at 12,000 RPM for 15 minutes to
remove the silver chloride precipitate, and the monoaquated cisplatin
supernatant was removed. An additional 5 minutes of centrifugation at 12,000
RPM ensured that all of the silver chloride had been removed. The supernatant
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was transferred to a new tube. The aquated samples of cisplatin in DMF were
stored at -20 °C and kept no longer than one week.

4.3.3 RNA preparation and purification
Three RNA constructs 5'-GGCGAUUAGAUACCGCC-3' (790 A○C) 5'GGCGGUUAGAUAUCGCC-3' (790 G○U), and 5'-GCAGGAUUAGAUACCC
UGC-3' (790 A○C wt) were chemically synthesized at the Keck Foundation,
School of Medicine, Yale University. These RNAs were received as the 2'protected species and deprotected by dissolving in TBAF, followed by incubation
at 35 ºC overnight. The RNA was then desalted with a Sep-Pak Light C18
cartridge (Waters), dried in a speed-vac evaporator, and reconstituted in ddH2O.
The RNA then underwent HPLC purification. Solvents were as follows: buffer A
was 25 mM triethyl ammonium acetate, pH 6.5; buffer B was 40% acetonitrile in
water. The column was pre-equilibrated with 80% buffer A and 20% buffer B with
a flow rate 1 ml/min. RNA purification was achieved using the following elution
gradient: 80% A and 20% of B to 50% A and 50% of B over 30 min at room
temperature. The RNA fractions were detected at 260 nm and collected
manually. Following HPLC purification, RNA were ethanol precipitated with
sodium acetate and renatured in 20 mM Tris·HCl and 50 mM NaCl by heating to
90 °C for 2 min followed by slow cooling.

4.3.4 Cisplatin reaction with 790 RNA
All cisplatin reactions were carried out with monoaquated complexes in
1:1 or 1:20 ratios of RNA:complex. Prior to platination, RNA was renatured as
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stated above. Platination was carried out in 20 mM sodium phosphate buffer, pH
6.5, 10 mM MgCl2 and 10 mM NaCl (buffer P) at 37 °C for 5 hours. The reactions
were quenched with 2 M NaCl followed by immediate freezing.

4.3.5 MALDI-TOF mass spectrometry
MALDI-TOF (Matrix Assisted Laser Desorption Ionisation Time of Flight)
mass spectrometry analyses were carried out with a Bruker Daltonics TOF-300
MALDI Ultraflex. After platination reaction, RNA oligos were separated by 20%
polyacrylamide gel electrophoresis in order to separate bound and unbound RNA
samples. The bands were cut out of the gel and electro-eluted. Following
desalting with the Sep-Pak Light C18 cartridge, the samples were prepared for
MALDI-TOF by mixing 1 µl (25 pmol) of platinated or unplatinated RNA with 3 µl
of freshly prepared matrix solution (3-hydroxypicolinic acid in 50% acetonitrile).
One μl of this mixture was placed on the MALDI plate and allowed to dry at room
temperature. For RNase T1 digestion, 1 μl (1 unit) of RNase T1 was added to the
sample and it was incubated at room temperature for 15 min. Then, one μl was
spotted on the MALDI plate and allowed to dry at room temperature. The spectra
of intact RNA molecules were acquired in positive-ion reflector mode using
method RP-3147.par.

4.3.6 Atomic absorption spectroscopy
Atomic absorption spectroscopy (AAS) was used to analyze the amount of
platinum bound to the 790 RNA constructs. The instrument used for this study
was equipped with a graphite furnace with hollow cathode platinum lamp (Perkin-
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Elmer AAnalyst 700). The AAS has adjustable slit width wavelength and direct
concentration readout capabilities. All 790 samples underwent 30 hours of
dialysis with Spectra/Por 7 dialysis tubing, 3.5 KDa molecular weight cut off
membrane to remove any excess platinum present in the reaction. The AAS was
optimized and calibrated using calibration standards prior to each analysis. The
platinum calibration standards were prepared from commercial standards of
platinum (High-Purity Standards, Charleston, SC) in 5% HCl. The data were
obtained by using the instrument protocol and the previously described methods
in the literature (265-266).

4.3.7 High performance liquid chromatography
HPLC was carried out with a Waters system equipped with a C18
Discovery column (250 x 4.6 mm, 0.5 µm). Separation was carried out by using
buffer A (40 mM ammonium acetate) and B (40% acetonitrile) with a linear
gradient in which the ratio of A to B changed from 95:5 to 70:30 over 30 minutes
at a constant flow of 1 ml/min. The retention times of the standard nucleosides
were confirmed by injection of known standard nucleosides. Control and
platinated RNAs were digested with nuclease P1 to convert to nucleotides, and
the CIP was used to remove phosphates and give free nucleosides. Nuclease P1
digestion was carried out in 50 µl of digestion buffer (1 mM ZnCl2, 20 mM sodium
acetate, pH 5.3), for both the control and the platinated RNAs with 10 µl (10 U) of
nuclease P1 at 37 ºC overnight. The enzyme was then deactivated by heating at
75 ºC for 15 min. Five µl of 1.5 M Tris·HCl, pH 8.8, and 1 µl (10 U) of calf
intestinal phosphatase (CIP) was added to each sample and incubated for 4 hrs
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at 37 ºC. After 4 hrs of incubation, samples were again heated at 75 ºC for 15
min, vortexed, and centrifuged at 12,000 rpm for 5 min. Finally, samples were
filtered through YM-3 microcon filters before injection into the HPLC or LC-MS.
Samples were analyzed by HPLC and peaks areas were normalized to
account for the differences in extinction coefficients at 260 nm, (C = 9,100 M-1
cm-1, U= 10,100 M-1 cm-1, G= 13,600 M-1 cm-1, A= 14,900 M-1 cm-1) (217) and
then peak ratios were calculated relative to the cytidine peak.

4.3.8 Liquid chromatography mass spectrometry
LC-MS (Liquid Chromatography Mass Spectrometry) is a powerful
technique to separate and analyze complex mixtures with high sensitivity. LC-MS
was carried out on an AQUITY Ultra Performance LC chromatography (UPLC)
system (Waters Corporation, MA USA) equipped with an HSST3 C18 column
(2.1 x 100 mm 1.8 µm). The column was maintained at 50 ºC and elution was
carried out with a linear gradient of acetonitrile and 100 mM ammonium acetate,
pH 6.0. The gradient was run for 3 min with a flow rate 700 µl/min, starting at
100% ammonium acetate and decreasing to 60% over the course of the gradient.
The column eluent was analyzed by directing it to the mass spectrometer. Mass
spectra were collected in the positive ion mode. The percentage of adducts were
calculated by normalizing the area with extinction coefficients followed by relative
ratios of adduct present in sum of adducts.
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4.4

Results

4.4.1 Cisplatin binding studies in 790 RNA constructs
Initially, two model systems of the 790 hairpin, 790 A○C and 790 G○U
(mutant) were selected to study cisplatin binding (Figure 4.1). This 790 loop is
part of helix 24 of 16S rRNA and is functionally important (249). In addition,
extensive mutational and structural studies have been carried out previously in
this helix (247, 258). MALDI mass spectrometry was used to check adduct
formation with small RNA constructs. RNAs were reacted with one equivalent of
monoaquated cisplatin for 5 hrs at 37 °C. The products were separated on 15%
denaturing gels and visualized by UV shadowing. For the 790 A○C model, two
bands were observed with cisplatin, whereas three bands were observed in the
case of the G○U variant.
The product bands A○C1, with higher mobility, and A○C2, with slower
mobility, were isolated by electro-elution and subjected to MALDI-TOF mass
spectrometry (Figure 4.2). The higher mobility product, A○C1, has a mass of
5426.53 Da, which corresponds to free RNA. The slower mobility product, A○C2,
has a mass 5653.2 Da, which is increased by 227 mass units [Pt(NH3)2] relative
to the free RNA, and corresponds to the formation of a bifunctional adduct.
Similarly, three products from the 790 G○U variant; G○U1 (higher mobility),
G○U2 (intermediate mobility), and G○U3 (slowest mobility) were also isolated
and analyzed by MALDI-TOF (Figure 4.2). In 790 G○U, the slower mobility
product, G○U1, corresponds to unmodified 790 G○U with a mass 5443.2 Da. The
other two products, G○U2 and G○U3, correspond to masses 5670.7 Da and
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5670.2 Da, respectively, increased by of 227 mass units relative to the free RNA,
equivalent to [(Pt(NH3)2] (Table 4.1). This result also indicates formation of
bifunctional adducts.

Figure 4.2. MALDI-mass spectrometry data show the masses of various products formed
with 790 hairpin loops after the reaction with monoaquated cisplatin. 790 model constructs
A○C and G○U with their sequence and calculated mass are also shown.
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Table 4.1. Observed molecular mass and predicted species of various cisplatin adducts
with 790 RNA model system.

Molecular Ion

Observed mass (Da)
(M+H)+

Predicted species

790 A○C1

5426.53

790 A○C (RNA only)

790 A○C2

5653.20

(+227)

790 A○C + Pt(NH3)2

790 A○C2

5880.27

(+2*227)

790 A○C + 2[Pt(NH3)2]

790 G○U1

5443.25

790 G○U2

5670.72

(+227)

790 G○U + Pt(NH3)2

790 G○U3

5670.20

(+227)

790 G○U + Pt(NH3)2

790 G○U (RNA only)

4.4.2 Mapping binding sites by RNase T1 cleavage
For further confirmation and mapping of the exact cisplatin-binding sites in
these model systems, the products were partially digested with RNase T1, and
the fragments were analyzed by MALDI-TOF mass spectrometry (Figure 4.3).
RNase T1 fragments show that A○C1 has no platination in any fragments of
RNase T1; however, in A○C2, the fragments corresponding to 3185.1 Da,
[GGCGAUUAG>p+Pt(NH3)2], and 1568.2 Da, [GGCG>p+Pt(NH3)2], suggested
platination at the 5' consecutive guanines (Figure 4.3 and Table 4.2). In the case
of 790 G○U, the highest mobility band has no platination in any fragments of
RNase T1 digestion; whereas, the other two slower mobility products, G○U2 and
G○U3, had fragments corresponding to formation of bifunctional adducts (Figure
4.4 and Table 4.3). The fragment corresponding to 1568.9 Da, [GGCG>p+
Pt(NH3)2], in G○U2, suggested a bifunctional adduct at the 5' consecutive
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Figure 4.3. MALDI-mass spectrometry data after digestion of 790 A•C construct with RNase
T1 are shown. RNA hairpin, platinated (♦) and corresponding unplatinated (◊) fragments,
and +2 charge states (▪) are also indicated. The platinated site is shown on A○C2 at
positions G1 and G2, which is consistant with the mass data.
Table 4.2. RNase T1 fragments of 790 A○C1 and A○C2 with calculated and observed mass.

RNA fragments (5' to 3')

Calculated
mass (Da)
[M+H]+

Observed mass
A○C1 (Da) [M+H]+

Observed mass A○C2
(Da) [M+H]+

GGCGp

1341.81

1341.55

1568.27 [+ Pt(NH3)2]

AUACCGp

1921.16

-

1920.74

AUACCGCC

2469.56

2469.93

2469.68

GGCGAUUAGp

2957.77

2957.83

3185.19 [+ Pt(NH3)2]

AUUAGAUACCGCC

4085.53

4086.55

4086.28

CGAUUAGAUACCGCC

4734.92

4734.31

-

(M+H)+

5425.3

5425.25

5653.27 [+ Pt(NH3)2]
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Figure 4.4. MALDI-mass spectrometry data after digestion of 790 G○U construct gel
fractions (G○U1, G○U2, and G○U3) with RNase T1 are shown. 790 G○U hairpin, platinated
(♦) and corresponding unplatinated (◊) fragments of RNA are also indicated. The platinated
site is shown on G○U2 at positions G1 and G2, and on G○U3 at positions G4 and G5,
which is consistent with the mass data.

guanines, and fragment with 2511.4 Da, [CGGUUAG>p+Pt(NH3)2], in G○U3
indicated formation of an adduct at the G○U mismatch region. The fragment
1568.9 Da is not significant in G○U3; but compared to G○U2, the mass
corresponding to 2511.4 Da had higher intensity. The result is opposite in G○U2,
which confirms adduct formation at two different sites.
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Since the cisplatin was shown to bind preferably to the 5' consecutive
guanosines on the modified construct, which were not the part of wild-type 16S
rRNA, we made another construct with an A○C mismatch (wild type), but lacking
the 5' consecutive guanosines. The rest of the binding studies in this chapter
focus on the 790 A○C wild-type (wt) construct.

Table 4.3. RNase T1 fragments of 790 G○U1, G○U2, and G○U3 with calculated and
observed mass.

RNA fragments
(5' to 3')

Calculated
mass (Da)
[M+H]+

Observed with
G○U1 (Da)
[M+H]+

Observed with
G○U2 (Da)
[M+H]+

Observed with
G○U3 (Da)
[M+H]+

UUAGp

1287.75

1287.58

1287.45

1287.40

GGCGp

1341.81

1341.84

1568.95
[+ Pt (NH3)2]

1568.7
[+ Pt (NH3)2]

GGCGGp

1687.02

1686.10

-

-

AUAUCGp

1922.14

1922.22

1922.42

1922.19

CGGUUAGp

2283.35

2283.42

-

2511.42
[+ Pt (NH3)2]

AUAUCGCC

2470.55

2471.60

2471.36

2471.26

GGCGGUUAGp 2973.77

2973.67

3202.13
[+ Pt (NH3)2]

3202.32
[+ Pt (NH3)2]

4.4.3 Binding studies in model system 790 A○C wild type
The new 790 model RNA (790 A○C wt) was reacted with monoaquated
cisplatin in an equimolar ratio with monoaquated platinum complex similar to the
other constructs and the products were separated by gel electrophoresis.
Separated products after desalting were examined by Ultraflex MALDI-TOF mass
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spectrometry in the positive-ion mode (Figure 4.5). The band with the faster
mobility was unplatinated RNA and the band with slower mobility contained a
mixture of various adducts. The expected and observed mass of the possible
adducts are summarized in Table 4.4. The reaction of cis-[PtCl(H2O)(NH3)2]+
resulted in the formation of what we believe to be a bifunctional adduct, RNAPt(NH3)2, which was identified through an observed molecular mass of 6288.53
Da. Two other products were observed in the MALDI spectrum with less
intensity, corresponding to two and three platinum complexes bound to the 790
RNA construct.

Figure 4.5. MALDI-TOF spectra of undigested control (bottom) and platinated 790 A○C wt
model (top) with aquated platinum complexes (stoichiometry of 1:1, 1:2, and 1:3 RNA:Pt
adduct) are shown.
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Table 4.4. Calculated and observed molecular mass of various cisplatin adducts with 790
RNA model system.

Molecular ion

Calculated mass (Da)
[M+H]+

Observed mass (Da)
[M+H]+

790 A○C wt control

6061.72

6061.70

790 A○C wt + Pt(NH3)2

6290.74

6288.53

(+227)

790 A○C wt + 2[Pt(NH3)2]

6519.76

6515.71

(+(2*227))

790 A○C wt + 3[Pt(NH3)2]

6748.78

6742.85

(+(3*227))

4.4.4 Mapping the binding site with RNase T1 cleavage
In order to determine the location of the cisplatin-binding sites, both RNA
samples (control and platinated) were partially digested with RNase T1. This
digestion was performed to produce fragments of various lengths and molecular
mass. The location of cisplatin-binding could then be localized to a specific
fragment for closer analysis. Following a five-hour incubation at 37 °C of
equimolar amounts of 790 RNA (A○C wt) and cis-[PtCl(H2O)(NH3)2]+, the
products and control were subjected to RNase T1 cleavage. Figure 4.6 and
Table 4.5 compare the mass spectra for the digested control and platinated 790
loop.
Three major fragments were observed in both samples and a fourth
fragment was only observed in the product. The three fragments that are
common to both spectra were the result of the RNase T1 digestion. The first
fragment, CAGp, was identified with an observed molecular mass of 979.4 Da.
whereas the second fragment, corresponding to AUUAGp, was identified with an
observed molecular mass of 1615.5 Da, and the third fragment, AUACCCUGp,
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contained the observed molecular mass of 2530.7 Da. The fourth fragment was
observed only on the platinated sample, which corresponds to CAGGAUUAGp+
Pt(NH3)2. This is because the RNase T1 cleavage at the 3' end of guanine
residues was likely blocked by a bifunctional platinum adduct at consecutive
guanosine residues (residues 785 and 786). This is further supported by the fact
that there is a mass peak with lower intensity at 1541.92 Da on the platinated
sample, which corresponds to formation of bifunctional adduct on CAGGp.

Figure 4.6. MALDI-TOF mass spectra of digested control and platinated 790 loop model
(790 A○C wt) are shown. The model RNA construct, platinated (♦) and corresponding
unplatinated (◊) fragments with RNA sequence are also indicated. The platinated site is
shown on A○C wt (platinated) at positions G4 and G5, which is consistant with the mass
data.
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Table 4.5. RNA fragments, calculated and observed m/z values of 790 A○C wt are listed for
the digested control RNA and platinated RNA.

RNA fragments
(5' to 3')

Calculated
mass (Da)
[M+H]+

Observed mass
control RNA
(Da) [M+H]+

Observed mass
platinated RNA (Da)
[M+H]+

CAGp

979.6

979.68

979.05

CAGGp

1324.81

1324.98

1541.42 [+ Pt (NH3)2]

AUUAGp

1615.96

1616.25

1615.31

AUACCCUGp

2531.51

2531.79

2530.65

CAGGAUUAGp

2940.77

-

3167.63 [+ Pt (NH3)2]

4147.28

4147.00

AUUAGAUACCCUGp 4147.48

4.4.5 Determination of number of adducts formed with 790 A○C wt hairpin
The 790 RNA (A○C wt) was reacted with a 20x excess amount of
monoaquated platinum complex, cis-[PtCl(H2O)(NH3)2]+, in 10 mm phosphate
buffer at 37 ºC for 5 hours. A control reaction was also prepared with a volume of
H2O equivalent to that of the cisplatin added to the other reactions. After 5 hours,
the reactions were quenched with NaCl followed by freezing. Next, all reaction
mixtures were dialyzed with a tubing of a MW cut off of 3.5 kDa for 30 hours in
order to remove any excess unbound platinum. The concentration of dialyzed
RNA samples were measured spectrophotometrically (ε = 188,800 mol-1cm-1)
and 0.1 OD was used for atomic absorption spectroscopy (AAS) to determine the
number of platinum atoms bound to RNA. A calibration curve prepared from
known concentrations of platinum was created and platinum concentrations of
the sample volumes were determined in triplicate. These values were used to
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determine the number of moles of platinum present in the sample and a ratio to
the number of moles of 790 RNA in the sample were calculated. When a 20x
excess of aquated platinum (80 nmol) was reacted with 790 RNA (4 nmol) nearly
three moles of platinum were bound to every mole of 790 model RNA construct
(Figure 4.7A).

Figure 4.7. The molar ratio of the bound platinum to 790 RNA with 20x excess platinum is
shown. A) Number of platinum atoms bound to each molecule of 790 construct (average of
triplicate data) and B) MALDI mass spectra showing various adducts formed with excess
aquated platinum complex are shown.

Further, MALDI mass spectrometry was employed to elaborate on the
findings of the excess platinum reaction previously analyzed with AAS. The
MALDI spectrum of the analyzed reaction with 20x excess cisplatin showed three
different products as shown in Figure 4.7B. The major molecular ion peak at
6741.9 Da corresponds to the three platinum adducts associated with 790
construct, while the other two peaks with lower intensities, 6514.9 Da and 6969.5
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Da, correspond to two and four cisplatin adducts bound to the RNA molecule.
This data supports the average three platinum complexes present in 790 RNA
construct determined from AAS.

4.4.6 Types of adducts
Five reactions of 790 RNA (A○C wt) with different molar amounts (1:1 to
1:5) of cis-[PtCl(H2O)(NH3)2]+ in 10 mm phosphate buffer were incubated at 37
ºC. After five hours, reactions were quenched with 2 M NaCl raising the
concentration to 200 mM of NaCl and stored in the freezer. For comparison, a
control reaction was also treated in a similar manner. All six reactions were
treated with P1 nuclease to separate nucleotides and then CIP to remove
phosphates. The concentrations of the sample volumes were determined by a
UV-vis spectrophotometer and a volume corresponding to 0.1 OD was injected
into the HPLC. An overlay of the resulting chromatograms showed that
concentration of guanosine is decreased as the reaction ratio increases. The
second major change is observed with adenosine, while the other two nucleotide
concentrations remain fairly constant (Figure 4.8A). Quantification was carried
out by Empower HPLC software and the peak areas were divided by the
corresponding extinction coefficients to account for the differences in absorbance
at 260 nm. The peak ratios were then normalized to the cytidine peak (Figure
4.8B).
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Figure 4.8. HPLC chromatograms (A) and quantification (B) of the digested 790 RNA after
reaction with cisplatin is shown. A) An overlay of the HPLC chromatograms of control
(digested 790 RNA) and platinated 790 RNA of different reaction ratios is shown. New
peaks following platination of 790 RNA are indicated by symbols (Δ o ♦ ●). B) Relative
molar concentrations of unreacted nucleosides to reaction ratios vs. relative moles are
plotted (this data was collected by Christopher Lajeunesse).
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Along with four standard nucleosides, several other peaks were observed
in the HPLC traces. These peaks were observed to increase in intensity as the
ratio of cisplain was increased in the reaction mixture. To characterize these
unknown peaks, LC-MS characterization was carried out.
To identify other unknown peaks, LC-MS was carried out with an Acquity
UPLC system equipped with an HSST3 (2.1 × 100 mm, 1.8 µm) C18 column.
The chromatogram and mass of the corresponding peaks are shown in Figure
4.9. The observed and calculated masses with retention times are shown in
Table 4.6. The major peak at retention time 0.90 min is assigned as the
bifunctional adduct, GpGPt(NH3)2, with a molecular mass of 856.16 Da. Similarly,
the peak at 1.60 min with mass 840.16 Da corresponds to ApGPt(NH3)2, and the
peak at 1.68 min with mass 794.20 Da is assigned as GGPt(NH3)2. The peak at
2.12 min with mass 778.22 Da is assigned as AGPt(NH3)2. Along with these, two
monofunctional adducts were also assigned. The peak at 1.49 min with mass
547.09 Da is GPt(NH3)2Cl and at 1.81 min with mass 531.08 Da is
GPt(NH3)2H2O. These results show that cisplatin preferentially reacts with
guanosine, forming both bifunctional and monofunctional adducts.
Further, the ratio of these adduct-formations was calculated and found to
be in favor of the GpG platinum adduct. The UV chromatogram from the LC-MS
analysis of the 5:1 (Pt:RNA) molar ratio reaction was quantified using Mass Lynx
software and Table 4.6 shows the relative percentage of adducts present in
solution. The GpGPt(NH3)2 adduct was the most prevalent adduct found in the
reaction volume accounting for 35% of the total adducts found. The bifunctional
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ApGPt(NH3)2 adduct contributed to the second most preferred product with 24%.
This was followed by the GGPt(NH3)2 and AGPt(NH3)2 adducts with values 12%
and 11%, respectively. The monofunctional adducts were not as prevailing as the
bifunctional adducts, but still provided 17% of the products with GPt(NH3)2Cl
accounting for 9% and GPt(NH3)2H2O, 8%. The formation of the bifunctional
adducts was the more preferred product by a factor of almost 4:1 in comparison
to the monofunctional adducts.

Figure 4.9. LC-MS data of digested 16S rRNA after reaction with cisplatin are shown. The
chromatograms with retention times (upper) and mass spectra of the corresponding peaks
(lower) are shown.
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Table 4.6. Masses, retention times, and % of various adducts of cisplatin with model RNA
construct.

Types of
adducts

+1 charged state (Da)
[M+H]+

+2 charged state (Da)
[M+H]+

Calculated Observed Calculated Observed

Retention Relative
time
%

GpG[Pt(NH3)2]

857.15

856.14

428.57

428.59

0.96 min

35

G[Pt(NH3)2Cl]

548.08

547.09

-

-

1.49 min

9

ApG or
GpA[Pt(NH3)2]

841.15

840.14

420.57

420.57

1.60 min

24

GG[Pt(NH3)2]

796.20

794.20

398.1

397.60

1.68 min

12

G[Pt(NH3)2H2O] 531.12

531.08

-

-

1.81

8

AG or
GA[Pt(NH3)2]

778.19

390.1

389.60

2.11 min

11

4.5

780.21

Discussion
The binding study with small RNA constructs has shown that cis-

[PtCl(H2O)(NH3)2]+ coordinates with the 790 RNA loop preferentially at
consecutive guanosines. MALDI and LC-MS data revealed that the aquated
complex is capable of forming bifunctional adducts with consecutive guanine
residues, as well as mono-functional adducts with single guanine residues.
Results from MALDI-TOF and AAS have uncovered that more than three
cisplatin molecules can bind to 790 RNA constructs, though there is only one
consecutive guanosine. HPLC can be utilized to identify various types of adducts
formed with RNA constructs; however, due to lack of authentic platinated
standards, LC-MS was used for further confirmation.
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Our work has shown that MALDI-TOF, AAS, HPLC, and LC-MS are useful
for characterizing and mapping the interactions between cisplatin and the 19nucleotide 790 RNA loop. Though HPLC has demonstrated to be effective in
determining whether a reaction has occurred between cisplatin and the RNA, the
information gained from this technique is limited. A high-resolution mass
spectrometry technique is needed for product identification. MADLI-TOF allows
for the detection of bound complexes, before or after digestion. In addition, the
relative number of bound species can be obtained from the mass spectra.
In MALDI-TOF, the platinated RNA showed masses with 227 Da
increments compared to the parent RNA, which is two mass units (Hs) less than
would be expected from the coordination of Pt(NH3)2 (229 Da). This is due to the
proton necessary to compensate for the charge of Pt2+ and still produce singly
charged molecular ions (267). However, it is still uncertain whether the products
are mono- or bifunctional adducts, because of less number of purines and high
laser intensity used for ionization. Previously, it has been suggested that the
lower mass observed with platinated-RNA complex in MALDI-TOF was the result
of possible ligand loss (chlorido) during the ionization process rather than
formation of a bifunctional adduct (170). Using the relatively soft ionization
method (LC-MS), both mono- and bifunctional adducts were detected. The
monofunctional adduct includes both the chlorido and aqua ligand. In LC-MS, the
monofunctional adduct with one chlorido ligand was detected with a mass one
Da less than calculated. In bifunctional adducts, loss of two protons was
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observed with GG-Pt(NH3)2 and AG-Pt(NH3)2, whereas only one proton loss was
observed with the GpG and ApG adducts.
In 16S rRNA and 790 model constructs, the preferable binding sites of
aquated platinum complex were similar; mostly targeting the consecutives Gs.
The similarity in type of adducts obtained from HPLC and LC-MS indicates that
the 790 construct is a good model to understand the mechanism of cisplatin
binding and kinetic studies. Due to the larger structure of 16S rRNA and
numerous binding sites, kinetics studies are challenging; hence, the information
obtained from a model system would be very useful.
The 790 loop is an ideal site for small-molecule binding studies because it
is highly conserved, and extensive genetic and NMR information are also
available (247-248). Mutational studies showed that a number of nucleotides in
this loop are functionally important, and cisplatin probing study revealed this loop
is accessible for small molecules. Thus, 790 loop is a promising target for
antibiotic development. The kinetics and chemical probing studies in 790 model
system can help us to understand the mechanism of small-molecule interactions
with RNA.
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CHAPTER 5
Synthesis of Amino-acid-linked Analogues of Cisplatin for
Probing the Ribosome Structure
5.1

Abstract
Cisplatin has several advantages as a chemical probe to determine

nucleotide accessibility in RNA structure. One advantage is the ease with which
its ligands can be modified. Ammine ligands of cisplatin can be modified with
various reagents to alter the size and charge of the complex. Several amino-acidlinked platinum complexes were synthesized and a binding study was carried out
with a model RNA system as well as 16S rRNA. Amino-acid-linked complexes
alter the reactivity with RNA by increasing the charge, size, and H-bonding
potential of the ligand. Lysine- and ornithine-linked platinum complexes showed
higher reactivity with AG-rich sequences and the arginine-linked complex showed
reactivity mostly in the bulge and loop regions of 16S rRNA.

5.2

Introduction
Cis-diamminedichloridoplatinum (II), cisplatin, is a clinically used antitumor

drug that has long been believed to react preferentially with DNA (156, 163). The
cross-links at GG sequences are considered to be crucial for its biological activity
(156, 175). The main coordination site of cisplatin with DNA is the N7 of guanine,
and the complex forms adducts mainly at runs of consecutive Gs, with less
damage at AG or GA sequences (191, 197). The acquired and intrinsic
resistance of tumor cells to the drug has lead researchers to look for other
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platinum complexes that have better chemotherapeutic applications (268-269).
Various platinum coordination compounds are currently used as clinical
anticancer drugs (166) and lot of effort has been made to improve the therapeutic
effectiveness of platinum compounds (181, 270). One of the strategies to
improve the effectiveness of the drug is to design complexes that interact with
the target DNA in a different manner. For this purpose, numerous cisplatin
analogues composed of ligands that have high affinity with DNA, such as
intercalators, have been synthesized (183, 271). A cisplatin analogue with a
tethered 9-aminoacridine-4-carboxamide showed an altered DNA sequence
specificity (272). This compound has a higher reactivity with purines (GA
sequences). The biological activity of this and related compounds was similar
compare to cisplatin, and they also exhibited activity against cisplatin-resistant
cell lines (273).
Several amino-acid-linked platinum complexes were synthesized and their
activity was compared with cisplatin in various cell lines (187-189, 274). Other
modifications include platinum complexes with charged, neutral, or hydrophobic
amino acids coordinated to the platinum. These modifications increase the
charge or hydrophobicity of the complex and potentially alter the binding
interactions with the target. Similarly, peptide-tethered platinum conjugates were
also synthesized and their interactions with DNA were studied; however, the
additional functionalities in those cases did not lead to increased reactivity (186,
190). The uncharged compounds had lower reactivity than cisplatin and the
positively charged compounds had higher reactivity than the negatively charged
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compounds, which may be due to electrostatic interactions (186). The overall
reactivity of the amino-acid platinum complexes was lower than the parental
compound cisplatin; however, their interactions with RNA were not discussed in
the literature, to the best of my knowledge (186, 189-190).
One of the advantages of using cisplatin as a probing agent is the ease
with which its size and charge can be altered. Cisplatin is relatively small in size
and numerous binding sites in 16S rRNA have been observed (Chapters 2 and
3). In order to reduce or alter the number of binding sites to gain more
information about accessibility of the RNA structure towards various ligands, the
platinum complex can be modified to contain different functionalities. Introducing
charged ligands such as lysine, arginine, and aspartic acid alters the net charge
of the complex; whereas, the addition of glycine or alanine would change the
bulkiness and hydrophobicity of the complex compared to the cationic amino
acids. Electrostatic interactions play an important role in ligand binding with RNA
(223), and it is expected that the introduction of positive charges or
hydrophobicity alters the binding site preference and reactivity. Similarly, the
presence of bulky groups may reduce the number of binding sites due to
inaccessibility of the target nucleotides in the folded RNA structure. Having
different functionalities tethered to the platinum complex could be useful in order
to probe the ribosome and discover charged pockets and/or accessibility of RNA
structural motifs as potential drug target sites. In this chapter, the interaction of
amino-acid-linked platinum complexes (Figure 5.1) with the model RNA system
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and their potential as chemical probes to study the ribosome structure will be
explored.

Figure 5.1. Structures of monoaquated amino-acid-linked platinum complexes used in this
study are shown. Note that only one possible isomer is shown.

5.3

Materials and Methods

5.3.1 General
Potassium tetrachloroplatinate (K2PtCl4) was purchased from Strem
Chemicals, Inc. (Newburyport, MA). L-Ornithine hydrochloride, L-lysine, Larginine and L-aspartic acid were purchased from Alfa-Asear (Ward Hill, MA). All
other chemicals and reagents were purchased from Sigma-Aldrich or Fisher,
unless otherwise stated. RNase-free, distilled, deionized ddH2O (Millipore water)
was used throughout the experiments.
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5.3.2 Synthesis of amino-acid-linked complexes
Amino-acid-linked complexes were synthesized as previously described in
the literature (187, 189). For the synthesis of [cis-PtCl2(N,O-Lys)], (Kplatin),
K2PtCl4 (0.21 g, 0.50 mmol) was dissolved in 500 µl of ddH2O in a centrifuge
tube, and the solution was vortexed until the crystals were completely dissolved.
In a separate tube, L-lysine monohydrochloride (0.18 g, 1.0 mmol), was
dissolved in 500 µl of ddH2O and vortexed. The pH of the amino-acid solution
was measured to ensure that it was between 5.0 and 6.0. Then, both solutions
were combined in a dry 10 ml round bottom flask and stirred, which produced a
reddish-colored solution. The flask was attached to a reflux condenser and
heated at 80 ºC for two hours, until the solution had turned a yellowish color. The
solution was allowed to cool and filtered by using gravity filtration. The filtrate was
transferred to a beaker and kept in dark. The crystals started to appear after 12
hours at room temperature. Yellow crystals formed over a period of 1-3 days.
The crystals were collected and washed with cold ddH2O, ethanol, and ether.
The yellowish-orange crystals, [cis-PtCl2(N,O-Lys)] (0.11 g, 46% yield), were
dried thoroughly using a pressurized vacuum pump and the final product was
confirmed and characterized by mass spectrometry and NMR spectroscopy.
Electrospray MS (H2O/methanol, positive ion): m/z found 433.99 (M+Na)+. 1H
NMR (δ, DMSO): 7.6, 5.6, 4.9, 3.0, 2.5, 1.8, 1.7 ppm.
To synthesize the L-ornithine and L-arginine-linked platinum complexes,
the procedure was the same as above, except 0.091 g (0.5 mmol) of L-ornithine
and 0.087 g (0.5 mmol) of L-arginine were used instead of L-lysine. Oplation was
precipitated as yellow crystals with a yield of 56%. Electrospray MS
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(H2O/methanol, positive ion): m/z found 419.98 (M+Na)+. 1H NMR (δ, DMSO):
7.67, 5.68, 4.91, 3.0, 2.4, 1.72, 1.6 ppm. Rplatin was obtained as light yellowish
crystals with a yield of 38%. Electrospray MS (H2O/methanol, positive ion): m/z
found 462.00 (M+Na)+. 1H NMR (δ, DMSO): 7.5, 5.6, 4.8, 3.0, 2.4, 1.7, 1.5 ppm.

5.3.3 RNA and DNA
RNA corresponding to the 790 loop (5'-GCAGGAUUAGAUACCCUGC-3')
of 16S rRNA was purchaged from the Keck Oligo facility (Yale University). This
RNA was received with 2' protection and was deprotected by dissolving in TBAF
(tetrabutylammonium fluoride), followed by incubation at 35 ºC overnight. The
RNA was then desalted with a Poly-pack cartridge (Glen Research) according to
the company protocol, and dried in a speed-vac evaporator. The dried RNA was
reconstituted in TE buffer (10 mM Tris·HCl and 1 mM EDTA) and gel purified.
DNA primers were purchased from Sigma Genosis, purified, and labelled as
described in Chapter 2. The 16S rRNA was isolated from E. coli MRE600 and
renatured as described in Chapter 2.

5.3.4 Platination reaction and primer extension
All amino-acid-linked complexes were converted to the mono-aquated
form by reaction with 1:1 molar ratios of complex:AgNO3, in dimethylformamide
(DMF). Platinum-DMF complex stock solutions were stored at -20 °C for up to 1
week and diluted as required just prior to use. The platination reaction with model
RNA and 16S rRNA were performed with monoaquated complexes. Prior to
platination, model RNA and 16S rRNA was renatured as described before. The
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reaction was carried out in 20 mM HEPES, pH 6.5, 20 mM K2SO4 and 10 mM
MgSO4 (buffer H) and incubated at 37 °C for 5 hours. In the model system, the
molar reaction ratio was 1:1 (RNA:metal complex) and in 16S rRNA, the ratio
was 1:20 (16S rRNA: complex) or 1:75 (complex: nucleotides). After the reaction,
unreacted complex was removed by ethanol precipitation. To map the binding
sites in 16S rRNA, primer extension was carried out as described in Chapter 2.

5.3.5 MALDI-mass spectrometry
MALDI-TOF mass spectrometry was carried out on a Bruker Daltonics in
the Central Instrument Facility of the Chemistry department. The samples were
reacted with cisplatin or amino-acid platinum complexes as described in section
5.3.4 and the unreacted complex was removed by ethanol precipitation. A
second ethanol precipitation with ammonium acetate was carried out, and the
resulting pellet was washed with 70% ethanol and dried in a speed vaccum.
Finally, the samples were resuspened in ddH2O. The concentration was
measured spectrophotometrically and about 2 μl of RNA (20 pmol) was mixed
with 3 μl of saturated hydroxypicolinic acid (HPA) matrix in 50% acetonitrile, and
0.5 μl of 100 mM ammonium citrate. On the MALDI plate, 1 μl of the HPA:RNA
mixture was spotted. For RNase T1 digestion, 1 unit of RNase T1 was added to
the remaining RNA sample and incubated at room temperature for 30 min. One
μl of the digested sample was spotted on the MALDI plate. All samples were
checked in the positive ion mode using method RP-3147.par.
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5.4

Results

5.4.1 Synthesis of amino-acid-linked complexes
Amino-acid-linked platinum complexes were synthesized in order to react
and determine the number of binding sites on RNA. Positively charged aminoacids such as ornithine, lysine, and arginine were linked to the platinum to
determine the effects of altered electrostatics and bulkiness. Similarly, the
platinum complex with the negatively charged amino acid, aspartic acid, was
synthesized (the net charge of this complex is neutral). Amino-acid-linked
platinum complexes were synthesized from potassium tetrachloroplatinate, and
formations of the products were confirmed by NMR spectroscopy and mass
spectrometry as described previously in the literature (188-189).

5.4.2 Binding studies in small RNA constructs
Amino-acid-linked complexes were converted to the corresponding
monoaquated species by reacting them with AgNO3 overnight. Small RNA
constructs (790 A○C loop) (Figure 5.2) and aquated amino-acid analogues were
reacted in a 1:1 molar ratio at 37 °C for 5 hrs. The reaction was quenched with
NaCl and followed by freezing. The samples were ethanol precipitated to desalt
and adduct formation was checked by MALDI-mass spectrometry. Mass data
showed the formation of bifunctional adducts with their corresponding aminoacid-linked complexes (Figure 5.2 and Table 5.1). Oplatin showed a major peak
with molecular mass of 6385.1 Da, which corresponds to the +1 adduct
(increased in mass of RNA by 325 Da corresponding to the control RNA) and a
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Figure 5.2. Mass spectral data of products after the reaction of amino-acid complexes with
790 A○C construct are shown. Model RNA construct (790 A○C loop) with its molecular
mass is also shown.

Table 5.1. M/z values of the various adducts for RNA-Pt complexes are listed.

RNA + Pt(amino-acid)
[M+H]+

RNA +2 [Pt(aminoacid)] [M+H]+

RNA + 3 [Pt(aminoacid)] [M+H]+

Complexes
Calculated Observed Calculated Observed Caluclated Observed

Oplatin

6388.7

6386.5

6715.8

6712.1

7042.8

-

Kplatin

6402.7

6400.3

6743.8

6739.2

7084.9

7078.4

Rplatin

6430.74

6428.3

6799.8

6795.6

7168.8

7162.4
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minor peak at 6710.7 Da, which corresponds to the +2 adduct formation
(increased in mass by 2 x 325 Da) (Figure 5.2). Kplatin and Rplatin showed the
formation of +1 adducts with masses corresponding to 6401.6 Da (RNA + 339
Da) and 6428.0 Da (RNA + 367 Da), respectively. These complexes also showed
molecular masses corresponding to +2 and +3 adduct formation with RNA
(Figure 5.2 and Table 5.1). Although there is only one set of consecutive
guanosines in this small RNA construct, more than one bifunctional adduct was
detected. Hence, other binding sites such as guanosine and/or adenosine in the
loop region had to be considered. This result is consistent with an increase in
mass of RNA that is equivalent to the formation of a bifunctional adduct (Table
5.1). Monofunctional adducts were not detected by MALDI-mass spectrometry
with any of these complexes. In the MALDI spectrum, peaks of RNA showed
masses corresponding to the parent RNA plus platinum complexes, with two less
H’s than would be expected from the attachment of a Pt(amino-acid) fragment for
each adduct. This result is due to a proton transfer necessary to counterbalance
the binding of a charged complex and still produce singly charged molecular ions
(267). This result is consistent with other adduct formation such as, 4 Da less in
[RNA+2(Pt-amino-acid)] and 6 Da lower in case of [RNA+3(Pt-amino-acid)].
Hence, the observed mass is 2 Da less than the calculated for each adduct
formed with 790 RNA construct.

5.4.3 RNase T1 cleavage study in small RNA construct
To locate the binding site of amino-acid-linked complexes in the model
RNA system, all reaction samples and controls were partially digested with
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RNase T1. The fragments were analyzed by MALDI-TOF mass spectrometry
(Figure 5.3) and compared to the control. Platinated RNA with Oplatin showed a
fragment

with

a

mass

of

3266.3

Da,

which

corresponds

to

[CAGGAUUAG>p+Pt(ornithine)]. The increase in mass (325 Da) on the
platinated fragment corresponds to the formation of a bifunctional adduct with
Oplatin. Similarly, Kplatin and Rplatin also showed a fragment of RNA with
complexes. The mass peak at 3624.9 Da with Kplatin suggested complex
formation with the GCAGGAUUAG>p fragment of RNA (increase in mass by 339
Da). Rplatin also showed RNA-complex formation with a mass of 3653.7 Da
(increase in mass by 367 Da) corresponding to the same fragment of RNA. No
other fragments of RNA shown in Table 5.2 contained platinum complexes. This
result suggests platination somewhere on the 5' half of the 790 RNA.
The complex-bound RNA fragment contains a pair of Gs and two AG
sites; hence, the exact location of the binding sites could not be identified.
Several RNA fragments were observed with these complexes; however, they
were slightly different than those with the parental compound cisplatin. For
example, cleavage occurred at the site of consecutive Gs with RNase T1 after
reaction with the Oplatin and Rplatin complexes. This result indicates a possible
alternation of sequence preference by the amino-acid-linked complexes
compared to cisplatin. For example, with Kplatin and Rplatin, the RNA fragment
GCAGG>p does not contain a platinum complex; however, GCAGGAUUAG>p was
detected with the complex, which is evidence for adduct formation in the loop
region. With cisplatin and Oplatin treated samples, the RNA fragment AUUAG>p
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Figure 5.3. MALDI-mass spectrometry data showing the mass after digestion of 790
constructs with RNaseT1. Platinated fragments are indicated with (♦).
Table 5.2.The masses of RNase T1 fragments of 790 RNA after reaction with cisplatin and
its analogues.

Calculated
Fragments
mass (Da)

Observed mass of RNase T1 fragments of 790 RNA
following platination (Da)
Control
Cisplatin
Oplatin
Kplatin
Rplatin

GCAG>p

1324.81

1324.98

-

1324.48

1324.32

1324.42

AUUAG>p

1615.96

1616.25

1615.31

1615.73

-

-

GCAGG>p

1670.02

-

-

-

1669.51

1669.63

AUACCCUG>p

2531.51

2531.79

2530.65

2531.15

-

-

3167.63

3266.31

CAGGAUUAG>p

2940.76

-

-

-

(+227)

(+325)
3624.97

3653.72

GCAGGAUUAG>p

3285.98

-

(+339)

(+367)

-
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did not contain a platinum complex, and the platinated CAGGAUUAG>p was
obtained with both complexes, suggesting adduct formation at the consecutive
guanosines (Figure 5.4).

Figure 5.4. Some of the possible adducts with cisplatin and amino-acid-linked complexes
with 790 RNA model system are shown. The expected and observed mass of the RNA-Pt
complexes are indicated. The observed masses are 2 Da less than the expected for the
bifunctional adducts, because proton transfer necessary to compensate for the positive
charges.
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5.4.4 Mapping binding sites in 16S rRNA by primer extension
Cisplatin and amino-acid-linked platinum complexes, after mono-aquation,
were used to probe 16S rRNA. The monoaquated species contain positive
charges that are different than the parental compound cisplatin, and hence, a
change in reactivity was expected. The binding sites of monoaquated complexes
were mapped on free 16S rRNA by using primer extension. The 16S rRNA was
isolated from E. coli and renatured as described in Chapter 2. The reaction was
carried out in 1:20 molar ratios of 16S rRNA:complex (or 1:75 molar ratios of
complex:nucleotides) in 20 mM HEPES buffer, pH 6.5, at 37 °C in the dark for 5
hours. The reaction was quenched by increasing the concentration of NaCl to
200 mM, followed by freezing. The unreacted complex was removed by ethanol
precipitation or dialysis. To compare the binding sites with the parental
compound, several functionally important helices such as h18, h24, h27, and h28
were selected for the probing studies. Primers corresponding to these helices of
16S rRNA were used to map the coordination sites of complexes.
The magnitudes of the reactivity were classified by the intensities of the
bands on the autoradiograms. The intensities of bands could be measured up to
approximately 100 nucleotides from the transcription start site. Coordination sites
of cisplatin and analogues were determined by comparing with a control treated
in a similar manner, but lacking metal complex. The positions of the stops due to
coordination of the complexes were identified by comparing with dideoxy
sequencing lanes on the same gel.
The results showed clear differences in the binding sites of amino-acidlinked complexes and cisplatin (Figure 5.5). Cisplatin showed reactivity mostly
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with consecutive Gs, or Gs in mismatched or loop regions; however, several of
the consecutive Gs that showed strong reactivity with cisplatin were not reactive
towards the amino-acid-linked complexes. These complexes showed quite
different patterns of reactivity, mostly with the ApG sequences and in the loop
regions.

Figure 5.5. Autoradiogram of probing results with amino-acid-linked complexes
corresponding to the helix 24 of 16S rRNA is shown. A) The secondary structure of 16S
rRNA corresponding to helix 24 is shown. Nucleotides with strong and moderate cisplatin
hits are shown with red and green, respectively. B) The autoradiogram showing the
reverse transcriptase pauses or stops is presented. In the gel, C, U, A, G represent the
sequencing lanes; the control is 16S rRNA lacking treatment with complexes; and other
lanes contain 16S rRNA treated with corresponding complexes Orn-Pt, Lys-Pt, Arg-Pt, or
Asp-Pt (complex:nucleotide is 1:75). The strong and moderate hits are indicated with
arrows and corresponding nucleotide numbers. Strong hits with: cisplatin (▲), Oplatin and
Kplatin (**), Rplatin (♦); moderate stops with: cisplatin (Δ), Oplatin and Kplatin (*), and
Rplatin (◊).
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In helix 24, the strong cisplatin-binding site observed at U801 was not
present with any of the amino-acid-linked complexes; however, a number of
binding sites were observed in the loop region with Oplatin and Kplatin
monoaquated complexes (Figure 5.5). The strong stops occurred at C795,
G791, and U788, which were all on the 3' side of the adenosines on the loop
region. Some additional minor stops were also observed, such as at U804 and
G778, which had shown strong reactivity with cisplatin. Rplatin showed strong
binding site on the three-nucleotide asymmetric bulge region of helix 24. Only
minor reactivity with Rplatin was observed on the sites that showed strong
reactivity with Kplatin and Oplatin. The preference for adenosine residues by
these complexes is highly unusual, and being explored currently in more depth
by another student in the laboratory. There were no such strong stops observed
with the Dplatin complex. This result indicates that electrostatics and structure
are likely to be important factors for platinum complexes to interact with RNA.
The strong stop that appeared at the consecutive Gs on the stem region at A787
with Oplatin and Kplatin might be the structural distortation caused by the A◦C
mismatch close to it. Various other bands are observed in all lanes, including the
control lane, possibly due to strong secondary structures in the RNA template
that block reverse transcriptase.
Helix 18 contains several universally conserved residues and showed
reactivity with the parental compound cisplatin, such as consecutive Gs at
residues 540-542 and 529-530; however, the amino-acid metal complexes
showed different sequence selectivity (Figure 5.6). Instead of a strong hit
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Figure 5.6. Autoradiogram of probing results with amino-acid-linked complexes at helix 17
and 18 of 16S rRNA are shown. A) The secondary structure of 16S rRNA corresponding to
helix 17 and 18 is shown. Nucleotides with strong and moderate cisplatin hits are shown
with red and green, respectively. B) The autoradiogram showing the reverse transcriptase
pauses or stops is presented. In the gel, C, U, A, G represent the sequencing lanes; the
control is 16S rRNA lacking treatment with complexes; and other lanes contain 16S rRNA
treated with corresponding complexes Orn-Pt, Lys-Pt, Arg-Pt, or Asp-Pt
(complex:nucleotide is 1:75). The strong and moderate hits are indicated with arrows and
corresponding nucleotide numbers. Strong hits with: cisplatin (▲), Oplatin and Kplatin
(**), Rplatin (♦); moderate stops with: cisplatin (Δ), Oplatin and Kplatin (*), and Rplatin (◊).
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present at U543 before the consecutive Gs, it appeared on the 3' side of A539,
which is present between the two sets of consecutive Gs, indicating possible
cross-links at the ApG sequence. Interestingly, this stop was strong with Oplatin
and Kplatin, although the intensity was shifted by one nucleotide, and did not
show strong reactivity with Rplatin. Another strong stop appeared at A533, which
was also found one nucleotide prior to the cisplatin stop site. A number of other
strong stops appeared at A510, G500, and A452, which were all different than
the stops observed with the parental compound cisplatin. These stops are on the
3' side of an ApG sequence on the RNA. From 490 to 500, there are three pairs
of consecutive ApG, which all showed strong reactivity with the cationic aminoacid complexes.
The binding sites of amino-acid platinum complexes were also mapped on
helices 27 to 31 (Figure 5.7). As observed in other regions, the stop sites were
mostly at ApG sequences. A number of sites with consecutive Gs did not show
reactivity with the amino-acid complexes, such as G953, G942, G927, and U904
(stops with cisplatin). Residue A946, before the consecutive Gs, showed
moderate reactivity with these analogues. One similarity with the parental
compound was observed at G885, which was a strong hit on free 16S rRNA, 30S
subunits, and the 70S ribosomes. Several sites with consecutive adenosines
were also not reactive towards these complexes indicating that a neighboring
guanosine is required for the adduct formation at these sites.
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Figure 5.7. Autoradiograms of probing results with amino-acid-linked complexes and
helices 27 to 31 of 16S rRNA are shown. A) The secondary structure of 16S rRNA
corresponding to helix 27 to 31 is shown. Nucleotides with strong and moderate cisplatin
hits are shown with red and green, respectively. B) The autoradiogram showing the
reverse transcriptase pauses or stops is presented. In the gel, C, U, A, G represent the
sequencing lanes; the control is 16S rRNA lacking treatment with complexes; and other
lanes contain 16S rRNA treated with corresponding complexes Orn-Pt, Lys-Pt, Arg-Pt, or
Asp-Pt (complex:nucleotide is 1:75). The strong and moderate hits are indicated with
arrows and corresponding nucleotide numbers. Strong hits with: cisplatin (▲), Oplatin and
Kplatin (**), Rplatin (♦); moderate stops with: cisplatin (Δ), Oplatin and Kplatin (*), and
Rplatin (◊).

5.5

Discussion
The amino-acid-linked platinum complexes were synthesized and a

binding study was carried out with a short RNA model system, as well as full
length 16S rRNA. In both RNAs, differences in reactivity and binding-site
preference of these complexes compared to the parent compound cisplatin were
observed. The amino-acid-linked complexes in the model RNA system (790
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RNA) showed the formation of more than one adduct indicating possible
coordination at sites other than Gs. The model RNA contained only one site with
consecutive Gs; hence, the strong mass signal with bis-adducts indicates the
altered binding preferences of the cationic amino-acid complexes. The RNase T1
cleavage experiments could not be used to locate the exact binding sites, but
showed evidence that an adduct might have formed on a sequence containing
many Gs. Probing studies on 16S rRNA showed that the binding-site preferences
for Oplatin and Kplatin complexes were quite similar, mostly at AG sequence in
the loop or bulge regions. This result was not surprising, because these two
amino-acid complexes differ only by a CH2 group and each contains a single
positive charge. Rplatin showed differences in reactivity compared to the other
two cationic analogues, such as a stronger binding preference for nucleotides in
the bulge or loop regions. The presence of the amino-acid ligand on these
complexes leads to increased bulkiness of the cis-ligand and introduced an
additional positive charge to the complex relative to the cisplatin; which, in turn,
altered the interactions with the negatively charged RNA. The negatively charged
amino-acid complex, Dplatin, did not show any significant reactivity compared to
the cationic complexes at the same reaction ratio, leading to the likelihood that
electrostatic repulsions prevented a favorable reaction with RNA.
Previously, the binding sites of Kplatin were mapped on an 82-bp DNA
fragment by exonuclease (274). This mapping study revealed that Kplatin
induced a significant stops at all d(ApG) and d(GpG) sites in DNA. It had no
apparent preference for d(GpG) over d(ApG)sequences. The authors of that
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study also observed stops at other polypurine sequences, which were presumed
to be monofunctional adducts. In this study, a similar result was observed with
RNA. Most of the ApG sequences showed strong reactivity with Oplatin and
Kplatin, whereas a number of GpG sequences did not show any reactivity. In
contrast, Rplatin reactivity was different from the other complexes. Rather than
being sequence selective, it showed a structural preference for reactivity, such as
three nucleotide bulges or in the loop regions. This might be the result of the
charge and larger size when compared to Oplatin and Kplatin. The reactivity of
Rplatin at the internal bulge on helix 24 is quite similar to the TAR-Tat interaction
in which the three-nucleotide bulge of TAR RNA is recognized by the argininerich Tat protein (275). Arginine is an ideal RNA-binding molecule because of its
positive charges, planar hydrogen-bonding patterns, and stacking interactions
with the bases (223). It has been observed that molecular contacts with RNA
occur at the bulge sites because they are more accessible to the ligand (223,
276). In crystal structures of the ribosome, it is not as obvious as in the case of
TAR RNA, but this interaction might be favorable due to a structural distortion
caused by the presence of the asymmetric bulge in 16S rRNA.
Another factor for coordination is the charge present in these complexes.
Electrostatic interactions and local accumulation of cationic concentration
determines the product formation. The amino-acid-linked complexes might
increase the local concentration differently than the parental compound due to
charge and hence, the binding sites are also different. The number of binding
sites of amino-acid-linked complexes is higher than parental compound cisplatin;
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however, Rplatin showed less number of hits in helix 24. In addition, the binding
sites are also altered, which indicates that more factors must be involved than
just electrostatic interaction. Previous studies showed that cisplatin preference
for guanine is due to a strong hydrogen bond between the amine-hydrogen of
cisplatin and the O=C6 moiety (Figure 5.8) (196) . In adenine, comparatively
weaker hydrogen bond forms between amine-hydrogen of cisplatin and the H2NC6 group. In addition, significantly stronger molecular orbital interaction was also
observed for guanine compared to adenine (196). The alternation of binding
preference for amino-acid-linked complex is not very clear; however, the
presence of NH2 group in adenosine might influence hydrogen bonding in the
transition state, which results in preference for coordination with amino-acidlinked complexes over cisplatin.

Figure 5.8. Possible transition state for the formation of cisplatin adducts with guanosine
and adenosine is shown.
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The altered binding preferences of these complexes are highly unusual
and further studies will be needed to understand the sites of interaction and types
of adducts formed. Previously, several platinum complexes have been made in
an attempt to alter the sequence specificity of cisplatin on DNA (269, 277). The
minor groove binder distamycin was linked with cisplatin with the expectation that
it would change the binding mode, but this approach was unsuccessful (277).
One successful alteration of cisplatin binding sites was made by Bierbach and
coworkers with the monofunctional platinum-acridinylthiourea conjugate, or PtACRAMTU, intercalators (278). They were able to increase sufficiently the
product formation with AT-rich regions in the DNA sequence. However, these
complexes were not studied with RNA to the best of my knowledge.
Small molecules that bind to DNA or RNA in a sequence-specific manner
have potential applications in cancer chemotherapy. In DNA, purine nitrogens are
susceptible to covalent modifications both in the major and minor grooves. In the
major groove, the most reactive site is guanine N7, while the N3 positions of
adenine and guanine are mainly attacked by nucleophiles in the minor groove
(279). The sugar edge of RNA is comparatively wider and shallower than the
Hoogsteen edge; hence, ligands can interact through the sugar edge in RNA.
The amino-acid-linked platinum complexes, due to their larger size compared to
the parental compound, may be able to access RNA through the sugar edge,
hence the preference would be for adenosine.
In conclusion, amino-acid-linked complexes cross-link to RNA with
different sequence specificity than cisplatin, preferably to ApG; therefore, the
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accessibility of adenosine in the 16S rRNA could be monitored. The higher
reactivity of Rplatin to the bulge or loop can give more information about
accessibility to RNA motifs for ligand binding. In addition, the charge present in
these complexes would be useful for monitoring the kinetics and interpreting how
small charged molecules find their target sites. To understand the mechanism of
action, however, further studies will be needed.
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CHAPTER 6
Targeting non-Hodgkin’s Lymphoma with siRNA Mediated
through Liposomes
6.1

Abstract
Non-Hodgkin’s lymphoma (NHL) is a cancer of the lymphocytes, which is

a significant cause of mortality in the United States. As a treatment for NHL, we
propose reducing expression of the associated protooncogene c-myc using
siRNAs. We first incorporated siRNAs into liposomes to improve drug delivery.
Then, we attempted to purify an antibody fragment (scFv) that specifically
recognizes CD20-positive NHL cancer cells. Our preliminary data suggest that
this is a promising strategy.

6.2

Introduction
Non-Hodgkin’s lymphoma (NHL) is a cancer that starts in lymphocytes

and can occur at any age. There are various types of non-Hodgkin lymphomas,
but they are mainly divided into two types: aggressive (fast growing) and indolent
(slow growing) (280). Out of various types of lymphomas, B-cell lymphoma is the
most common in the United States (281). The National Cancer Institute
estimated 65,540 new cases and 20,210 deaths from non-Hodgkin’s lymphoma
in the United States in 2010 (282).
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6.2.1 Non-Hodgkin’s lymphoma and c-myc
MYC regulates over 15% of all cellular gene expression and is involved in
almost every aspect of cell biology (283). MYC contributes to the regulation of
various genes including those involved in cell-cycle progression, protein
biosynthesis, cell growth, and metabolism (283-284). The c-myc proto-oncogene
is activated in a number of human tumors (283). In a normal cell, expression of
the c-myc gene is under exquisitely fine control, and translocations in the B cell
activate the c-myc gene and promote lymphoid malignancies (285). In cells
affected by aggressive B-cell lymphomas, known as Burkitt lymphoma (BL), there
is an arrangement of the c-myc oncogene, usually associated with a t(8;14)
translocation (286). In addition, point mutations in the coding sequences of c-myc
have been observed (287). The consequence of mutations is a negative
regulation of c-Myc activity. In composite lymphoma, both the low (not
aggressive) and high-grade (aggressive) components have an identical
rearrangement of bcl-2; however, only the high-grade component has a c-myc
oncogene rearrangement (288).

6.2.2 Targeting non-Hodgkin’s lymphoma with siRNA
Small-interfering RNAs (siRNA) suppress gene expression by a process
called RNA interference (RNAi) (22, 289). RNAi is a highly regulated enzymemediated process by which sequence-specific siRNA selectively targets and
cleaves complementary mRNA (290). Long pieces of double-stranded RNA are
cleaved by Dicer into small fragments of RNA (21 nucleotides), called siRNAs
(291). Small-interfering RNAs can be directly introduced into the cell, thus
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bypassing the Dicer mechanism (Figure 6.1) (292). In the cytoplasm, siRNA is
incorporated into a protein complex called the RNA-induced silencing complex
(RISC) (293). Argonaute 2, present in the RISC complex, unwinds the siRNA and
cleaves the sense

Figure 6.1. The mechanism of RNA interference is shown (292). Long double-stranded
RNA (dsRNA) is cleaved by the enzyme Dicer into small-interfering RNA (siRNA). siRNA
can be directly introduced into the cell by various methods. The siRNA is incorporated
into the RNA-induced silencing complex (RISC), which results in cleavage of the sense
strand and activation of siRNA-RISC complex. This activated complex binds to the
targeted mRNA and degrades it, which causes silencing of the gene and reactivation of the
siRNA-RISC complex.
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strand (294). The activated RISC containing the antisense strand selectively
degrades the complementary mRNA (295). After cleaving one mRNA strand, the
activated RISC complex can then move on to destroy additional mRNA targets
until siRNAs are diluted below the threshold concentration or degraded within the
cell (292, 296). In theory, appropriately designed siRNAs can be used to silence
any gene in the body. It has been shown that siRNA can be used to knock down
targets in a number of diseases in vivo, such as liver cirrhosis (297), hepatitis B
virus (298), human papillomavirus (299), ovarian cancer (300), and bone cancer
(301). Since higher expression of c-Myc has been observed in non-Hodgkin’s
lymphoma, siRNA specifically designed to target c-myc mRNA in NHL cells
would be useful. For clinical purposes, however, a safe and effective delivery
system is essential.
The major challenge of siRNA therapy is to find an efficient delivery
method to the intended target to minimize side effects. This approach is
challenging due to off-target effects, aggregation with serum proteins, poor
cellular uptake, and enzymatic degradation by nucleases (292, 302). To
overcome these difficulties, a number of drug-delivery vehicles have been used,
including liposomes, nanoparticles, synthetic polymers, carbon nanotubes,
dendrimers, and polypeptides (303-305). Out of these, liposomes are used quite
often because of their low toxicity and efficient cellular uptake.

6.2.3 Drug delivery vehicles
Liposomes are small, spherical, artificially prepared vesicles consisting of
a lipid bilayer with an internal aqueous compartment (304). When phospholipids
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are hydrated, they spontaneously form an internal aqueous environment
surrounded by a phospholipid bilayer membrane. Liposomes, which can be
prepared from cholesterols, glycolipids, sphingolipids, and long chain fatty acids,
are good carriers for a variety of molecules such as drugs, nucleic acids, and
proteins (306). The work of Bangham and coworkers about 40 years ago
revealed that phospholipids can form liposomes in aqueous solution (307), and
this versatile method has been applied to biology, biochemistry, and medicine.
This discovery is very important because liposomes are excellent carriers for
delivering specific compounds to targets of interest. Preferred site targeting with
liposomes can be achieved by the attachment of an antibody or appropriate
fragments that specifically recognize the receptors present on the cells (308309). Liposomal drug delivery has several advantages such as enhanced drug
solubilization, protection of sensitive drugs, enhanced uptake, and altered biodistribution (309).
Liposomes are of many different sizes and shapes (310). Small-sized
liposomes called small unilamellar vesicales (SUVs) are usually 100 nm in
diameter. Larger-sized liposomes (200-800 nm) are classified as large
unilamellar vesicles (LUVs), and multilamellar (MLVs) range in sizes from 5005000 nm and consist of several concentric bilayers (309-310). There are several
methods for synthesizing liposomes including sonication, detergent dialysis,
mechanical mixing, freeze-thaw, and solvent evaporation (309-310). Unequal
vesicle sizes, low yields, uneven size distribution, and inconsistent encapsulation
efficiencies are the major problems associated with these methods. It is essential
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to generate liposomes with uniform size and distribution for therapeutic
applications and to overcome these problems, a high pressure technique was
used to prepare them (311). Liposome extruders use high pressures,
approximately 200-800 lb/in2, and small-pore-size (~100 nm) membranes to
generate relatively uniform vesicles. Membranes with different pore sizes can be
utilized to generate liposomes of various sizes (310-311). Hence, the extruder
can be utilized to generate either SUVs or LUVs. The advantages of this method
include relatively rapid liposome preparation and potentially high encapsulation
efficiencies.
The application of liposomes has considerably expanded over the years. It
is now possible to engineer a wide range of liposomes with various sizes,
phospholipid compositions, and surface morphologies for increased therapeutic
potential (304). In addition, biocompatibility and targeted delivery are important
advantages of liposomes (312). Liposome encapsulation can also be used to
increase delivery of hydrophilic drugs or oligonucleotides that often have difficulty
crossing the cellular membrane. After entrapment, the drug does not interact with
the lipid bilayer of a cell. In contrast, the liposome interacts favorably with the
natural lipid and is embedded into the cellular membrane. A liposome can
release the entrapped drug after its integration into the cellular membrane or by
the mechanism of endocytosis (304, 312). Liposomes constitute an effective
carrier of siRNA for in vivo delivery; when incorporated into a liposome, they are
protected from nuclease degradation, which increases the half life and potency of
RNA (313).
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To increase the target specificity, at least three criteria need to be
considered (313). First, the drug-delivery vehicle, such as a liposome, should
reach and deliver theraupetic agents to the target cells. Second, the targeted
mRNA should be preferentially expressed in tumor cells. Third, the carrier and
siRNA should both eventually degrade. Targeting and selectively delivering
siRNA to tumor cells in liposomes is an attractive therapeutic strategy. Cancer
cells can be specifically targeted because many express unique antigens that are
not available in normal cells.
To study non-Hodgkin’s lymphoma, a human B-cell line (WSU-FSCCL)
was used, which was established from peripheral blood of a patient (314). B cells
express a wide variety of cell-surface antigens, such as CD20, throughout their
development. B-cell-specific, cell-surface antigen CD20 is an appropriate target
for therapeutic monoclonal antibodies (315). It is expressed at most stages of Bcell development. Our collaborators (Ayad Al-Katib and coworkers) have
engineered an antibody fragment (scFv) and GPI (glycosylphosphatidylinositol)tagged scFv by cloning VH and Vn regions from a widely available mouse
hybridoma (HB-9645) directed against human CD20 (308). Previous studies
showed that when this GPI-tagged scFv has been loaded onto the surface of
sheep erythrocytes (Esh), it specifically forms rosettes with CD20-bearing tumor
cells (308). In this study, we are extending this study to target specifically the
CD20-positive cancer cells with siRNA.
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6.3

Objectives
siRNA has been widely used for silencing the oncogenic genes; however,

the major challenge with siRNA is selective delivery to specific target cells (292).
To achieve this we will use the newly engineered antibody fragment (scFv) to
deliver liposome-encapsulated cytocidal agents to specific cancer cells. This
antibody fragment can also be utilized for cell imaging using quantum dots or
fluorescent tags packed into liposomes. Hence, the main goal is to generate a
complex with siRNA, liposome, and antibody that would specifically target c-myc
mRNA in NHL cells (Figure 6.2).

Figure 6.2. Overview of targeting CD20-positive cancer cells by siRNA-GPI-scFv-liposome
complex is shown.

6.4

Materials and Methods

6.4.1 General
Lipids were purchased from Avanti Polar Lipids, Alabaster, AL. The
extruder was obtained from LipexTM Extruder, Vancouver, BC, Canada.
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Polycarbonate filters (0.1 μm) were purchased from Osmonics, Inc., Minnetonka,
Minnesota. Sepharose 4B was purchased from Sigma. siRNAs were purchased
from the Keck Foundation, School of Medicine, Yale University, CT. γ-32P-CTP
was obtained from Perkin Elmer Life Sciences, Inc. Boston, MA. RPMI and
Express Five SFM culture media were obtained from Invitrogen Corp. Primary
antibody (HA.11 MoAb) was purchased from Covance, Princeton, NJ and
seconday antibody (goat anti-mouse HRP conjugate) was obtained from Santa
Cruz Biotechnology, Santa Cruz, CA. Other chemicals and buffers were
purchased from Sigma Chemical or Fisher. Sterilized ddH2O was used for all
experiments.

6.4.2 RNA purification and labeling
The siRNA obtained from Keck Foundation was deprotected, desalted and
purified by polyacrylamide gel electrophoresis. Deprotection was carried out in
TBAF (tetrabutylammonium fluoride) at 35 °C overnight. After deprotection, the
RNA was desalted using poly pack (II) cartridges using 100 mM TEAA (triethyl
amine acetate), pH 7.4. For the labeling and cell growth inhibition study, RNA
was purified by polyacrylamide gel electrophoresis followed by ethanol
precipitation. The trace amounts of organic reagents that may have been present
in RNA were removed by ether extraction. In order to monitor the stability of RNA
in buffer and media, the 3' end of the RNA was labeled with γ-32P-CTP. The
PAGE-purified siRNA, 2 μl (25 pmol/μl), 5 μl of T4 RNA ligase buffer, and 41 μl of
ddH2O were added to a centrifuge tube. The solution was mixed gently and
centrifuged, 1 μl of γ-32P-CTP and 1 μl of T4 RNA ligase (10 units) was added.
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The solution was incubated for 4 hours in ice. After the incubation, the contents
of the labeling tube was quenched with ammonium acetate, added to a
Sephadex G-25 column, and centrifuged for 2 min at 3,000 rpm to remove
excess CTP. The radioactivity of the sample was measured using a scintillation
counter.

6.4.3 Lipid mixture preparation
Lipids were brought to room temperature in desiccators just prior to
weighing. First, 11 mg of cholesterol (294.1 g/mol, 28.4 μmol), 26.2 mg of DPPC
(734 g/mol, 35.6 μmol), 10.4 mg of DODAP (684.5 g/mol, 16.2 μmol), and 0.6 mg
of DPPE (692 g/mol, 0.8 μmol) were weighed and transferred to a tube. After
that, 500 μl of CHCl3 was added to the lipid mixture, and the solution was
vortexed to suspend the lipids. Aliquots containing 42 μl (6.5 μmol total lipids) of
lipid mixture was transferred to several tubes. These aliquots were dried under
reduced pressure and kept in the freezer until further use.

6.4.4 Liposome size determination
Dynamic light scattering (DLS), was performed on a Malvern Zetasizer
Nano-ZS instrument. DLS analyzes the particle size by measuring dynamic
fluctuations of light scattering caused by the particle. Liposomes were prepared
by resuspending the lipid mixture in 500 µl ddH2O and passed through the
extruder ten times by using a 0.1 µm polycarbonate membrane. In a low volume
plastic cuvette, the measurements were carried out at a temperature of 25 °C. In
order to eliminate dust particles, the samples were filtered through syringe filters
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with 0.2 µm pore size membrane. At least three repeat measurements on each
sample were taken. The intensity size distributions were obtained from analysis
of the correlation functions in the instrument software.

6.4.5 RNA incorporation and stability test
The lipid mixture was hydrated by resuspending a dried sample of 6.5
μmol mixed lipids with 200 μl of 300 mM sodium citrate (pH 4.0) and then
vortexed to yield a white suspension. After that, 300 μl of 300 mM sodium citrate
was added to approximately ~ 50 μg of unlabeled siRNA and a small amount of
32

P-labeled siRNA (~10,000-20,000 cpm) in another tube. Both solutions were

vortexed and the lipid-containing solution was heated at 65 °C for five minutes.
The clear siRNA solution was added drop-wise to the lipid suspension and the
500 μl mixture was then passed ten times through 0.1 μm polycarbonate filters at
200-300 psi using an extruder. The liposome was collected in a glass container
and the extruded solution was dialyzed against 1 L of 25 mM HEPES and 50 mM
NaCl buffer (pH 7.4) for 24 hours at 4 °C to raise the pH from 4.0 to 7.4. The
unbound

RNA

from

the

complexes

was

separated

by

gel-exclusion

chromatography with Sepharose 4B. The radioactivity present in various fractions
was measured with a Beckman scintillation counter.
To test the stability of the RNA, the RNA was labeled at the 3' end and
renatured with unlabelled RNA by heating to 90 °C for 2 min followed by a slow
cooling. For double-stranded RNA, the sense strand was labeled. Equimolar
amount of both strands with trace amounts of labeled strand were annealed by
heating to 90 °C for 2 min followed by slow cooling. The renatured RNA was
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incubated with RPMI culture media (containing 5% serum) at 37 °C for various
time intervals.

6.4.6 Transfection of plasmid to Hi Five cells
Plasmid (GPI-scFv) obtained from the Al-Katib laboratory was transfected
in High Five cabbage looper cells using cellfectin according to the manufacturer’s
protocols (InsectSelect system, Invitrogen). The pIZT/V5-His plasmid was used
to clone the engineered scFv containing GFP-Zeocin fused in-frame for selection.
The transfected insect cells express the GFP-Zeo and scFv with similar
efficiencies; hence, GFP can be used to estimate the transfection efficiencies
and Zeocin as a selection marker. Selection of stable transfectants was carried
out using 200 μg/ml of Zeocin until the control cells completely died after which
the concentration of Zeocin was lowered to 50 μg/ml. Approximately 15 μl of
transfected and control High Five cells were spotted on microscope slides for
checking GFP expression with an Olympus 1X71 microscope, equipped with a
TH4 100 Olympus lamp and an Olympus UCMAD 3 camera. The magnification
used was 60X, and images were taken in bright field and fluorescence mode for
200 ms exposure times.

6.4.7 Isolation and purification of protein
For isolation of protein (GPI-scFv), stable transfected cells were grown to
confluent in T-75 flasks in serum-free media at 27 °C. The cells were scraped out
and spun down to remove the media. Cells were lysed in lysis buffer (300 mM
NaCl, 50 mM Tris HCl pH 7.6, 0.5% Triton X-100, 10 mM PMSF, and EDTA free
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cocktail protease inhibitor) using a French Press. After lysis, centrifugation was
carried out at 13,000 rpm for 15 min at 4 °C to remove cellular debris. The
clarified supernatant was transferred into the new tube and protein was purified
using a Ni+2 affinity column (HisTrap, Amersham Biosciences) according to the
manufacturer’s protocol.
The crude cell lysate (10 μl) and aliquots from various stages of protein
purification (10 μl each) were electrophoresed on a 12% SDS polyacrylamide gel
at 170 V until the bromophenol blue migrated off the gel. The gel was transferred
to a nitrocellulose membrane (Hybond- C Extra, Amersham Biosciences) at 300
mA for one hour. After the proteins were transferred to the membrane, it was
washed two times with TBST buffer for 15 min. The membrane was blocked with
5% skim milk for one hour in TBST buffer and incubated with primary antibody
(HA.11 MoAb) overnight at 4 °C. The membrane was again washed twice with
TBST buffer for 15 min and incubated with secondary antibody (goat anti-mouse)
coupled to horseradish peroxidase for one hour. After washing with TBST, the
protein bands were visualized with the ECL Advance Western Blot detection
system. The chemiluminescense was scanned by a Typhoon and analyzed by
Image QuantTM software.

6.5

Results
Human cancers frequently show altered expression of c-Myc emphasizing

the importance of this gene in cancer (287). The c-Myc protein or the c-myc gene
is overexpressed in a wide variety of human cancers. To check our system, we
are specifically targeting expression of c-Myc in lymphoma cells (WSU-FSCCL)
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using siRNA. These cells express CD20 antigens that can be specifically
recognized by an antibody fragment (scFv) (308). CD20 is a highly
phosphorylated, non-glycosylated 33-37 kDa membrane protein found on both
normal and neoplastic B-cells. CD20 is an excellent target for therapeutic
purposes, because it is neither shed from the cell nor internalized upon binding
with antibodies (316).

6.5.1 Designing siRNA for targeting c-myc mRNA
Humans have evolved a number of mechanisms to fight against viral
infections, which also work against siRNA. Hence, siRNA is degraded before
reaching the target by several mechanisms (317). To increase the stability of
siRNA, a number of methods are currently in use such as RNA modification and
encapsulation using various carrier molecules (292). Several modifications have
been used in siRNA to increase its stability and efficiency. 2'-O-methyl
modifications are resistant to endonucleases and also abolish off-target effects
when incorporated into nucleotides 2-8 on the antisense strand (318). Similarly,
introduction of phosphorothioate backbone linkages at the 3' end of the RNA
reduces susceptibility to exonucleases, and a substitution of fluorine at the 2'–
position increases resistance to endonucleases (302).
Initially, single-stranded RNA 5’-AAG CUA ACG UUG AGG GGC AU-3’,
which is complementary to the c-Myc mRNA at positions 1 to 20 from the start
codon, and the scrambled version 5’-GAU CGA UCG AGC GAU GAU AG-3’,
were used to check the incorporation efficiency, stability, and effect on cell
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growth. These RNAs contained 2'–OCH3 groups on the first three nucleotides at
the 5'-end, which is the optimal site of modification.
The second RNA is a double-stranded construct in which all pyrimidines
have a 2'-F group and the 3' ends contain phophorothiorates to increase stability.
To design this RNA, the following four rules were considered, as described in the
literature (319) : i) A/U at the 5' end of the antisense strand; ii) G/C at the 5' end
of the sense strand; iii) AU-richness on the 5' terminal one-third of the antisense
strand; and iv) absence of any GC stretch over nine base-pairs in length. The
double-stranded

siRNA

targeting

the

c-Myc

mRNA

and

a

schematic

representation of four rules used to designed siRNA are shown in Figure 6.3.

Figure 6.3. An overview of the four rules to design siRNA and siRNA targeting c-Myc
mRNA is shown. A) A schematic representation of siRNA with four rules is indicated. B)
The siRNA designed according to the rules for targeting c-Myc mRNA in NHL cells is
shown.

6.5.2 Encapsulation of siRNA into the liposomes
For efficient encapsulation of oligonucleotides into the liposomes, many
variables have to be considered, such as lipid types and buffer pH. Currently, all
types of phospholipids are available for liposome preparation: neutral, cationic,
and anionic. Among them, cationic lipids are most commonly used to prepare
encapsulated oligonucleotides. The positively charged lipids can interact with
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negatively charged oligos through electrostatic interactions, which are considered
an initial driving force for encapsulation. Previously, it has been shown that
cationic liposomes are useful to efficiently encapsulate and deliver nucleic acids
to the target. In this study, the protocol for liposome formulation was based on a
previous study conducted in our lab (320), which was a modified protocol of
Zelphati et al. (321). This composition contains four lipids: 1,2-dioleoyl-3dimethylammoniumpropane (DODAP), dipalmitoylphosphotidyl choline (DPPC),
cholesterol, and dipalmitoylphosphotidyl ethanolamine (DPPE). They were used
in the ratio of 20:44:35:1 of DODAP:DPPE:cholesterol:DPPC to prepare
liposomes (Figure 6.4). DODAP has improved encapsulation efficiencies
because of an ionizable aminolipid with a tertiary amine (pKa 6.6), which
becomes positively charged at low pH. Hence, pH 4.0 was used to encapsulate
the siRNA into the liposomes. Furthermore, backbone modification with
phosphorothiorates and the presence of a methyl group at 2'-positions also
increases encapsulation efficiency and stability of the RNA.
To check encapsulation efficiency, single-stranded RNA was labeled at
the 3'-end with

32

P in order to track the amount of RNA incorporated into the

liposomes. A small amount of RNA (50 μg) and a trace amount of labeled RNA
(5,000 cpm) was mixed with a hydrated lipid mixture and passed through the
extruder at ~ 200 psi. The mixture was prepared in sodium citrate buffer at pH
4.0, and after extrusion, the liposomal mixture was dialyzed against HEPES
buffer at pH 7.5 for 12 hrs. Separation of unincorporated RNA from liposomeRNA was done by using a Sepharose 4B column.
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The level of encapsulation was determined by measuring the radioactivity
of all fractions. The level of RNA encapsulation was found to be more than 30%
by using the following equation (Figure 6.5 A);

Cpm (liposome fraction)
Encapsulation effenciency = ---------------------------------------------- X 100 %
Cpm (liposome fraction + void fraction)

Figure 6.4. A liposome-siRNA complex is shown. Four different lipids; cholesterol,
DODAP, DPPC, and DPPE were mixed at low pH with siRNA to generate the complexes.

Particle sizes of liposomes were measured by using a dynamic light
scattering (DLS) instrument. From the time-correlation function, the size of the
particles were determined by the instrument software. The output can be used to

177
plot as a number or intensity percentage vs. size of the particles. Larger particles
scattered more light compared to small particles and the plot of intensity vs. size
may not reflect the actual distribution of the particles size. Thus, a histogram with
number percentage vs. size of the liposome particles was plotted. The majority of
liposomal particle size was found to be ~100 nm (Figure 6.5 B).

Figure 6.5. Incorporation efficiencies and liposomal particle size are shown A) the %
incorporation of single-stranded RNA into the liposomes; fractions 2 and 3 from column
contain liposomes with RNA, whereas fractions 4 and 5 show the presence of
unincorporated RNA. The data represents an average of three independent experiments.
B) Particle size distribution of liposomes measured by DLS is represented.

6.5.3 siRNA stability
The single-stranded RNAs (modified and scrambled) were labeled at the
3' end to test stability. After labeling, trace amounts of labeled RNA and 20 μg of
unlabelled RNA were renatured in 25 mM HEPES and 50 mM NaCl. Fifty μl
culture media or an equivalent amount of buffer were added to the renatured
RNA (50 μl) and incubated at 37 °C for various time intervals. In the presence of
media, both the modified and scrambled versions of single-stranded RNA were
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degraded in less than 30 min (Figure 6.6 A). Similarly, to check the stability of
double-stranded RNA, both strands of RNA (20 μg each) were annealed with
trace amounts of 3' labeled sense strand. Fifty μl of annealed siRNA and 50 μl of
the culture media was combined and incubated at 37 °C for various time
intervals. After each time interval, the samples were quenched on dry ice and run
on a polyacrylamide gel. The double-stranded RNA with modifications was found
to be stable for more than 18 hours in RPMI media with serum (Figure 6.6 B).
The presence of 2'-F and phosphorothiorate modifications makes the doublestranded RNA less susceptible to the nucleases present in the medium.

Figure 6.6. Autoradiogram of modified single- and double-stranded siRNA stability test in
RPMI culture media at different time intervals is shown. A) Single-stranded RNA and the
scrambled version with different buffers and media and B) double-stranded RNA with
media at various time intervals are shown (autoradiogram B was done by Gayani Dedduwa
Mudalige).
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6.5.4 Transfection of GPI-scFv and protein purification
The GPI-scFv expression plasmid (obtained from Al-Katib’s lab) (Figure
6.7) was stably transfected into High FiveTM cells. After 4 rounds of selection with
Zeocin (200 μg/ml), control cells died and green fluorescence from GFP was
readily visible in transfected cells using fluorescence microscope (Figure 6.8).
The presence of fluorescence compared to untransfected High FiveTM insect cells
confirms the generation of stably transfected cells. Plasmid concentration (2-5
µg), number of High Five cells (~ 1*106), and viability (> 90%) are important
factors to generate the stable transfection. To avoid the contamination often
found with the use petri dishes (as described in protocol), T75 flasks were used.

Figure 6.7. A schematic diagram of the pIZT-GPI-anti-CD20 scFv expression construct
obtained from Al-Katib laboratory (upper) and GPI-tagged SKLH6FG (lower) cloned in
multiple cloning site are shown: The abbreviations are S: secretory signal, K: light chain
variable region, L: linker, H: heavy chain variable region, 6: six histidine residues, F: Flu
tag HA, and G: GPI (glycosylphosphatidyl inositol) signal. Modified with permission from
Hamdy et al. (308).
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Figure 6.8. GPI anchored scFv after stable transfection to the Hi Five cells are shown. The
left panel represents the bright field and right panel represents the corresponding GFP
fluorescence at 200 ms exposure time. Control (no transfection) cells do not show any
fluorescence and most of the transfected cells showed fluorescence.

GFP fluorescence and Zeocin resistance indicated the formation of stably
transfected High Five cells. Protein purification was carried out from stably
transfected cells using a Ni2+ column, and the presence of protein at various
stages was detected by Western blotting. Western blotting showed presence of
the desired protein in the crude lysate and in purified fractions of ~32 KDa,
corresponding to the protein GPI-scFv (Figure 6.9).
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Figure 6.9. A 12% SDS-polyacrylamide gel and immunobloting analysis of GPI-anchored
scFv proteins at different stages of purification are shown: A) before protein purification
showing lysate (control) from untransfected High Five cells; pellet and lysate from
transfected cells; and B) fractions from different stages of protein purification from
transfected cells.

6.6

Conclusions and Future Directions
The double-stranded siRNA with specific modifications was found to be

stable long periods of time (> 20 h), even in the culture media.

We have

successfully stably transfected High Five cells with a GPI-scFv expression
plasmid and purified small amounts of the expressed protein. The stably
transfected cells can be used to purify larger quantities of the GPI-anchored scFv
for further experiments. Liposomes, siRNA, and the GPI-scFv complex can be
used to deliver siRNA to CD20-positive cells. This can be confirmed by
measuring the level of c-Myc expression in CD20-positive WSU-FSCCL cells.
Further, instead of siRNA, quantum dots can be used to check the targeted
delivery by scFv. Quantum dots can be incorporated into the liposomes and
complexes with GPI-scFv can be generated. When this complex is incubated
with cells, it is expected that QDs will be delivered to the cells. As QDs are highly
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luminescent, they can be detected by fluorescence microscopy. This method will
have the advantage of simultaneous cell imaging and targeted delivery of
cytocidal agents to cancer cells.
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CHAPTER 7
Conclusions and Future Directions
7.1

General Conclusions
The ribosome is the protein synthesis machinery and serves as an ideal

target for various classes of antibiotics because of its accessibility and structural
diversity (68, 71). In the last decade, the growth of multiple-drug-resistance
bacterial pathogens is rapidly evolving, while the development of new
antibacterials is lagging behind.

To overcome the ever-growing problem of

resistance, we can either design new drugs for traditional target sites, or explore
novel target sites. Despite the existence of validated antibiotic binding sites, very
few attempts have been made to explore novel drug target sites in the ribosome
(2, 103). The ideal target sites should not only be functionally important, but also
accessible to various small molecules. In this thesis, a new role for cisplatin as a
discovery tool for potential new drug target sites on the ribosome was explored.
Cisplatin has several advantages over other chemical probes due easy detection
of its target sites and the possibility to use it in vitro as well as in vivo. In addition,
the positive charge in aquated complex and stable adduct formation are useful to
monitor binding and kinetics of the reaction.
The first objective of this thesis was to understand the binding interaction
of cisplatin with model RNA constructs and 16S rRNA. A number of methods
were employed to obtain information about the binding sites, number of adducts,
and types of cross-links formed with RNA. The binding studies showed that
cisplatin interacts preferably with guanosine-rich RNA sequences. Many of the

184
consecutives Gs on the 16S rRNA that showed reactivity with cisplatin were
involved in G○U wobble base pairs. Since G○U pairs are known to be
functionally important for RNA-protein interactions (219, 221), the cisplatin
complex may reveal preferential sites for protein binding on RNA that have ideal
accessibility and structural compatibility. The various adduct profiles obtained
from the small RNA construct and 16S rRNA also showed that RNA is a viable
target and may be part of an alternate pathway for cisplatin anticancer activity.
Cisplatin mainly forms bifunctional adducts with purine bases; however, it
showed a unique adduct profile with RNA compared to that of DNA. In DNA, the
most common cross-links are the 1,2-intrastrand with purine bases, mainly the
1,2-intrastrand d(GpG) adduct (~65%) and the 1,2-intrastrand d(ApG) (~25%),
and less common 1,3-intrastrand d(GpXpG) adducts (172, 191). In 16S rRNA,
the adduct distribution is 63% GpG, ~20% ApG, 6% GG, and 11% AG. Strong
reactivity with nonconsecutive Gs such as G462 and G791 may be the result of
structural differences between DNA and RNA. RNA contains several secondary
structural motifs, such as hairpins, internal loops and bulges, which cause
distortion of the RNA structure and therefore change accessibility of the
nucleotides.
The second objective of this thesis was to map on the ribosome accessible
binding sites that could possibly be used as a novel target sites for new
antibiotics. This study showed that several helices of the ribosome are clearly
accessible to platinum complexes, such as helix 18, 24, 27, and 34, and thus
could also be accessible to small molecules and serve as targets for novel drug
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leads. Several nucleotides in these helices that are functionally important, such
as G530-531, G791, and G1058, were found to be highly reactive towards
cisplatin. Mutational studies showed that these cisplatin reactive sites when
mutated lead to deleterious phenotypic effects (2). A number of these mutations
has impaired assembly of the ribosome and growth of the bacteria (1).
Several sites in the 16S rRNA showed different platinum reactivity
between 30S subunits and 70S ribosomes, which could be exploited for
structure-based or mechanism-based drug design. Recently, a model system of
helix 18 was used as a target to find ligands by phage display (254). Hence,
phage display or SELEX could be carried out to find the ligands targeting the
sites that showed different reactivity in 16S rRNA, 30S subunits and 70S
ribosomes.
The fact that the platinum complex generates stable adducts that can be
quantified is significant, because the kinetics of the reaction can be monitored.
This will allow determination of how positively charged compounds such as
aminoglycosides identify their target sites from a number of possible reactive
sites on the ribosome. In RNA, we do not know whether the known sites are the
only ones for effective inhibition, or whether there are more possible target sites
on the ribosome. Hence, it will be important understand the kinetic preference for
charged small molecules binding to the functionally important sites on the
ribosome.
The third objective of this thesis was to exploit another aspect of cisplatin,
namely, the ease with which its charge and size can be altered. Unlike other
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probing agents, aquated cisplatin has a positive charge; thus, accessibility and
kinetic information can be obtained simultaneously. For this purpose, a number
of platinum complexes with various charges and sizes were synthesized by
tethering amino acids. The binding studies with amino-acid-linked complexes
with 16S rRNA showed a clear alteration of the binding sites compared to
cisplatin. The positively charged Kplatin and Oplatin showed a preference for AG
over GG sites on 16S rRNA. Similarly, Rplatin showed a preference for loop and
bulge regions. The negatively charged amino-acid-linked complex Dplatin did not
show any reactivity under similar reaction conditions. These results indicate that
an electrostatic interaction is likely a primary driving force for charged small
molecules to react with the negatively charged nucleic acids, although H-bonding
might also play a role.
In a different aspect of my thesis work, the use of siRNA to target nonHodgkin’s lymphoma was explored. siRNA has great therapeutic applications,
including those related to anticancer approaches; however, it has been often
difficult to achieve selective targeting, efficient delivery, and appropriate stability
of the siRNA, while at the same time minimizing toxic side effects. A newly
engineered antibody fragment (scFv) in conjugation with liposomes was
proposed for this purpose. An scFv plasmid obtained from Al-Katib’s lab was
successfully transfected to High Five insect cells to generate stably transfected
cell lines. This step of the project presented a number of challenges that were
overcome, and now with stably transfected cell lines, sufficient quantities of
protein can be generated for future studies. siRNA stability in cell-growth media
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and its incorporation into liposomes were also optimized. The siRNA with 2'-F,
phopshorothiate, and 2'-OMe modifications were found to be stable in culture
media for extended periods of time (24 hours), and gave ~30% incorporation
efficiency into the liposome.

7.2

Future Directions
Future experiments include the use of these probing techniques to monitor

the accessibility of purines in 23S rRNA, functional ribosomes in the presence of
mRNA and tRNA, as well as polysomes. Mapping of cisplatin binding sites in 23S
rRNA in vitro and in vivo will greatly increase accessibility information for various
functionally important regions, such as the peptidyl-transferase center, helix 69,
and the peptide exit tunnel. In addition, in vitro probing of the ribosome in
presence of mRNA and/or tRNA can generate information about nucleotide
accessibility in fully functional ribosomes. This work could be further expanded to
the polysomes. Previous studies showed that a number of nucleotides were
protected when mRNA, tRNA or initiation factors were assembled on the
ribosome. Thus, cisplatin probing result can be compared with previously
obtained results from biophysical and biochemical methods to find novel target
site for antibiotics on the ribosome.
The binding studies with amino-acid-linked cisplatin analogues and the
790 region of 16S rRNA revealed an alteration of binding sites relative to the
parent cisplatin; thus, the adduct profiles on 16S rRNA are expected to be
different. The binding sites of cisplatin analogues on the 30S subunits and 70S
ribosomes can be obtained by primer extension and in small constructs by
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MALDI (TOP-DOWN sequencing or RNase cleavage) and chemical probing. The
types and number of adducts formed with cisplatin analogues with varying
ligands will further increase our understanding of RNA-platinum complex
interaction. HPLC and LC-MS can be used for this purpose, as described in
Chapter 2. In addition, NMR analysis of various products obtained with individual
nucleosides or nucleotides could be useful to find the exact coordination site of
platinum on the nucleotide base, which has not yet been verified on RNA. As
charge and size of cisplatin can be altered easily, various analogues with bulkier
groups, higher charge, or varying hydrophobic or H-bonding moieties can be
synthesized. These compounds could be exploited to gain information about
nucleotide or helix accessibility on the ribosome, as well as map the interaction
modes.
Cisplatin and its analogues were demonstrated as probing tools to gain
information about nucleotide accessibility in the RNA tertiary or higher-order
structure. Probing the ribosome from other organisms will have the great
advantage of predicting accessibility and assisting with the design of selective
structure-based drug targeting agents for pathogenic bacteria. It has been of
great interest to know how charged small molecules such as aminoglycosides
find their target sites out of the numerous possible sites in the ribosome. Cisplatin
and analogues, due to their stable coordination and charges present in the
aquated species, can be used as a model to understand how charged molecules
find their target sites. This kinetic interaction combined with thermodynamic
preferences will also aid in future drug design.
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Small interfering RNAs (siRNA) were designed to specifically target the cMyc mRNA in non-Hodgkin’s lymphoma cells. High Five cells with stable
transfection of GPI-scFv have been generated, which showed expression of the
desired protein. The stably transfected cells can be used to purify larger
quantities of the GPI-anchored scFv for further experiments. Liposome, siRNA,
and the GPI-scFv can be combined to generate a complex that can be used to
deliver siRNA to CD20-positive cells. This targeting can be confirmed by
examining the levels of c-Myc expression in CD20-positive WSU-FSCCL cells or
related cancer-cell lines. Further, instead of siRNA, quantum dots can be used to
monitor the targeted delivery by scFv. Quantum dots can be incorporated into the
liposomes, and complexes with GPI-scFv can be generated. When this complex
is incubated with cells, it is expected that QDs will also be delivered to the cells
and can be utilized for imaging purposes. As QDs are highly luminescent, they
can be detected by fluorescence microscopy. This method will have the
advantage of simultaneous cell imaging and targeted delivery of cytocidal agents
to cancer cells. These projects taken together provide the basis for new
applications directed towards novel drug discovery or selective targeting as
antibacterial or anticancer agents.
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APPENDIX
Figures in this appendix are additional autoradiograms for Chapters 2 and 3. The
primer and RNA used for probing are mentioned in figure captions.

Figure. Probing results of 16S rRNA at the 3' domain with primers 171 and 323 are
shown. (A) Autoradiogram showing the reverse transcriptase pauses or stops by
using primer 171. (B) Autoradiogram showing the reverse transcriptase pauses or
stops by using primer 323. In both gels, C, U, A, G represent the sequencing
lanes, 0 represents the control, and other 3 lanes are 16S rRNA treated with
increasing concentrations of monoaquated cisplatin (cisplatin:nucleotide is 1:150,
1:75, and 1:30). The strong and moderate hits are indicated with arrows and
corresponding nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿).
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Figure. Probing results of 16S rRNA with primers 485 and 686 are shown. (A)
Autoradiogram showing the reverse transcriptase pauses or stops by using
primer 485. (B) Autoradiogram showing the reverse transcriptase pauses or stops
by using primer 686. In both gels, C, U, A, G represent the sequencing lanes, 0
represents the control, and other 3 lanes are 16S rRNA treated with increasing
concentrations of monoaquated cisplatin (cisplatin:nucleotide is 1:150, 1:75, and
1:30). The strong and moderate hits are indicated with arrows and corresponding
nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿).
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Figure. Probing results of 16S rRNA with primers 746 and 982 are shown. (A)
Autoradiogram showing the reverse transcriptase pauses or stops by using
primer 746. (B) Autoradiogram showing the reverse transcriptase pauses or stops
by using primer 982. In both gels, C, U, A, G represent the sequencing lanes, 0
represents the control, and other 3 lanes are 16S rRNA treated with increasing
concentrations of monoaquated cisplatin (cisplatin:nucleotide is 1:150, 1:75, and
1:30). The strong and moderate hits are indicated with arrows and corresponding
nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿).
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Figure. Probing results of 16S rRNA with primers 1199 and 1296 are shown. (A)
Autoradiogram showing the reverse transcriptase pauses or stops by using
primer 1199. (B) Autoradiogram showing the reverse transcriptase pauses or
stops by using primer 1296. In both gels, C, U, A, G represent the sequencing
lanes, 0 represents the control, and other 3 lanes are 16S rRNA treated with
increasing concentrations of monoaquated cisplatin (cisplatin:nucleotide is 1:150,
1:75, and 1:30). The strong and moderate hits are indicated with arrows and
corresponding nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿).
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Figure. Crystal structures and secondary structure regions of 16S rRNA
corresponding to helix 15 and 42 are shown with reactive nucleotide (colored).
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Figure. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the 5'
domain with primers 171 and 323 are shown. (A) Autoradiogram showing the reverse
transcriptase pauses or stops by using primer 171. (B) Autoradiogram showing the
reverse transcriptase pauses or stops by using primer 323. In both gels, C, U, A, G
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿ and
● (minor hits)).
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Figure. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the 5'
and central domain with primers 485 and 687 are shown. (A) Autoradiogram showing the
reverse transcriptase pauses or stops by using primer 485. (B) Autoradiogram showing
the reverse transcriptase pauses or stops by using primer 687. In both gels, C, U, A, G
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿ and
● (minor hits)).
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Figure. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the
central and 3' major domain with primers 748 and 978 are shown. (A) Autoradiogram
showing the reverse transcriptase pauses or stops by using primer 748. (B)
Autoradiogram showing the reverse transcriptase pauses or stops by using primer 978. In
both gels, C, U, A, G represent the sequencing lanes, 0 represents the control, and other
lanes are 30S subunits and 70S ribosomes treated with increasing concentrations of
monoaquated cisplatin (cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate
hits are indicated with arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿
and Δ ﴾moderate hits﴿ and ● (minor hits)).
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Figure. Probing results of 16S rRNA of the 30S subunits and the 70S ribosomes at the 3'
domain with primers 1199 and 1296 are shown. (A) Autoradiogram showing the reverse
transcriptase pauses or stops by using primer 1199. (B) Autoradiogram showing the
reverse transcriptase pauses or stops by using primer 1296. In both gels, C, U, A, G
represent the sequencing lanes, 0 represents the control, and other lanes are 30S subunits
and 70S ribosomes treated with increasing concentrations of monoaquated cisplatin
(cisplatin:nucleotide is 1:150 and 1:75). The strong and moderate hits are indicated with
arrows and corresponding nucleotides numbers (▲ ﴾strong hits﴿ and Δ ﴾moderate hits﴿ and
● (minor hits)).
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Cis-diamminodichloridoplatinum (II), cisplatin, is an antitumor drug that
has been used to treat several types of cancers. The reaction of cisplatin with
DNA has been studied and discussed extensively in the literature; however, the
effects of cisplatin on RNA function are poorly understood. In this thesis, two
aspects of cisplatin, its preferred sites of interaction with RNA and its use as a
chemical probe to gain accessibility information, were explored.
To understand the site-selectivity of cisplatin with RNA, model RNA
constructs and full-length 16S rRNA were employed. The binding studies
revealed a cisplatin preference for guanosine-rich sequences. Primer extensions
in 16S rRNA and MALDI-TOF in model constructs were used to locate the
binding sites of cisplatin. HPLC and LC-MS were useful to determine the types
and ratios of various adducts formed. Cisplatin and its analogues were employed
to probe the accessibility of nucleotides on 16S rRNA, 30S subunits and 70S
ribosomes in vitro as well as in vivo. This study revealed that many functionally
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important sites, such as helix 18, 24, 27, and 34 are accessible to the aquated
platinum complex. Thus, these accessible sites can potentially be utilized as a
new target sites in the design of structure-based antibiotics. When charge and
size of the complex were changed, the binding preference was altered. In
addition to the expected consecutive Gs, cisplatin analogues preferentially
targeted AG sites on loop or bulge regions. Thus, several new complexes could
be synthesized and utilized to gain more information about drug accessibility on
the ribosome.
The last part of the research focused on the application of siRNA to target
non-Hodgkin’s lymphoma (NHL). Small interfering RNAs were designed to
downregulate the c-Myc expression in NHL cells. Stabilities of designed siRNAs
in media and their incorporation into liposomes were studied. Complexes of
siRNA, liposomes, and antibody fragments (scFv) could be utilized in future
applications to target specifically the c-Myc expression in NHL cells.
Overall, this thesis work explored cisplatin binding to RNA and a number
of possible new antibiotic target sites on the ribosome were identified. In the long
term, further studies with fully functional ribosomes and comparisons with other
organisms will have a greater impact on identifying novel drug target sites in
pathogenic bacteria.
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